

Stock Code: 3218



UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

2025 Annual Report

This annual report is available at:

<http://mops.twse.com.tw>

<http://www.uvb.com.tw>

Published on March 31, 2026

1. Name, Position, Tel No. and E-mail address of Spokesperson and Deputy Spokesperson

Title	Name	Position	Tel No.	E-mail address
Spokesperson	Liu Chun-Chieh	Senior Director	(02)2655-8000#210	jay.liu2@eyecenter.com.tw
Deputy Spokesperson	Chang Yu-Chi	Director	(02)2655-8000#500	yuchi.chang@eyecenter.com.tw

2. Address and Tel Number of Headquarters, Branches

Headquarters, Branches	Address	Tel No.
Headquarters	4F, No. 3-1, Yuanqu St., Nangang District, Taipei City (Nankang Software Park G Building)	(02)2655-8000
Pingtung Chaozhou Branch	1F and 2F, No. 304, Chaosheng Rd., Chaozhou Township, Pingtung County	(08)789-6711
Taipei City Zhongxiao Branch	1F and 2F, No. 178, Sec. 4, Zhongxiao E. Rd., Daan District, Taipei City	(02)8979-1531
Xinzhuang Xintai Branch	1F and 2F, No. 1, Lane 238, Xintai Rd., Xinzhuang District, New Taipei City	(02)2279-6711
Chiayi Chuiyang Branch	1F, No. 507, Chuiyang Rd., Chuiyang Village, West District, Chiayi City	(05)294-9531
Taichung Fengyuan Branch	1F, No. 30, Zhongzheng Rd., Fengyuan Village, Fengyuan District, Taichung City	(04)2369-3389
Taoyuan Longtang Branch	No. 255, and No. 257, Beilong Rd., Zhongshan Village, Longtang District, Taoyuan City	(03)499-1311
Kaohsiung Zuoying Branch	1F and 2F, No. 378, Mingcheng 2 nd Rd., Zuoying District, Kaohsiung City	(07)262-0338
Taoyuan Zhongli Branch	No. 483-1, Yanping Rd., Zhongli District, Taoyuan City	(03)427-0311
Taipei Neihu Branch	1F, No. 100, Wende Rd., Neihu District, Taipei City	(02)2793-6311
Taichung Dongshi Branch	1F, No. 356, Fengshi Rd., Dongshi District, Taichung City	(04)2369-2991
Taichung Xitun Branch	1F and 2F, No. 164-20, No. 164-19, Sec. 3, Xitun Rd., Xitun District, Taichung City	(04)2369-6080
Taoyuan Fuxing Branch	1F, No. 112, Fuxing Rd., Taoyuan District, Taoyuan City	(03)333-3811
Banqiao Zhongxiao Branch	1F, No. 35, Zhongxiao Rd., Banqiao District, New Taipei City	(02)2962-0811
Sanxia Fuxing Branch	1F, B1, No. 11, Fuxing Rd., Sanxia District, New Taipei City	(02)2674-5911
Tainan Minsheng Branch	2F, No. 2, Ren'ai St., West Central District, Tainan City	(06)220-1167
Taoyuan Yiwen Branch	No. 1117, Zhongzheng Rd., Taoyuan District, Taoyuan City	(03)286-8661
Hsinchu Zhubei Branch	1F, No. 285, Sec. 1, Wenxing Rd., Zhubei City, Hsinchu County	(03)659-0227

Headquarters, Branches	Address	Tel No.
Taichung Chongde Branch	No. 635, Sec. 1, Chongde Rd., Beitun District, Taichung City	(04)2369-3611
Tainan Changrong Branch	1F, No. 73, Sec. 2, Changrong Rd., East District, Tainan City	(06)300-1508
Yunlin Douliu Branch	No. 227, Taiping Rd., Douliu City, Yunlin County	(05)552-9968
Yonghe Branch	1F, No. 237-1, Sec. 2, Yonghe Rd., Shangxi Village, Yonghe District, New Taipei City	(02)2921-2711
Taoyuan Zhongzheng Branch	No. 81, Zhongzheng Rd., Taoyuan District, Taoyuan City	(03)333-3811
Keelung Yiyi Branch	1F, No. 13, Yi 1 st Rd., Zhongzheng District, Keelung City	(02)8692-0628

3. Name, address, website and telephone number of handling stock transfer agency

Name: Stock Agency Department, Grand Fortune Securities Co., Ltd.

Address: 6F, No. 6, Sec. 1, Zhongxiao W. Rd., Zhongzheng District, Taipei City

Website: <http://www.gfortune.com.tw>

Tel No.: (02) 2371-1658

4. Names, Firm Name, Address, Website and Tel No. of CPA for recent financial reports

Name of CPAs: CPA Liao Wan-I, CPA Tsai Tsung-Yuan

Name: Deloitte & Touche

Address: 20F, No. 100, Songren Rd., Xinyi District, Taipei City

Website: <http://www.deloitte.com.tw>

Tel No.: (02)2725-9988

5. Website of Overseas Securities Exchange Office & the way to inquire into information of securities: None

6. Company Website: www.uvb.com.tw

Contents

I. Letter to Shareholders.....	1
II. Corporate Governance Report	
1. Profiles of Directors, Supervisors, Presidents, Vice Presidents, Assistant Vice Presidents, Division Heads, and Branch Heads	6
2. Remuneration paid during the most recent year to directors, supervisors, president and vice presidents	19
3. Operational status of corporate governance.....	26
4. Disclosure of the CPAs' fee	137
5. Changes of CPA	138
6. The Chairperson, president, managers in charge of financial or accounting affairs of the Company, who have worked in the firm or affiliated company of the certified public accountant within the last year	139
7. In the most recent year as of the date of publication of the annual report, the directors, supervisors, managerial officers and the shareholders holding more than 10% of the shares in the transfer of shares and pledge of shares under lien, and any change thereof	139
8. Information on shareholders among the top 10 by proportion of shareholding who are related parties to one another or spouse, kindred within the 2nd degree of kinship	140
9. The number of shares held by the Company, the Company's directors, supervisors, managers and enterprises directly or indirectly controlled by the Company in the same reinvested enterprise, and the comprehensive shareholding ratio.....	141
III. Capital Overview	
1. Capital and Shares.....	142
2. Status of corporate bond	146
3. Status of preferred share	146
4. Status of overseas depository receipt.....	146
5. Status of employee stock options.....	146
6. Status of new employee restricted share undertaking.....	146
7. Status of issuance of new shares due to merger and acquisition or acceptance of shares transferred by other companies	146
8. Implementation status of the fund utilization plan	146
IV. Operation Overview	
1. Business Contents	147
2. Market, production and marketing overview	159
3. The number of employees, average years of seniority, average age, and educational level in the last two years and as of the publication date of the annual report	169
4. Information on environmental protection expenditures.....	169
5. Labor-management relations.....	169
6. Cyber security management.....	170
7. Important Contracts	174

V. Review of Financial Position, Financial Conditions, and Risk Matters	
1. Financial Position.....	175
2. Financial Conditions	177
3. Cash Flow	179
4. The impact of major capital expenditures on finance and business in the most recent year.....	179
5. Reinvestment policy in the most recent year, the main reasons for its profit or loss, improvement plan, and investment plan for the next year.....	179
6. Risk events in the most recent year and up to the date of publication of the annual report that should be analyzed and assessed	180
7. Other Important Matters	182
VI. Special Disclosure	
1. Information regarding the Company's Affiliates	184
2. Private placement of securities in the most recent year and up to the date of publication of the annual report	184
3. Other necessary supplementary notes	184
VII. Any matter in the most recent year and up to the date of publication of the annual report which has a significant impact on shareholders' equity or securities prices as stipulated in subparagraph 2 of paragraph 3 of Article 36 of the Securities and Exchange Act	184

I. Letter to Shareholders

Dear shareholders, ladies and gentlemen:

I would like to report on the operating status in 2025 and the business plan for 2026 to all shareholders as follows:

1. Operating Status in 2025

(1) Operating results:

The Group's consolidated operating revenue in 2025 was NT\$4,204,086 thousand, a decrease of 0.57% over the previous year; consolidated net profit attributable to the Company's owners of the parent was NT\$1,042,637 thousand, a decrease of NT\$22,084 thousand, or 2.07% over the previous year.

The independent operating revenue of the parent company in Taiwan was NT\$3,649,649 thousand in 2025, an increase of 3.88% over the previous year, and the parent company's operating revenue accounted for 86.81% of the Group's consolidated operating revenue. In Taiwan (including Penghu), there were 34 self-owned eyewear stores, contributing sales revenue of NT\$952,943 thousand, making up 26.11% of the total operating revenue and representing a year-on-year increase of 13.34%. With a total of 31 partner clinics, the income generated from brand licensing, technical services, consulting, and rental to the clinics was NT\$2,128,196 thousand, accounting for 58.31% of the total operating revenue and representing a year-on-year decrease of 3.37%. The income from medical supplies was NT\$568,510 thousand, accounting for 15.58% of the total operating revenue and representing a year-on-year increase of 20.92%.

(2) Budget implementation status:

The Company's internal budget for the year 2025 had been approved by the Board of Directors, but the financial forecast has not been disclosed to the public. The overall operating condition was good.

(3) Profitability analysis:

Unit: Thousand NT\$

Item \ Year		2025	2024
Financial revenue and expenditure	Net consolidated operating revenue	4,204,086	4,228,302
	Consolidated gross profit	2,482,587	2,533,286
	Consolidated net profit attributable to owners of the parent	1,042,637	1,064,721
Profitability	Consolidated return on assets (%)	18.13	19.59
	Consolidated return on shareholders' equity (%)	26.65	29.59
	Consolidated gross margin (%)	25.09	24.84
	Consolidated earnings per share (NT\$)	12.31	12.57

(4) Research and development status:

In recent years, the Company has continued to introduce advanced ophthalmic technologies and equipment, including femtosecond laser assisted cataract surgery and SMILE Pro, the next-generation of SMILE Laser Vision Correction. In 2024, the Company further introduced SMILE Pro 2.0, featuring an enhanced AI tracking function, along with a new type of intraocular lens designed to minimize glare. In 2025, the Company further introduced the EVO implantable collamer lens (EVO ICL) technology. This is a vision correction solution for people who have advanced nearsightedness, but who lack sufficient corneal thickness for LASIK. The technology has a market history of 30 years, and more than 3,000,000 corrections have been performed worldwide. The Company has introduced the new implantable lens with central hole (Hole ICL) technology. In addition, the Company has supported its partner clinics by providing training and

implementation programs related to these new technologies, which have been highly praised by partner clinics' medical teams. Such efforts have significantly optimized surgical efficiency and service quality, offering partner clinics more advanced medical options and enhancing the overall brand reputation through positive word-of-mouth recognition.

Furthermore, adhering to the business philosophy of providing high-quality products to the public, the Company established a cross-disciplinary team integrating biotechnology and food science to jointly develop "Universal Gold Lutein", an eye nutrition supplement suitable for the entire family. The raw materials and manufacturing processes are subject to strict quality control, with formulations specifically tailored to meet the nutritional needs of seniors, adults, and children. In response to the demands of modern digital lifestyles, the Company launched a new "SOS Enhanced" formula, offering comprehensive solutions for maintaining visual clarity and moisture. Since its launch, "Universal Gold Lutein" has received numerous prestigious awards, including the "SNQ Award", "National Biotechnology and Medical Care Quality Award", "National Brand Yushan Award", "Taiwan Excellent Manufacturer Award", "National Biotechnology Award", "Monde Selection Gold Quality Award", and "iTQi Superior Taste Award". These accolades highlight the Company's unwavering commitment to quality and dedication to safeguarding public health.

2. Summary of Business Plan for 2026

(1) Management Policy and Operation Objectives

A. Ophthalmology market

(a) Refractive correction market

The refractive correction market has experienced rapid growth in recent years, with increasing acceptance among the general public. At the end of 2022, the Company introduced SMILE Pro, the next-generation laser vision correction surgery, which features a minimally invasive procedure that reduces dry-eye symptoms while offering enhanced comfort, speed, and safety. This technology has helped partner clinics provide their customers with comprehensive and high-quality vision correction solutions. In 2025, the Company also introduced EVO implantable collamer lens (ICL) technology, which is a non-eyeglass vision correction solution for people who have advanced nearsightedness but lack sufficient corneal thickness for LASIK. In the first quarter of 2026, the Company is also introducing SMILE Pro 3.0 Max. Built on the Zeiss SMILE Pro platform, this solution integrates big data AI software developed through 130,000 surgeries at partner clinics. The platform first correlates a variety of patient exam data; then, with consideration given to patients' eye usage needs and habits, the platform plots out surgery parameters and provides surgeons with a basis for reference during the treatment process. The platform thus serves as a strategy for differentiation in the highly-competitive laser vision correction market. In addition to existing refractive laser technologies, the Company has also introduced and developed PresbyLASIK and myopia laser technology equipment for its partner clinics to address the increasing demand from the presbyopic population.

(b) Cataract market

The Company has continued to support its partner clinics in promoting advanced technologies and applications for femtosecond laser-assisted cataract surgery combined with premium intraocular lens (IOL) selections. This approach offers the advantages of precision medicine and superior post-operative visual outcomes, assisting partner clinics in continuously increasing the adoption rate of the femtosecond laser-assisted cataract procedure. In addition, the Company has introduced a new type of intraocular lens featuring reduced glare and extended depth of focus, further enhancing patient satisfaction with cataract surgery.

(c) Dry-eye treatment market

Demand in the dry eye treatment market is substantial, as many contact lens users, middle-aged individuals, and seniors require ongoing care. Moreover, continuous dry eye management is often necessary following laser vision correction and cataract surgeries. Since 2022, the Company has gradually introduced the dry eye treatment program and

equipment into its partner clinics, and patient acceptance has steadily increased over the past two years. It is anticipated that, as patient satisfaction continues to spread through word of mouth, the service volume will grow progressively in the coming years.

B. Optometry market

(a) Innovative technology and precise services: The e-Universal brand leading the Optometry Sector

Leveraging innovative technology, the Company launched “i-Precision Intelligent Prescription”, which integrates 21 examination steps and 21 myopia management measures. By implementing the core philosophy of “Medical Optometry, Scientific Eyewear Prescription” throughout this process, the Company creates prescriptions that offer a high degree of expertise and reproducibility. The Company has taken the lead by deploying multi-focal, stress-relief real lens experience equipment from Japan’s Hoya and France’s Essilor across all stores. With this equipment, optometrists can guide customers through a real experience of different lenses’ clarity, comfort, and dynamic visual performance. This helps customers get a clear sense of the real benefits that each optical design brings.

The Company has also continued to optimize in the multi-focal experience domain by creating the Smart Multi-Focal Real Lens Experience. Using scenario-based design, this helps customers experience switching between far, middle, and near vision in environments that approximate real life. This gives them a clear sense of the smoothness and stability of different lenses’ fields of view. The Company is also adding in Essilor’s newest EyeRuler 2 precision application, which combines expert optometric personnel and technology with AI computing, to make sure that every lens is highly personalized and precisely prescribed.

In the smart eyeglass applications field, in addition to offering diverse eyeglass prescription choices, the Company is also introducing optical waveguide prescription lens prescription technology. This will create next-level flexibility for future smart vision applications; make for integrated prescription solutions equipped with both forward-looking technology and practical value; and put the Company’s overall service even further ahead of existing prescription modes on the market, in terms of expertise, fashionability, and technical advancement.

Looking to the future, the Company will continue to strengthen its offerings in myopia control products; senior vision service packages; lutein and other eye health supplements; and personalized value-added product services. Through systematic product strategies and enhanced experiences, the Company will drive steady growth in both revenue and profitability, while building the competitive edge that will enable long-term expansion.

(b) Big Vision Project: Comprehensive eye health management

By integrating the technological strengths and equipment of partner clinics with the Company’s self-operated optical stores, the Company actively promotes systematic management for myopia control and axial length tracking among school-age children. Through technological innovation and AI applications, the Company continues to introduce advanced optometry equipment and continues introducing a diverse range of myopia control products, thus strengthening vision care engagement and long-term retention for students and their parents.

Centered around the philosophy of “Lifelong Eye Health Solutions for the Entire Family,” the Company has integrated optometry services, myopia prevention and control, and related vision health solutions under the e-Universal brand. By creating a vision health model for continuous tracking and management, the Company has become customers’ reliable partner at every stage of life. This integrated strategy not only strengthens the brand’s market value, but also delivers comprehensive, stable, and reliable eye health solutions to an expanding consumer base.

(2) Important production and marketing strategies

A. Marketing strategy

The Company actively establishes long-term strategic partnerships with major optical and biotechnology corporations, both domestically and internationally, to integrate R&D, product, and marketing resources, and thus to jointly drive innovation and application in optical products and technologies. Concurrently, the Company continues to invite partner clinics to participate in vision care and public welfare-promotion initiatives, integrating professional services with corporate social responsibility. Through these efforts, the Company promotes public awareness of vision health and hygiene, thereby naturally cultivating good habits for healthy eye care among the public, while also building brand trust and a long-term customer base.

B. Brand strategy

Centering on the “e-Universal” brand, the Company integrates Taiwan’s leading ophthalmic medical and optometric services to build a one-stop solution for vision health, based on Medical Optometry and Dual-Expert Precision, thus providing comprehensive, integrated solutions. To further enhance the customer experience, the Company has launched an exclusive e-commerce platform for prescription eyewear and eye care products, achieving seamless integration between online and offline services. This not only expands online points of contact, but also guides traffic to physical stores, thus enhancing both overall service efficiency and the customer experience.

To achieve long-term development objectives, the Company continues to optimize its operational capabilities and enhance the per-store productivity of its existing locations. Additionally, by leveraging the channel resources of partner clinics and implementing cross-marketing strategies, the Company is comprehensively strengthening its brand impact. Through continuous innovation and professional excellence, the Company is committed to leading the market and achieving its goal of becoming the leading brand in Taiwan’s vision optics industry.

(3) Impact of external competitive environment, regulatory environment, and overall business environment

While pursuing stable growth and enhanced operating efficiency, the Company also continues to systematically integrate ESG sustainable development into the corporate governance structure, operating strategies, and day-to-day management. Through systematic, concrete action, the Company is strengthening corporate resilience to create corporate value that is both long-term and sustainable.

Looking at corporate governance, in the 11th Corporate Governance Evaluation in 2025, the Company was ranked among the “Top 5% of TPEX-listed Companies” for a third straight year; and received the highest honor as a “Top 10% of Non-financial/electronic TWSE/TPEX-listed Companies with a Market Value of NT\$10 Billion or Above” for a second time. This highlights the Company’s outstanding performance in the four aspects of protecting shareholder rights and interests, board of directors’ operations, information transparency, and sustainable development. This year, the Company maintained its AA rating in the Morgan Stanley Capital International (MSCI) ESG Ratings. This represents one of the highest ratings among all listed companies, and makes the Company a standout among biotech stocks. These achievements make clear the Company’s outstanding performance in both sustainable governance and risk management, and have won the Company high praise in international capital markets.

In continued response to rapid changes in the external competitive environment and legal requirements, the Company also launched many governance and sustainability reinforcement measures for the first time in 2025. The Corporate Value Enhancement Plan has been formulated and submitted to the board of directors, to serve as the major guidance for medium- and long-term operations and capital allocations. In addition, this year’s in-person general shareholders meeting will adopt a simultaneous hybrid shareholders meeting mechanism. This will enhance shareholder participation and promote corporate governance. Also, in the event of disaster or other force majeure circumstances, such flexible participation options will help ensure that shareholder rights and interests remain unaffected.

Turning to environmental and climate risks, in 2025, the Company formally formulated its Environmental Management System and its Energy Management Plan. These will continue to strengthen the efficiency of energy usage and environmental management performance. Assessing the potential effects of climate change on the Company's finances and operations in a quantified way will serve as a major reference for future operational decision-making and risk management.

In terms of the social aspect, the Company is concerned with talent cultivation, care for employees, and protecting customers' rights and interests. The Company has formulated an Employment Training and Development Plan, aimed at enhancing employee career capacity; and the Company periodically holds Employee Satisfaction Surveys, in order to continuously optimize the working environment, enhance employee cohesion, and increase overall organizational efficiency. In addition, the Company has established a Personal Data Protection Policy, and with relation to topics such as the health and security of customers for products and services, marketing and labeling, etc., the Company has put in place a consumer protection policy and a complaint mechanism. These help ensure that customers' rights and interests receive appropriate protections.

Looking at continuous improvement for governance structures, the Company established the board of directors-level Sustainable Development Committee in 2025. This committee is responsible for overseeing the corporate sustainability strategy, policy formulation, and implementation status. This further strengthens the board of directors' oversight and strategy functions with regard to sustainability topics.

The Company will continue to respond to the changes in the external competitive environment, legal systems, and the overall operating environment. The Company will deepen the foundation for ESG governance, and strengthen its operating resilience and sustainable competitive advantages, in order to build long-term value for shareholders, employees, customers, and society as a whole, with stable operations as the core.

(4) Future Development Strategy

Universal Vision Biotechnology Co., Ltd. ("UVB") upholds the corporate philosophy inspired by the "Great Learning"—to manifest one's bright virtue, to love the people, and to pursue the highest good. UVB will continue to firmly advance long-term development for the eye care industry, with expert medical care as the core. The Company will continue to introduce advanced medical technologies and equipment that possess clinical value and market competitiveness. Through systematic training and operational support, the Company will help partner clinics enhance their quality of medical care, surgical efficiency, and overall customer satisfaction. All of this will help to further consolidate the Company's trusted reputation for medical expertise.

In terms of optometric services, UVB is integrating resources from the Company's self-operated optical stores and partner clinics, to deepen the "Medical Optometry, Scientific Eyewear Prescription" service model. By continuing to develop prescription processes and product service experiences with both high standards and strong reproducibility, UVB is providing consumers with eye health solutions that are more precise, more personalized, and hold greater long-term value. This is enhancing the customer's life-long service experience.

Going forward, UVB will use platform-based thinking to continue expanding service channels and operating models. UVB will integrate medical ophthalmology, optometric services, and eye health products to build an eye health ecosystem for the customer's entire lifespan, thus responding to long-term trends toward changes in the population structure and increasing market demand. The Company will continue to strengthen operational resilience and organizational efficiency, to maintain stable growth momentum. By moving toward the corporate vision of "See Clear, See Comfort, See the Future!", we will continue doing our utmost to be the primary force driving continued enhancement of Taiwan's eye health industry; and by doing this, we will create long-term, sustainable value for shareholders, customers, and society as a whole.

Chairperson: Ou Shu-Fang

II. Corporate governance report

1. Profiles of Directors, Supervisors, Presidents, Vice Presidents, Assistant Vice Presidents, Division Heads, and Branch Heads

(1) Director's name, nationality or place of registration, principal work experience and academic qualifications, shares held and nature:

March 30, 2026 Unit: shares; %

Title	Nationality or place of registration	Name	Gender/ Age (Note 2)	Date on which current position was assumed (elected)	Term of contract	Commencement date of the first term	Shares held at having assumed office / election		Current shares		Current shares held by spouse & minor children		Shares held through nominees		Principal work experience and academic qualifications	Position(s) held concurrently in the company and/or in any other company	Other officer, director or supervisor with a spousal or other 2nd degree of kinship			Remark (Note 1)
							Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding			Title	Name	Relation	
Chairperson	Taiwan	Quny Development Enterprise Co., Ltd.	-	June 19, 2024	3 years	June 28, 2012	7,515,138	8.87	7,515,138	8.87	-	-	-	-	PhD in Biomedical Engineering, Jinan University, China/ CEIBS Global EMBA/ Department of Chinese-Western Medicine, China Medical University/ Industrial Consultant of National Taiwan University Innovation and Incubator Center/ Supervising Physician of Global Budget Payment System Executive Committee-Taiwan Medical Association/ Ophthalmologist of Cardinal Tien Hospital/ Ophthalmologist of Taipei Municipal Zhongxiao Hospital/ Ophthalmologist of Cathay General Hospital	Independent Director, Member of Audit Committee and Member of Compensation and Remuneration Committee of Maywufa Company Ltd./ Independent Director, Member of Audit Committee, Member of Compensation and Remuneration Committee, Member of Sustainable Development of Gudeng Precision Industrial Co., LTD./ Vice Chairperson of National Association of Small & Medium Enterprise, R.O.C./ Director of Ten Outstanding Young Persons Foundation/ Honorary Executive Director, Global Federation of Chinese Business Women/ Honorary President, Global Federation of Chinese Business Women of Chinese Chairwomen Chapter/ Chairperson of Taipei Neihu Technology Park Development Association/ Director of Taiwan Listed Companies Association/ President of Taiwan Elite Entrepreneurs Association/ Director of Association for Industry Academia Development, NTU/ Vice President of Alumni Association, Leadership Succession Program, SEED, NTU/ Vice President of Taiwan Tai-Fu Startup Association/ Director of World Taiwanese Chambers of Commerce/ Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	Director	Lin Pi-Jung	Spouse	None
	Taiwan	Representative: Ou Shu-Fang	Female 61~70				3,282,895	3.87	2,895	-	19,274,713	22.75	3,280,000	3.87						
Director	Taiwan	Quny Development Enterprise Co., Ltd.	-	June 19, 2024	3 years	June 2, 2003	7,515,138	8.87	7,515,138	8.87	-	-	-	-	PhD in Biomedical Engineering, Jinan University, China/ College of Medicine, National Taiwan University/ EMBA, National Taiwan University/ Attending Physician, Department of Ophthalmology, National Taiwan University Hospital	Chairperson of BOOKS. COM CO., LTD./ Independent Director, Member of the Audit Committee, Member of Remuneration Committee of Simplo Technology Co., Ltd./ Independent Director, Member of Audit Committee and Member of Compensation and Remuneration Committee of BIONET Therapeutics Corp. Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	Chairperson	Ou Shu-Fang	Spouse	None
	Taiwan	Representative: Lin Pi-Jung	Male 61~70				19,274,713	22.75	19,274,713	22.75	2,895	-	-	-						

Title	Nationality or place of registration	Name	Gender/ Age (Note 2)	Date on which current position was assumed (elected)	Term of contract	Commencement date of the first term	Shares held at having assumed office / election		Current shares		Current shares held by spouse & minor children		Shares held through nominees		Principal work experience and academic qualifications	Position(s) held concurrently in the company and/or in any other company	Other officer, director or supervisor with a spousal or other 2nd degree of kinship			Remark (Note 1)
							Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding			Title	Name	Relation	
Director	Taiwan	Quny Development Enterprise Co., Ltd.	-	June 19, 2024	3 years	June 14, 2018	7,515,138	8.87	7,515,138	8.87	-	-	-	-	Ph.D., Graduate Institute of Education, National Chengchi University/ Master, Graduate Institute of Education, National Taiwan Normal University/ Bachelor, Department of Guidance & Counselling, National Changhua University of Education/ President of Hsing Wu University Administrative Deputy Minister, Ministry of Education/ Director-general, Department of Technological and Vocational Education, Ministry of Education/ Director-general, Department of Lifelong Education, Ministry of Education/	Professorial Chair of Cheng Shiu University	None	None	None	None
	Taiwan	Representative: Chou Tsan-Der	Male 71~80				-	-	-	-	-	-	-	-						
Director	Taiwan	Quny Development Enterprise Co., Ltd.	-	June 19, 2024	3 years	June 14, 2018	7,515,138	8.87	7,515,138	8.87	-	-	-	-	EMBA, College of Management, National Taiwan University/ Founding President, Global Federation of Chinese Business Women of Chinese Chairwomen Chapter/	Chairperson of WEB Point Co., Ltd./ Chairperson of LEECO OUTLET/ Chairperson of LEEUWENHOEK LABORATORIES CO. LTD./ Director of Turn Cloud Technology Service Inc./ Vice Chairperson of Landagent Real Estate Management Co., Ltd./ Managing Supervisor of Taiwan Chain Stores and Franchise Association/ Director of Taipei Culture Foundation/ President of Association for Industry Academia Development, NTU/ Honorary Chairperson of Taipei Neihu Technology Park Development Association/ Honorary Executive Director, Global Federation of Chinese Business Women/	None	None	None	None
	Taiwan	Representative: Weng Su-Hei	Female 61~70				-	-	-	-	-	-	-	-						

Title	Nationality or place of registration	Name	Gender/ Age (Note 2)	Date on which current position was assumed (elected)	Term of contract	Commencement date of the first term	Shares held at having assumed office / election		Current shares		Current shares held by spouse & minor children		Shares held through nominees		Principal work experience and academic qualifications	Position(s) held concurrently in the company and/or in any other company	Other officer, director or supervisor with a spousal or other 2nd degree of kinship			Remark (Note 1)
							Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding			Title	Name	Relation	
Director	Taiwan	Quny Development Enterprise Co., Ltd.	-	June 19, 2024	3 years	June 19, 2024	7,515,138	8.87	7,515,138	8.87	-	-	-	-	Master of Health Administration, Harvard T.H. Chan School of Public Health/ Master of Public Health, National Taiwan University/ Doctor of Medicine, College of Medicine, National Yang Ming University/ Deputy Minister, Department of Health, Executive Yuan/ Director-General, Bureau of National Health Insurance / Director-General, Centers for Disease Control, Department of Health, Executive Yuan/ President of Taiwan Global Biofund	Chairman of YFY Biotech Management Co., Ltd./ President of Micareo Taiwan Co., Ltd./ President of Eusol Biotech Co.,Ltd./ President of Xiang Yong Biotech Management Consulting Co., Ltd./ Independent Director of Maywufa Co, Ltd./ Vice Chairperson, Taiwan Research-Based Biopharmaceutical Manufacturers Association (TRPMA)/ Corporate Representative Director of TaiGen Pharmaceutical Research & Development Holdings Co., Ltd./ Corporate Representative Director of TaiGen Biotechnology Co., Ltd./ Corporate Representative Director of Taiwanania Capital Biotechnology Corporation/ Independent Director of TOT BIOPHARM/ Director of TCCD Angels Investment Co., Ltd./ Director of AmMax Bio Inc./ Adjunct Professor, National Yang Ming Chiao Tung University	None	None	None	None
	Taiwan	Representative: Chang Hong-Jen	Male 61~70	-	-	-	-	-	-	-	-	-	-							
Independent Director	Taiwan	Xiao Min-Zhi	Male 61~70	June 19, 2024	3 years	June 28, 2012	-	-	-	-	-	-	-	Department of Accounting, Tunghai University/ President of Sirtec International Co., Ltd.	President of Mayer Steel Pipe Corporation/ Director of Mei Kung Development Co., Ltd./ Supervisor of Mayer Inn Corporation/ Director of Mei Yi Construction Co., Ltd./ Director of LUEN JIN ENTERPRISE CO., LTD./ Director of Grand Tech Precision Manufacturing (Thailand) Corporation Limited Member of the Audit Committee, Member of the Remuneration Committee, Member of Nominating Committee and Member of Sustainable Development of UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	None	None	None	None	
Independent Director	Germany	Liu Vincent	Male 61~70	June 19, 2024	3 years	June 14, 2018	-	-	-	-	12,243	0.01	-	EMBA of National Chengchi University/ Vice President of LCY Chemical Corp./ Vice President, Electronic Materials Division, BASF, Germany/ Chief Marketing Officer of Clariant/ Director and President of Hoechst Taiwan Co., Ltd.	President of LCY Chemical Corp./ Member of the Audit Committee, Member of the Remuneration Committee, Member of Nominating Committee and Member of Sustainable Development of UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	None	None	None	None	

Title	Nationality or place of registration	Name	Gender/ Age (Note 2)	Date on which current position was assumed (elected)	Term of contract	Commencement date of the first term	Shares held at having assumed office / election		Current shares		Current shares held by spouse & minor children		Shares held through nominees		Principal work experience and academic qualifications	Position(s) held concurrently in the company and/or in any other company	Other officer, director or supervisor with a spousal or other 2nd degree of kinship			Remark (Note 1)
							Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding			Title	Name	Relation	
Independent Director	Taiwan	Yang Yun-Hua	Male 51-60	June 19, 2024	3 years	Aug. 27, 2021	-	-	-	-	-	-	-	-	Doctor of Laws, University of Tübingen, Germany/ Bachelor and Master of Laws, National Taiwan University/ Passed the Bar Senior Examination/ Law Amendment Member of Judicial Yuan/ Director of NCCU College of Law Center for Criminal Law/ Court Appraiser of Supreme Court/ Anti-corruption Member of Ministry of Justice Investigation Bureau/ Lectures at the Academy for the Judiciary and Judges Academy, Ministry of Justice/ Unjustified Review Member of Taiwan High Prosecutors Office Independent Director of YULON NISSAN MOTOR CO., LTD.	Professor of College of Law, National Chengchi University/ Member of Crime Prevention Research Center, Committee for the Judiciary, Ministry of Justice/ Law Amendment Member of Ministry of Justice/ Member of the Prisoner Transfer Committee, Ministry of Justice/ President of New Era Law Society/ Independent Director, Member of Audit Committee, Member of Remuneration Committee, Member of Sustainable Development of YULON MOTOR CO., LTD./ Member of the Audit Committee, Member of the Remuneration Committee, Member of Nominating Committee and Member of Sustainable Development of UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	None	None	None	None
Independent Director	Singapore	Chen Wei-Ru	Male 51-60	June 19, 2024	3 years	June 19, 2024	-	-	-	-	-	-	-	-	Doctor of Philosophy in Strategic Management, Purdue University, USA/ Master of Business Administration, Tamkang University/ Bachelor of Business Administration, National Taiwan University/ Independent Director, WPG Holdings Co., Ltd./ Independent Director, DIAN Diagnostics Group Co., Ltd.	Associate Professor of Strategy, China Europe International Business School (CEIBS)/ Independent Director, Oppl Lighting Co., Ltd./ Independent Non-Executive Director, Country Garden Services Holdings Company Limited/ Independent Non-Executive Director, Sinopharm Group Co. Ltd./ Independent Director, Jack Technology Co., Ltd./ Member of the Audit Committee, Member of the Remuneration Committee, Member of Nominating Committee and Member of Sustainable Development of UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	None	None	None	None

Note 1: If the Chairperson and the president or the person with the equivalent position (the top manager) of the Company are the same person, the spouse or first-degree relative of each other, the reasons, reasonableness, necessity, countermeasures (such as increasing the number of independent directors with more than half of the directors not concurrently serving as employees or managers, and other methods), and the relevant information shall be explained.

Note 2: The age is expressed in a range, such as 51-60 years old or 61-70 years old.

1. Major shareholders of the corporate shareholder that serves as the director

Table 1: Major Shareholders of Corporate Shareholders

March 30, 2026

Name of Corporate Shareholders	Major Shareholders of Corporate Shareholders	Rate of shareholding
Quny Development Enterprise Co., Ltd.	Chang Fu Investment Co., Ltd.	100%

Table 2: Table 1 Major shareholders of the Company's major corporate shareholders

March 30, 2026

Name of Corporate	Major shareholders of corporate	Rate of shareholding
Chang Fu Investment Co., Ltd.	Lin Pi-Jung	83.34%
	Ou Shu-Fang	8.33%
	Lin Ting-Yu	8.33%

2. Professional knowledge and independence of directors

(1) Disclosure of information on the professional qualifications of directors and supervisors, and the independence of independent directors:

Conditions Name	Professional qualification and experience (Note 1)	Status of independence (Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
Representative of Quny Development Enterprise Co., Ltd.: Chairperson Ou Shu-Fang	<p>Education: PhD in Biomedical Engineering, Jinan University, China/ CEIBS Global EMBA/ Department of Chinese-Western Medicine, China Medical University</p> <p>Current position: Chairperson of this Company/ Independent director, member of audit committee and member of Compensation and Remuneration Committee of Maywufa Company Ltd./ Independent Director, Member of Audit Committee, Member of Compensation and Remuneration Committee, Member of Sustainable Development of Gudeng Precision Industrial Co., LTD./ Vice Chairperson of National Association of Small & Medium Enterprise, R.O.C./ Director of Ten Outstanding Young Persons Foundation/ Honorary Executive Director, Global Federation of Chinese Business Women/ Honorary President, Global Federation of Chinese Business Women of Chinese Chairwomen Chapter/ Chairperson of Taipei NeiHu Technology Park Development Association/ Director of Taiwan Listed Companies Association/ President of Taiwan Elite Entrepreneurs Association/ Director of Association for Industry Academia Development, NTU/ Vice President of Alumni Association, Leadership Succession Program, SEED, NTU/ Vice President of Taiwan Tai-Fu Startup Association/ Director of World Taiwanese Chambers of Commerce</p> <p>Experience: Industrial Consultant of National Taiwan University Innovation and Incubator Center/ Supervising Physician of Global Budget Payment System Executive Committee-Taiwan Medical Association/ Ophthalmologist of Cardinal Tien Hospital/ Ophthalmologist of Taipei Municipal Zhongxiao Hospital/ Ophthalmologist of Cathay General Hospital</p>	There is no situation listed in Article 30 of the Company Act.	2
Representative of Quny Development Enterprise Co., Ltd.: Director Lin Pi-Jung	<p>Education: PhD in Biomedical Engineering, Jinan University, China/ College of Medicine, National Taiwan University/ EMBA, National Taiwan University</p> <p>Current position: CTO of this Company/ Chairperson of BOOKS. COM CO., LTD./ Independent Director, Member of the Audit Committee, Member of Remuneration Committee of Simplo Technology Co., Ltd./ Independent Director, Member of Audit Committee and Member of Compensation and Remuneration Committee of BIONET Therapeutics Corp.</p> <p>Experience: Part-time Attending Physician, Department of Ophthalmology, National Taiwan University Hospital</p>		2
Representative of Quny Development Enterprise Co., Ltd.: Director Chou Tsan-Der	<p>Education: Ph.D., Graduate Institute of Education, National Chengchi University/ Master, Graduate Institute of Education, National Taiwan Normal University/ Bachelor, Department of Guidance & Counselling, National</p>		0

Conditions Name	Professional qualification and experience (Note 1)	Status of independence (Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
	Changhua University of Education Current position: Professorial Chair of Cheng Shiu University Experience: President of Hsing Wu University/ Administrative Deputy Minister, Ministry of Education/ Director-general, Department of Technological and Vocational Education, Ministry of Education/ Director-general, Department of Lifelong Education, Ministry of Education		
Representative of Quny Development Enterprise Co., Ltd.: Director Weng Su-Hei	Education: EMBA, College of Management, National Taiwan University Current position: Chairperson of WEB Point Co., Ltd./ Chairperson of LEECO OUTLET/ Chairperson of LEEUWENHOEK LABORATORIES CO. LTD./ Director of Turn Cloud Technology Service Inc./ Vice Chairperson of Landagent Real Estate Management Co., Ltd./ Managng Supervisor of Taiwan Chain Stores and Franchise Association/ Director of Taipei Culture Foundation/ President of Association for Industry Academia Development, NTU/ Honorary Chairperson of Taipei Neihu Technology Park Development Association/ Honorary Executive Director, Global Federation of Chinese Business Women Experience: Founding President, Global Federation of Chinese Business Women of Chinese Chairwomen Chapter		0
Representative of Quny Development Enterprise Co., Ltd.: Director Chang Hong-Jen	Education: Master of Health Administration, Harvard T.H. Chan School of Public Health/ Master of Public Health, National Taiwan University/ Doctor of Medicine, College of Medicine, National Yang Ming University Current position: Chairman of YFY Biotech Management Co., Ltd./ PRESIDENT OF MICAREO TAIWAN CO., LTD./ President of Eusol Biotech Co.,Ltd./ President of Xiang Yong Biotech Management Consulting Co., Ltd./ Independent Director of Maywufa Co, Ltd./ Vice Chairperson, Taiwan Research-Based Biopharmaceutical Manufacturers Association (TRPMA)/ Corporate Representative Director of TaiGen Pharmaceutical Research & Development Holdings Co., Ltd./ Corporate Representative Director of TaiGen Biotechnology Co., Ltd./ Corporate Representative Director of Taiwan Capital Biotechnology Corporation/ Independent Director of TOT BIOPHARM/ Director of TCCD Angels Investment Co., Ltd./ Director of AmMax Bio Inc./ Adjunct Professor, National Yang Ming Chiao Tung University Experience: Deputy Minister, Department of Health, Executive Yuan/ Director-General, Bureau of National Health Insurance / Director-General, Centers for Disease Control, Department of Health, Executive Yuan/ President of Taiwan Global Biofund	There is no situation listed in Article 30 of the Company Act.	1

Name	Professional qualification and experience (Note 1)	Status of independence (Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
Xiao Min-Zhi Independent Director	<p><u>Education:</u> Department of Accounting, Tunghai University/ <u>Current position:</u> President of Mayer Steel Pipe Corporation/ Director of Mei Kung Development Co., Ltd./ Supervisor of Mayer Inn Corporation/ Director of Mei Yi Construction Co., Ltd./ Director of LUEN JIN ENTERPRISE CO., LTD./ Director of Grand Tech Precision Manufacturing (Thailand) Corporation Limited <u>Experience:</u> President of Sirtec International Co., Ltd.</p>	<p>(1) Not an employee of the Company or any of its affiliates. (2) Not a director or supervisor of the Company or any of its affiliates. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.) (3) Not a natural-person shareholder who holds shares, together with those held by the person's spouse, minor children, or held by the person under others' names, in an aggregate amount of 1% or more of the total number of issued shares of the Company or ranking in the top ten in holdings.</p>	0
Liu Vincent Independent Director	<p><u>Education:</u> EMBA of National Chengchi University/ <u>Current position:</u> President of LCY Chemical Corp. <u>Experience:</u> Vice President of LCY Chemical Corp./ Vice President, Electronic Materials Division, BASF, Germany/ Chief Marketing Officer of Clariant/ Director and President of Hoechst Taiwan Co., Ltd.</p>	<p>(4) Not a manager in preceding subparagraph (1) or a spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship, of any of the persons in the preceding subparagraph (2) and (3).</p>	0
Yang Yun-Hua Independent Director	<p><u>Education:</u> Doctor of Laws, University of Tübingen, Germany/ Bachelor and Master of Laws, National Taiwan University/ Passed the Bar Senior Examination <u>Current position:</u> Professor of College of Law, National Chengchi University/ Member of Crime Prevention Research Center, Committee for the Judiciary, Ministry of Justice/ Law Amendment Member of Ministry of Justice/ Member of the Prisoner Transfer Committee, Ministry of Justice/ President of New Era Law Society/ Independent Director, Member of Audit Committee, Member of Remuneration Committee, Member of Sustainable Development of YULON MOTOR CO., LTD. <u>Experience:</u> Law Amendment Member of Judicial Yuan/ Director of NCCU College of Law Center for Criminal Law/ Court Appraiser of Supreme Court/ Anti-corruption Member of Ministry of Justice Investigation Bureau/ Lectures at the Academy for the Judiciary and Judges Academy, Ministry of Justice/ Unjustified Review Member of Taiwan High Prosecutors Office/ Independent Director of YULON NISSAN MOTOR CO., LTD.</p>	<p>(5) Not a director, supervisor, or employee of a corporate shareholder who directly holds 5% or more of the total number of issued shares of the Company, or that ranks among the top five in shareholdings, or designates its representative to serve as a director or supervisor of the Company under Article 27(1) or (2) of the Company Act. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.) (6) Not a director, supervisor or employee of other company such that a majority of the Company's director seats or voting shares are controlled by the same person. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.) (7) The chairperson, president, or a person holding an equivalent position of the Company is not a director (or governor), supervisor, or employee of other company or institution, or are spouses. (Not applicable in cases where the</p>	1

Name \ Conditions	Professional qualification and experience (Note 1)	Status of independence (Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
Chen Wei-Ru Independent Director	<p>Education: Doctor of Philosophy in Strategic Management, Purdue University, USA/ Master of Business Administration, Tamkang University/ Bachelor of Business Administration, National Taiwan University</p> <p>Current position: Associate Professor of Strategy, China Europe International Business School (CEIBS)/ Independent Director, Opple Lighting Co., Ltd./ Independent Non-Executive Director, Country Garden Services Holdings Company Limited/ Independent Non-Executive Director, Sinopharm Group Co. Ltd./ Independent Director, Jack Technology Co., Ltd./</p> <p>Experience: Independent Director, WPG Holdings Co., Ltd./ Independent Director, DIAN Diagnostics Group Co., Ltd.</p>	<p>person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(8) Not a director (or governor), supervisor, manager, or shareholder holding five percent or more of the shares, of a specified company or institution that has a financial or business relationship with the Company. (Not applicable in cases where the specified company or institution holds at least twenty percent but not exceeding fifty percent of the total number of issued shares of the Company, and the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(9) Not a professional, sole proprietorship, partnership, business owner of a company or institution, partner, director, supervisor, manager, and the spouse thereof that provides audit or business, legal, financial, accounting, or other related services for which the cumulative amount of remuneration received in the last two years is less than NT\$500,000 for the Company or its affiliated companies. However, this shall not apply to the members of the Remuneration Committee, the Public Tender Offer Review Committee or the Special Committee on Mergers and Acquisitions who perform their functions and responsibilities in accordance with relevant provisions of the Securities and Exchange Act or the Business Mergers and Acquisitions Act.</p> <p>(10) Not a spouse of or a relative within the second degree of kinship with other directors.</p> <p>(11) There is no situation listed in Article 30 of the Company Act.</p> <p>(12) Not elected as a director on behalf of the government, a legal person, or the representative thereof under Article 27 of the Company Act.</p>	0

(2) Diversity and independence of the Board of Directors:

1. Diversity of the Board of Directors:

(1) Board diversity policy:

The Company has formulated the “Corporate Governance Practice Principles”, and the composition of the Board of Directors shall take diversity into consideration. In addition to the requirement that the number of directors who also serve as managers of the Company shall not exceed one-third of the director seats, the Company has also formulated an appropriate diversity policy according to its own operation, operating mode, and development needs, including but not limited to the standards in the following two dimensions:

- (1) Basic conditions and values: gender, age, nationality, culture, etc.
- (2) Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing, or technology), professional skills, and industry experience, etc.

In order to achieve the ideal goals of corporate governance, Board members must have the following relevant knowledge, skills, and literacy required to perform their duties:

- (1) Operation judgment abilities.
- (2) Accounting and financial analysis abilities.
- (3) Operations management abilities.
- (4) Crisis management abilities.
- (5) Industry knowledge.
- (6) International market perspective.
- (7) Leadership abilities.
- (8) Decision-making abilities.
- (9) Risk management knowledge and abilities.

(2) Board diversity status and objectives:

There are 9 directors for the 9th term of the Board of Directors of the Company. In addition to their abilities to lead decision-making, crisis management, risk management, international market perspective, etc., each member also possesses his/her own expertise in various fields for deep cultivation: The Chairperson Ou Shu-Fang and the director Lin Pi-Jung are both ophthalmologists; the director Chou Tsan-Der had been serving in the education and public affairs system for a long time, and used to be the administrative deputy minister of the Ministry of Education; the director Chang Hong-Jen currently serves as the Chairman of a biotechnology and medical company and has a background in public health and medicine; the director Weng Su-Hei as well as the independent directors Xiao Min-Zhi and Liu Vincent are all part of the core management team of the enterprise, and they specialize in the operational management of manufacturing and retail industries, leadership, and efficient decision-making, respectively; the independent director Yang Yun-Hua is a professor at the National Chengchi University College of Law and has a professional background in law; and the independent director Chen Wei-Ru is an Associate Professor of Strategy at China Europe International Business School (CEIBS) and serves as an Independent Director for several publicly listed companies in Mainland China. All members of the Board of Directors have the necessary capabilities to perform their duties.

The Company places great importance on the independence of the Board of Directors, with independent directors currently accounting for at least one-third (33%) of the total seats to ensure a sound board structure. Additionally, the Company is committed to promoting gender equality among board members, with the goal of increasing the proportion of female directors to at least one-third (33%).

The current Board of Directors consists of nine members, including five directors and four independent directors, with independent directors accounting for 4/9 (44%), achieving the established target. In terms of gender ratio, male directors account for 78% (7 members), whereas female directors account for 22% (2 members). Moving forward, the Company will continue its efforts to increase the number of female directors to achieve the goal of having at least one-third female representation on the Board.

(3) The implementation status of board diversity is set out as follows:

Core item Name Title	Basic composition								Industry experience					Professional skills					
	Nationality	Gender	Concurrentl y serving as an employee of the Company	Age			Term of independent director			Biotech- nology and medicine	Retail	Manufa cturing	Education	Legal affairs	Financial accounting	Law	IT	Marke ting	Risk Manage ment
				51 to 60	61 to 70	71 to 75	Less than 3 years	3 to 9 years	9 years or more										
Ou Shu-Fang Chairperson	ROC	Female			✓				✓	✓							✓	✓	
Lin Pi-Jung Director	ROC	Male	✓		✓				✓	✓				✓			✓	✓	
Chou Tsan-Der Director	ROC	Male				✓						✓						✓	
Weng Su-Hei Director	ROC	Female			✓					✓						✓	✓	✓	
Chang Hong-Jen Director	ROC	Male			✓				✓			✓			✓			✓	
Xiao Min-Zhi Independent director	ROC	Male			✓						✓			✓				✓	
Liu Vincent Independent director	German	Male			✓			✓			✓			✓				✓	
Yang Yun-Hua Independent director	ROC	Male		✓				✓				✓	✓		✓			✓	
Chen Wei-Ru Independent director	Singapore	Male		✓			✓			✓	✓	✓					✓	✓	

2. Independence of the Board of Directors:

(1) Board structure:

The Company has established a director selection system, ensuring that the nomination and election process for all directors is transparent and fair. The selection process complies with the Articles of Incorporation, the Director Election Procedures, the Corporate Governance Practice Principles, the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies, and Article 14-2 of the Securities and Exchange Act, among other relevant regulations.

The current Board of Directors consists of nine members, including four independent directors (44%) and five non-independent directors (56%). Among them, two non-independent directors have a spousal relationship (22%), which does not exceed half of the total board seats. Additionally, one non-independent director (11%) holds an employee position, complying with Article 26-3, Paragraph 3 of the Securities and Exchange Act.

(2) The Board of Directors is independent:

The Board of Directors of the Company shall guide the Company's strategy, supervise the management team, and be responsible to the Company and its shareholders. For all the operations and arrangements of its corporate governance system, it shall ensure that the Board of Directors shall exercise its functions and powers in accordance with laws and regulations, the Company's Articles of Incorporation, or the resolutions of the Shareholders Meeting.

The Company emphasizes the functions of independent operation and transparency of the Board of Directors. Directors and independent directors are all independent individuals and independently exercise their due powers. All the 4 independent directors serve as members of the Audit Committee in accordance with the law, reviewing the management and control of the Company's existing or potential risks, and accordingly supervising the fair presentation of the Company's financial statements and the effective implementation of internal controls.

Note 1: Professional qualifications and experience: Describe the professional qualifications and experience of individual directors. If they are members of the Audit Committee and have accounting or financial expertise, please state clearly their accounting or financial background and work experience, and also explain whether they are in various circumstances specified in the subparagraphs of Article 30 of the Company Act.

Note 2: For independent directors, their independence status shall be stated clearly, including but not limited to whether they, their spouse, or relatives within the second degree of kinship serve as directors, supervisors or employees of the Company or its affiliated companies; the number of and percentage in the Company's shares held by the directors themselves, their spouse, or relatives within the second degree of kinship (or in the name of others); whether they serve as directors, supervisors or employees of a company that has a specific relationship with the Company (please refer to the provisions of Article 3, Paragraph 1, Subparagraphs 5 to 8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies); the amount of remuneration received for providing business, legal, financial, accounting and other services to the Company or its affiliated companies in the last two years, and whether they are not in various circumstances specified in the subparagraphs of Article 30 of the Company Act.

(2) Profiles of Presidents, Vice Presidents, Assistant Vice Presidents, Division Heads, and Branch Heads:

March 30, 2026 Unit: shares; %

Title	Nationality	Name	Gender	Date on which current position was assumed (elected)	Shares		Shares held by spouse & minor children		Shares held through nominees		Principal work experience and academic qualifications	Position(s) held concurrently in any other company	Managerial officer with a spousal or other 2nd degree of kinship			Remark (Note 1)	
					Number of Shares	Rate of shareholding	Number of Shares	Rate of shareholding	Number of Shares	Rate of shareholding			Title	Name	Relation		
Managerial Officer	President	Taiwan	Lu Kenneth	Male	Feb. 1, 2010	9,000	0.01	-	-	-	-	Graduate Institute of Business Administration, National Taiwan University President of Giordano Taiwan	Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	None	None	None	None
	Director of Finance & Accounting Division	Taiwan	Sun Yu-Chiao	Female	Oct. 20, 2022	-	-	-	-	-	-	Graduate Institute of Accounting, Chung Yuan Christian University/ Assistant Vice President, Financial Department, Yellowstone Holding Co., Ltd./ Manager, Auditing Department, PwC Taiwan	None	None	None	None	None
	Director of Governance and Sustainable Development Office	Taiwan	Lien Su-Ping	Female	Apr. 11, 2022	-	-	-	-	-	-	Graduate Institute of Accounting, National Taiwan University/ CPA of Mao Chun CPA Firm Vice President of YFY Biotech Management Co., Ltd. (Yuen Foong Yu)	None	None	None	None	None
Management Team	Chief Technology Officer	Taiwan	Lin Pi-Jung	Male	Jan. 1, 2001	19,274,713	22.75	2,895	-	-	-	PhD in Biomedical Engineering, Jinan University, China/ College of Medicine, National Taiwan University/ EMBA, National Taiwan University Part-time Attending Physician, Department of Ophthalmology, National Taiwan University Hospital	Chairperson of BOOKS. COM CO., LTD./ Independent Director, Member of the Audit Committee, Member of Remuneration Committee of Simplo Technology Co., Ltd./ Independent Director, Member of Audit Committee and Member of Compensation and Remuneration Committee of BIONET Therapeutics Corp. Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	Chairperson	Ou Shu-Fang	Spouse	None
	Director of Optometry Business Division	Taiwan	Wu Hung-Yen	Male	June 1, 2009	20,000	0.02	-	-	-	-	Executive Master of Business Administration, NSYSU/ Regional Manager of Johnson & Johnson	None	None	None	None	None
	Senior Director of Ophthalmology Business Division	Taiwan	Liu Chun-Chieh	Male	Nov. 1, 2007	1,507	-	-	-	-	-	Graduate Institute of Public Health, National Taiwan University/ Biotechnology Specialist of N.T.U. Innovation Incubation Center	Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	None	None	None	None
	Director of Marketing Division	Taiwan	Yu Chien-Hsiang	Male	Sep. 1, 2012	-	-	-	-	-	-	Department of Information Management, Fu Jen Catholic University/ Manager of Marketing Planning Department of China Times	None	None	None	None	None
	Director of Human Resources & Administration Division	Taiwan	Chang Yu-Chi	Male	May 12, 2010	8,000	0.01	-	-	-	-	Department of Public Affairs, NCHU Deputy Human Resources Manager of An-Shin Food Services Co., Ltd.	Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	None	None	None	None
	Director of Store Expansion & Construction Division	Taiwan	Wang Yu-Chang	Male	Apr. 16, 2010	2,232	-	-	-	-	-	Department of Architectural Engineering, Nanya Institute of Technology/ Director of Expansion Business Department, Tsann Kuen Enterprise Co., Ltd.	None	None	None	None	None
	Director of Information System & Equipment Division	Taiwan	Hu Hung-Yi	Male	Apr. 27, 2009	-	-	-	-	-	-	Department of Information Science, Soochow University/ Information Manager of UL Taiwan	Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	None	None	None	None
	Chief Auditor of Audit Office	Taiwan	Lin Shu-Hsin	Female	Jan. 15, 2010	-	-	-	-	-	-	Department of Banking and Insurance, Hsing Wu College of Business/ Director of Audit Office, TONS Lightology Inc.	Please refer to "relevant information of affiliated enterprises" for details of employment in affiliated enterprises	None	None	None	None

Note 1: If the Chairperson and the president or the person with the equivalent position (the top manager) of the Company are the same person, the spouse or first-degree relative of each other, the reasons, reasonableness, necessity, countermeasures (such as increasing the number of independent directors with more than half of the directors not concurrently serving as employees or managers, and other methods), and the relevant information shall be explained.

2. Remuneration paid during the most recent year to directors, supervisors, president and vice presidents

(1) Remuneration to general directors and independent directors

Unit: NT\$ thousand

Title	Name	Remuneration to directors								The sum of A, B, C and D and proportion to net profit after tax		Remuneration received by directors for concurrent service as an employee						The sum of A, B, C, D, E, F and G and proportion to net profit after tax		Remuneration received from an invested company other than the company's subsidiary or parent company		
		Base compensation (A)		Retirement pay and pension (B)		Director profit-sharing compensation (C) (Note 1)		Expenses and perquisites (D)				Salary, rewards, and special disbursements (E)		Retirement pay and pension (F)		Employee profit-sharing compensation (G)						
		The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	Cash	Stock	Cash	Stock		The Company	All companies mentioned in the financial reports
Chairperson	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang	2,184	2,184	-	-	2,311	2,311	50	50	4,545 0.44%	4,545 0.44%	-	-	-	-	-	-	-	-	4,545 0.44%	4,545 0.44%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	962	962	58	58	-	-	-	-	3,381 0.32%	3,381 0.32%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Xiao Min-Zhi	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Liu Vincent	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Yang Yun-Hua	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Chen Wei-Ru	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None

- The remuneration policy, system, standard and structure of independent directors, and state clearly as well the relationship between the remuneration amount and their responsibilities, risks, time invested, and other factors:
The director remuneration of the Company is authorized to be determined by the Board of Directors according to the level of participation in the Company's operations and the value of their contributions as well as taking account of domestic industry standards in accordance with the provisions of the Company's Articles of Incorporation.
In addition, the Company's Articles of Incorporation also prescribes that director remuneration shall be distributed at a rate not higher than 3% of the profit for the year. However, if the Company still has accumulated losses, it shall make up for the loss.
Further, according to the organizational rules of the Company's Remuneration Committee, the performance evaluation and the director remuneration shall take account of the common standard in the industry, as well as considering the reasonableness of the relationship between that and individual performance, company operating performance, and future risks.
To sum up, the Company's director remuneration policy, system, standard and structure have a positive correlation with operating performance, which will also be reviewed in a timely manner based on the actual operating conditions as well as relevant laws and regulations so as to seek the balance between sustainable operation and risk control of the Company.
- Except as disclosed in the above table, the remuneration received by the directors of the Company for providing services to all the companies in the financial report in the most recent year (such as serving as a consultant, but not an employee thereof, for the parent company/all companies in the financial report/reinvested enterprises): None.

Note 1: The 2025 director remuneration was an estimate.

Classification of remuneration

Classification of Remuneration paid to directors	Name of Directors			
	Sum of the 4 Remunerations (A+B+C+D)		Sum of the 7 Remunerations (A+B+C+D+E+F+G)	
	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports
Less than NT\$1,000,000	None	None	None	None
NT\$1,000,000(inclusive) ~ NT\$2,000,000(exclusive)	None	None	None	None
NT\$2,000,000(inclusive) ~ NT\$3,500,000(exclusive)	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung (Director); Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der (Director); Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei (Director); Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Director); Xiao Min-Zhi (Independent Director); Liu Vincent (Independent Director); Yang Yun-Hua (Independent Director); Chen Wei-Ru (Independent Director)	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung (Director); Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der (Director); Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei (Director); Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Director); Xiao Min-Zhi (Independent Director); Liu Vincent (Independent Director); Yang Yun-Hua (Independent Director); Chen Wei-Ru (Independent Director)	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung (Director); Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der (Director); Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei (Director); Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Director); Xiao Min-Zhi (Independent Director); Liu Vincent (Independent Director); Yang Yun-Hua (Independent Director); Chen Wei-Ru (Independent Director)	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung (Director); Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der (Director); Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei (Director); Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Director); Xiao Min-Zhi (Independent Director); Liu Vincent (Independent Director); Yang Yun-Hua (Independent Director); Chen Wei-Ru (Independent Director)
NT\$3,500,000 (inclusive) ~ NT\$5,000,000(exclusive)	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang (Chairperson)	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang (Chairperson)	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang (Chairperson)	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang (Chairperson)
NT\$5,000,000(inclusive) ~ NT\$10,000,000(exclusive)	None	None	None	None
NT\$10,000,000(inclusive) ~ NT\$15,000,000(exclusive)	None	None	None	None
NT\$15,000,000(inclusive) ~ NT\$30,000,000(exclusive)	None	None	None	None
NT\$30,000,000(inclusive) ~ NT\$50,000,000(exclusive)	None	None	None	None
NT\$50,000,000(inclusive)~ NT\$100,000,000(exclusive)	None	None	None	None
Over NT\$100,000,000	None	None	None	None
Total	9 persons	9 persons	9 persons	9 persons

(2) Supervisor remuneration: On June 14, 2018, the Company changed the supervisor system to the Audit Committee system.

(3) Remuneration to President and Vice Presidents

Unit: NT\$ thousand

Title	Name	Salary (A)		Retirement pay and pension (B)		Rewards and special disbursements (C)		Employee profit-sharing compensation (D) (Note)				The sum of A, B, C and D and proportion to net profit after tax (%)		Remuneration received from an invested company other than the company's subsidiary or parent company
		The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company	All companies mentioned in the financial reports	The Company		All companies mentioned in the financial reports		The Company	All companies mentioned in the financial reports	
								Cash	Stock	Cash	Stock			
Chief Technology Officer	Lin Pi-Jung	962	962	58	58	-	-	-	-	-	-	1,020 0.10%	1,020 0.10%	None
President	Lu Kenneth	3,960	5,117	108	108	4,643	7,583	4,937	-	4,937	-	13,648 1.31%	17,745 1.70%	None

Note 1: It was estimated based on the equivalent distribution ratio of the previous year.

Classification of remuneration

Classification of Remuneration paid to President and Vice Presidents	Name of President and Vice Presidents	
	The Company	All companies mentioned in the financial reports
Less than NT\$1,000,000	None	None
NT\$1,000,000(inclusive) ~NT\$2,000,000(exclusive)	Lin Pi-Jung	Lin Pi-Jung
NT\$2,000,000(inclusive) ~NT\$3,500,000(exclusive)	None	None
NT\$3,500,000 (inclusive) ~NT\$5,000,000(exclusive)	None	None
NT\$5,000,000(inclusive) ~NT\$10,000,000(exclusive)	None	None
NT\$10,000,000(inclusive) ~NT\$15,000,000(exclusive)	Lu Kenneth	None
NT\$15,000,000(inclusive) ~NT\$30,000,000(exclusive)	None	Lu Kenneth
NT\$30,000,000(inclusive) ~NT\$50,000,000(exclusive)	None	None
NT\$50,000,000(inclusive)~NT\$100,000,000(exclusive)	None	None
Over NT\$100,000,000	None	None
Total	2 persons	2 persons

- (4) The Company shall disclose the remuneration of individual directors and supervisors in one of the following circumstances:
1. If there is a loss after tax in the parent company only or individual financial report for the last three years, the remuneration of individual directors and supervisors shall be disclosed. However, if the parent company only or individual financial report shows that there has been net profit after tax in the most recent year which is sufficient to cover the accumulated losses, this requirement is not applicable: None.
 2. If the director's shareholding ratio is insufficient for three or more consecutive months in the most recent year, the remuneration of individual directors shall be disclosed; If the supervisor's shareholding ratio is insufficient for three or more consecutive months in the most recent year, the remuneration of individual supervisor shall be disclosed: None.
 3. If the average pledge ratio of directors and supervisors for any three months in the most recent year is greater than 50%, the remuneration of individual directors and supervisors whose pledge ratio is greater than 50% in each of such month shall be disclosed: None.
 4. If all directors and supervisors receive remunerations for directors and supervisors of all companies in the financial report that account for more than 2% of the net profit after tax, and individual directors or supervisors receive remuneration exceeding NT\$ 15 million, the remuneration of such individual directors or supervisors shall be disclosed: None.
 5. A TWSE/TPEX listed company of which the corporate governance evaluation results in the most recent year rank in the lowest two tiers, or that has been subject to changes in trading methods, suspension of trading, or delisting from the TWSE/TPEX market in the most recent year and as of the date of publication of the annual report, or the Corporate Governance Evaluation Committee has resolved that the Company shall be excluded from evaluation: None.
 6. The average annual salary of the non-supervisory full-time employees of TWSE/TPEX companies in the most recent year has not reached NT\$500,000: None.
 7. If the TWSE/TPEX listed company had an increase of 10% or more in net profit after tax for the most recent year, but the average annual salary of its full-time non-management employees did not increase relative to the preceding fiscal year: None.
 8. If the TWSE/TPEX listed company had a decline in after-tax net income reaching 10% and exceeding NT\$5 million for the most recent year, as well as an increase in its average remuneration per director (excluding the remuneration for directors who are also employees) reaching 10% and exceeding NT\$100,000: None.
- (5) Remuneration of the Company's top five executives with the most remuneration: The Company is not in any of the circumstances specified in the preceding paragraph-1 or the preceding paragraph-5.
- (6) The name of the manager with distributed employee compensation in the most recent year (2025), and the distribution status:

December 31, 2025

Title		Name	Stock amount	Cash amount	Total	Percentage of the total amount in the net profit after tax (%)
Managerial Officer	President	Lu Kenneth	None	7,543 thousand (Note 1)	7,543 thousand (Note 1)	0.72%
	Director of Finance and Accounting Division	Sun Yu-Chiao				
	Director of Governance and Sustainable Development Office	Lien Su-Ping				

Note 1: It was estimated based on the equivalent distribution ratio of the previous year.

Note 2: On March 5, 2026, the Board of Directors of the Company approved that the total employee compensation for 2025 was in the amount of NT\$41,457 thousand, accounting for 3.98% of the net profit after tax.

(7) Compare and explain the analysis of the total remuneration paid to the directors, supervisors, the president, and Vice Presidents of the Company in the most recent two years by the Company and all companies in the consolidated financial statements as a percentage in the net profit after tax of the parent company only or individual financial reports, and explain the remuneration payment policy, standards and combinations, procedures for determining remuneration, and their relationship to operating performance and future risks.

1. Analysis of the percentage of the total remuneration paid by the Company and all companies in the consolidated statements to the Company's directors, president and Vice Presidents in the profit or loss after tax:

Item	The Company		All companies mentioned in the consolidated financial statements	
	2024	2025	2024	2025
Director	2.30%	2.35%	2.30%	2.35%
Supervisor	(Note)	(Note)	(Note)	(Note)
President and Vice President	1.38%	1.41%	1.62%	1.80%

Note: On June 14, 2018, the Company changed the supervisor system to the Audit Committee system.

2. The remuneration policy, standard and combination, the remuneration determination procedure, and the relationship between operating performance and future risks:

According to the Company's Articles of Incorporation, the Company shall distribute 1% to 10% of the profit of the current year as employee compensation; shall distribute no less than 10% of the said employee compensation to non-executive employees; and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses. Employee compensation may be in stock or cash, and the recipients of the stock or cash may include employees of subordinate companies who meet certain conditions. The distribution of employee remuneration and director remuneration will be implemented through a resolution passed by a majority of the directors at a Board meeting with at least two-thirds of the directors in attendance and will be reported to the shareholders meeting.

(1) Policies, standards, and packages of remuneration payment:

1. In accordance with Article 25-1 of the Company's Articles of Incorporation, the Company's Board of Directors is authorized to determine director remuneration based on the extent of the directors' participation in operations and the value of their contributions, taking into consideration the standards of domestic peers. Moreover, if the Company makes a profit for the current year, in accordance with Article 30 of the Company's Articles of Incorporation, the distribution of director remuneration shall not exceed 3% of the current year's profits.

The Company regularly evaluates director remuneration in accordance with the Board of Directors Performance Evaluation Guidelines. The important remuneration evaluation items are as follows. The distribution of director remuneration will be reviewed by the Remuneration Committee, then sent to the Board of Directors for a resolution and reported to the shareholders meeting:

- (1) Operational Performance: Considers comprehensive operational factors such as an approximate 4% growth in annual revenue and flat pre-tax net profit.
- (2) Annual Evaluation: The Company was ranked in the top 5% of TPEX-listed companies in the Corporate Governance Evaluation. Additionally, the annual performance assessments of the Board of Directors and functional committees demonstrated outstanding excellence.
- (3) Industry Standards: References the average remuneration of directors at peer TPEX-listed companies.

In summary, the overall operations of the Company's Board of Directors are sound, and the directors have demonstrated exceptional performance.

2. The manager remuneration of the Company adopts a remuneration policy that balances salary and bonuses, taking into account the salary standard for the position in the same industry, the scope of powers and responsibilities of the position in the Company, and the contribution level to the Company's operating goals.

The standard and combination of remuneration for the Company's managers is based on Work Rules 5.3 Salary, which specifies that it includes salaries, allowances, bonuses and other recurring payments of any kind. The salary is based on the grade of the position, and the year-end bonus shall be granted according to the Company's annual operation performance, financial status and personal performance in order to appreciate and reward the managers' efforts in their work. Moreover, in accordance with the Company's Articles of Incorporation, the Company shall distribute employees' compensation based on 1% to 10% of the Company's earnings for the year, and shall distribute no less than 10% of the said employee compensation to non-executive employees; which may be paid in the form of stock or cash.

- (2) Procedure for setting remuneration:
1. Procedure for setting director remuneration
 - (1) Director remuneration is periodically assessed based on the Company's Remuneration Policy, Standards and Structure, the Board Performance Evaluation Measures, and the results of the Corporate Governance Evaluation.
 - (2) The reasonableness of director remuneration is regularly reviewed by the Compensation Committee and the Board of Directors. In addition to considering individual contributions to the Company, the assessment also takes into account the Company's overall operational performance, industry trends, and future risks. The remuneration system is reviewed and adjusted as necessary in accordance with the Company's actual business conditions and relevant regulations.
 - (3) For the current year, director remuneration accounts for 2.35% of after-tax net profit. The actual amount distributed is reviewed by the Compensation Committee and approved by the Board of Directors.
 2. Procedure for setting manager remuneration
 - (1) The Company periodically evaluates manager salaries and remuneration, and conducts personnel and payroll cycle performance appraisals that apply to managers and employees in accordance with the relevant provisions of the Work Rules. In addition to considering the Company's overall operating performance, individual performance and degree of work goal achievement are also evaluated to serve as a reference for year-end bonuses and as an important basis for annual salary adjustment and promotions.
 - (2) Relevant appraisal data is properly classified and safekept by the Human Resources Department after being included in its personnel records.
 - (3) Year-end bonuses and employee remuneration are proposed by the Human Resources Department every year, submitted to the Remuneration Committee for review, and then submitted to the Board of Directors for approval. The proposal is then forwarded by the General Manager to the Chairperson for approval in accordance with the Operating Rules for the Payment of Year-end Bonuses and Employee Remuneration, and finally, the amount is distributed.
 - (3) Correlation between operating performance and future risks:
 1. The Company's Director Remuneration Policy and Its Relationship with Business Performance and Future Risks.

The Company's director remuneration policy is positively correlated with business performance and future risks. The review of remuneration standards and related systems is primarily based on the Company's overall operational status. Remuneration is determined by considering the directors' responsibilities, contributions, and business performance, ensuring that compensation aligns with corporate governance principles and enhances the efficiency of the Board of Directors.

2. The Company's payment of manager remuneration shall be based on operating performance, departmental risk management and control, etc. The manager's relevant performance appraisal and salary reasonableness shall not only refer to the individual's performance appraisal achievement rate and the extent of contribution to the Company's performance, but also the Company's overall operating performance as well as future risks and development trends in the industry, comprehensively considering the current achievements of corporate governance for providing reasonable remuneration so as to achieve a balance between the Company's sustainable operations and risk control.

The Company's procedures for goal setting and performance evaluation for managers are as follows:

- (1) Semi-annual action plans (project works and routine affairs)
- (2) Weekly, monthly and quarterly work progress management and tracking
- (3) Semi-annual work review form review and rating
- (4) The annual appraisal is implemented and scored based on the work items of the Work Objectives and Performance Appraisal Checklist (e.g., revenue expansion, gross profit achievement, cost control, routine affairs, and project completion), evaluation criteria KPIs, and work results. The performance score (grade 4-0) is then linked to the bonus payment.

The Company conducts managers' performance evaluation twice a year. The Company's revenue and profitability have been growing steadily in 2025, so the results of the 2025 managers' performance evaluation have met the objectives set. The Company's managers' performance objectives are integrated with risk management to ensure that possible risks within the scope of their duties are managed and controlled. The performance of important decisions made by the Company's management is reflected in the profitability of the Company, and the remuneration of managers is positively correlated with the performance of future risk management.

3. Operational status of corporate governance

(1) Operational status of the Board of Directors

The Board of Directors had held 6 meetings in 2025 and as of the date of publication of the annual report, and the attendance status of the directors was as follows:

Title	Name	Actual number of attendance	Attend through proxy	Actual attendance rate (%) (note)	Remark
Chairperson	Quny Development Enterprise Co., Ltd. Representative: Ou Shu-Fang	6	0	100%	Re-elected on June 19, 2024.

Title	Name	Actual number of attendance	Attend through proxy	Actual attendance rate (%) (note)	Remark
Director	Quny Development Enterprise Co., Ltd. Representative: Lin Pi-Jung	6	0	100%	Re-elected on June 19, 2024.
Director	Quny Development Enterprise Co., Ltd. Representative: Chou Tsan-Der	6	0	100%	Re-elected on June 19, 2024.
Director	Quny Development Enterprise Co., Ltd. Representative: Weng Su-Hei	6	0	100%	Re-elected on June 19, 2024.
Director	Quny Development Enterprise Co., Ltd. Representative: Chang Hong-Jen	6	0	100%	Newly-assumed on June 19, 2024.
Independent Director	Xiao Min-Zhi	6	0	100%	Re-elected on June 19, 2024.
Independent Director	Liu Vincent	6	0	100%	Re-elected on June 19, 2024.
Independent Director	Yang Yun-Hua	6	0	100%	Re-elected on June 19, 2024.
Independent Director	Chen Wei-Ru	6	0	100%	Newly-assumed on June 19, 2024.

Other items to be recorded:

- If the operation of the Board of Directors falls under any of the following circumstances, please state clearly the date, session, content of motions, opinions of all independent directors, and the Company's handling of the opinions of independent directors:

(1) Items set forth in Article 14-3 of the Securities and Exchange Act:

Date of Board meeting (session)	Content of motions and resolutions	Opinions of independent directors	The Company's handling of independent directors' opinions
Mar. 6, 2025 (The 5 th meeting of the 9th term)	Motion: Distribution of 2024 employee remuneration and director remuneration. Resolution: Passed by all directors in attendance.	None	None
	Motion: 2024 business report and financial statements. Resolution: Passed by all directors in attendance.	None	None
	Motion: 2024 earnings distribution. Resolution: Passed by all directors in attendance.	None	None
	Motion: Matters related to the Company's ex-dividend in 2025. Resolution: Passed by all directors in attendance.	None	None

	Motion: Appointment, remuneration, and independence assessment of the Company's certified public accountant in 2025. Resolution: Passed by all directors in attendance.	None	None
	Motion: Pre-approval of the 2025 provision of non-assurance services by the certified public accountant. Resolution: Passed by all directors in attendance.	None	None
	Motion: Proposal for short-term credit line set by the financial institution. Resolution: Passed by all directors in attendance.	None	None
	Motion: Establishment of the branch. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Articles of Incorporation." Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Procedures for Acquisition or Disposal of Assets." Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Procedures for Lending Funds to Other Parties." Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Rules of Procedure for Shareholders Meetings." Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Authority and Responsibility Matrix for Administrative Approvals." Resolution: Passed by all directors in attendance.	None	None
	Motion: The 2024 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter. Resolution: Passed by all directors in attendance.	None	None
	Motion: Convening the Company's 2025 general shareholders meeting. Resolution: Passed by all directors in attendance.	None	None
May 14, 2025 (The 6 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to March 31, 2025. Resolution: Passed by all directors in attendance.	None	None
	Motion: Proposal for short-term credit line set by the financial institution. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the "Human Resources and Payroll Cycle." Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the "Internal Audit System." Resolution: Passed by all directors in attendance.	None	None
	Motion: Payment of director remuneration. Resolution: Except for directors who recused themselves in accordance with the law, the motion was passed as proposed without objection after the chair consulted with the directors in attendance.	None	None
	Motion: Distribution of remuneration for managers and employees. Resolution: Passed by all directors in attendance.	None	None
	Motion: Change of the branch. Resolution: Passed by all directors in attendance.	None	None
Aug. 13, 2025 (The 7 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to June 30, 2025. Resolution: Passed by all directors in attendance.	None	None
	Motion: Proposal for short-term credit line set by the financial institution. Resolution: Passed by all directors in attendance.	None	None

	Motion: Establishment of the branch. Resolution: Passed by all directors in attendance.	None	None
	Motion: Change of the branch. Resolution: Passed by all directors in attendance.	None	None
	Motion: The Company's 2024 Sustainability Report. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's Corporate Governance Practice Principles. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's Sustainable Development Practice Principles. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's Nominating Committee Charter. Resolution: Passed by all directors in attendance.	None	None
	Motion: Establishment of the Company's Sustainable Development Committee and formulation of the Sustainable Development Committee Charter. Resolution: Passed by all directors in attendance.	None	None
	Motion: Appointment of members of the Company's 1 st Sustainable Development Committee. Resolution: Passed by all directors in attendance.	None	None
Nov. 12, 2025 (The 8 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to September 30, 2025. Resolution: Passed by all directors in attendance.	None	None
	Motion: Proposal for short-term credit line set by the financial institution. Resolution: Passed by all directors in attendance.	None	None
	Motion: Application for extension of the Company's endorsement and guarantee for its reinvested enterprise in Mainland China. Resolution: Passed by all directors in attendance.	None	None
	Motion: Establishment of the branch. Resolution: Passed by all directors in attendance.	None	None
	Motion: Ministry of Economic Affairs Company Major Seal safekeeper proposal. Resolution: Passed by all directors in attendance.	None	None
	Motion: Revision of the Company's "Research and Development Cycle." Resolution: Passed by all directors in attendance.	None	None
	Motion: Internal audit operation inspection plan for 2026. Resolution: Passed by all directors in attendance.	None	None
Dec. 18, 2025 (The 9 th meeting of the 9 th term)	Motion: 2026 operating plan. Resolution: Passed by all directors in attendance.	None	None
	Motion: Establishment of the branch. Resolution: Passed by all directors in attendance.	None	None
	Motion: 2025 year-end bonus payment criteria and payment amount for managers. Resolution: Passed by all directors in attendance.	None	None
Mar. 5, 2026 (The 10 th meeting of the 9 th term)	Motion: Distribution of 2025 employee remuneration and director remuneration. Resolution: Passed by all directors in attendance.	None	None
	Motion: 2025 business report and financial statements. Resolution: Passed by all directors in attendance.	None	None
	Motion: 2025 earnings distribution. Resolution: Passed by all directors in attendance.	None	None
	Motion: Matters related to the Company's ex-dividend in 2026. Resolution: Passed by all directors in attendance.	None	None
	Motion: Appointment, remuneration, and independence assessment of the Company's certified public accountant in 2026. Resolution: Passed by all directors in attendance.	None	None

Motion: Pre-approval of the 2026 provision of non-assurance services by the certified public accountant. Resolution: Passed by all directors in attendance.	None	None
Motion: Proposal for short-term credit line set by the financial institution. Resolution: Passed by all directors in attendance.	None	None
Motion: Establishment of the branch. Resolution: Passed by all directors in attendance.	None	None
Motion: The 2025 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter. Resolution: Passed by all directors in attendance.	None	None
Motion: Convening the Company's 2026 general shareholders meeting. Resolution: Passed by all directors in attendance.	None	None

(2) Except for the matters mentioned above, other matters resolved by the Board of Directors where independent directors expressed objections or reservations, with records or written statements: None.

2. Where director recusal is implemented due to conflict of interest, please state clearly the director's name, content of the motion, reason for recusal, and participation in the voting:

Date	Director's name	Content of motion	Reason for recusal	Participation in the voting
May 14, 2025	Ou Shu-Fang Lin Pi-Jung Chou Tsan-Der Weng Su-Hei Chang Hong-Jen Xiao Min-Zhi Liu Vincent Yang Yun-Hua Chen Wei-Ru	Payment of director remuneration.	Because this motion involves the determination of director remuneration, Chairperson Ou Shu-Fang, Director Lin Pi-Jung, Director Chou Tsan-Der, Director Weng Su-Hei, Director Chang Hong-Jen, Independent Director Xiao Min-Zhi, Independent Director Liu Vincent, Independent Director Yang Yun-Hua, and Independent Director Chen Wei-Ru all recused themselves in accordance with the law, and the Chairperson designated Independent Director Xiao Min-Zhi to act as the interim chair.	Except for directors who recused themselves in accordance with the law, the motion was passed as proposed without objection after the chair consulted with the directors in attendance.

3. Information on the evaluation cycle and period, evaluation scope, method, evaluation content, etc. of the board self-evaluation (or peer evaluation):

Evaluation cycle	Evaluation period	Evaluation scope	Evaluation method	Evaluation content
Implemented once a year	Jan. 1, 2025~ Dec. 31, 2025	Board of Directors	Board members self-evaluation	1. Extent of participation in Company operations 2. Improving the quality of Board decision-making 3. Board composition and structure 4. Selection and continuing education of directors 5. Internal control
Implemented once a year	Jan. 1, 2025~ Dec. 31, 2025	Individual directors	Board members self-evaluation	1. Understanding of the Company and awareness of responsibilities 2. Extent of participation in Company operations 3. Internal relationship management and communication 4. Professionalism and continuing education of directors 5. Internal control

Implemented once a year	Jan. 1, 2025~ Dec. 31, 2025	Audit Committee	Committee members self-evaluation	1. Extent of participation in Company operations 2. Awareness of committee responsibilities 3. Improving the quality of Board decision-making 4. Committee composition and member selection 5. Internal control
Implemented once a year	Jan. 1, 2025~ Dec. 31, 2025	Remuneration Committee	Committee members self-evaluation	1. Extent of participation in company operations 2. Understanding of committee responsibilities 3. Improving the quality of Board decision-making 4. Committee composition and member selection
Implemented once every 3 years	Aug. 1, 2022~ July 31, 2023	Board of Directors and functional committees	External evaluation institution	Eight major aspects including Board composition, guidance, authorization, supervision, communication, internal control and risk management, and self-discipline, etc.

4. Objectives for strengthening the functions of the Board of Directors in the current and the most recent year (for example, establishing the Audit Committee and improving information transparency) and evaluation of the implementation status:
- (1) The Company established the Remuneration Committee, the Audit Committee, the Nomination Committee, and the Sustainability Development Committee on October 17, 2011, June 14, 2018, June 23, 2022, and August 13, 2025, respectively, and formulated relevant organizational rules to assist the Board of Directors in fulfilling its supervisory responsibilities.
 - (2) As of the publication date of the Company's 2025 Annual Report, all proposals that should be submitted to the Audit Committee for approval before being submitted to the Board of Directors for resolutions in accordance with the provisions of the Company Act and the Securities and Exchange Act have been approved by the Audit Committee in accordance with the law and then submitted to the Board of Directors for resolutions and implementation.
 - (3) As of the publication date of the Company's 2025 Annual Report, all proposals that must be submitted to the Remuneration Committee for approval before being submitted to the Board of Directors for resolutions in accordance with the Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of a Company Whose Stock is Listed on the Taiwan Stock Exchange or the Taipei Exchange have been approved by the Remuneration Committee in accordance with the law and then submitted to the Board of Directors for resolutions and implementation.
 - (4) The Company has formulated and implemented the Rules of Procedure for Board of Directors Meetings in accordance with the Regulations Governing Procedure for Board of Directors Meetings of Public Companies.
 - (5) Board performance evaluation: In order to implement corporate governance, improve the functions of the Company's Board of Directors, and set performance targets to enhance the operational efficiency of the Board of Directors, the Company has formulated the Board of Directors Performance Evaluation Guidelines in accordance with the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies. These Guidelines are applicable to the entire Board of Directors, individual directors, and functional committees. The Company's Board of Directors Performance Evaluation Guidelines were formulated on March 29, 2017, and the latest revision was approved by the resolution of the Board of Directors on November 12, 2020.

(a) External evaluation: The Taiwan Corporate Governance Association was commissioned in July 2023 to perform the external board performance evaluation. This institution and the implementation experts have no business dealings with the Company and are independent. The external evaluation used questionnaires and on-site interviews to evaluate the operational performance of the Board of Directors. Through the review of the professional institution coupled with the guidance given by and communication with the evaluation committee members, the Company obtained professional and objective evaluation results and suggestions; the evaluation results have been used as a reference for the continued refinement of Board functions for the future so as to continuously refine and optimize the quality of deliberations.

The overall evaluation, recommendations of the external evaluators, and the Company's improvement plan are as follows:

General comments	
1.	The Company continues to strengthen corporate governance, and its corporate governance evaluation ranking among TWSE/TPEX Listed Companies continues to improve. According to the results of the 9th Corporate Governance Evaluation in 2022, the Company ranked among the top 5% of TPEX Listed Companies. This year, the Company has once again commissioned an independent professional institution to conduct an external evaluation of the Board of Directors, demonstrating the Board's proactive attitude toward implementing the corporate governance system and improving the effectiveness of the Board of Directors.
2.	The Company attaches great importance to the diversity of the composition of the Board of Directors, including gender, professional capabilities, and other factors. The selection of Board members requires consideration of corporate governance requirements, and suitable candidates are sought out based on the needs of the Company's development strategy. The Board of Directors consists of eight directors, including two female directors, making its Board composition superior to that of most TWSE/TPEX listed companies in Taiwan in terms of gender diversity. The Board members possess diverse industrial experience and complementary capabilities across industries, which aligns with the Company's need for business growth.
3.	The Chairperson of the Company respects the expertise and industry experience of the Board members and takes their opinions into account. The atmosphere of the Board meetings is good, and all Board proposals are fully discussed. Directors are also consulted about major proposals concerning the Company's development prior to the meeting, which improves efficiency of decision-making and also helps form a Board meeting culture of brainstorming.
4.	The Company's independent directors are all outstanding figures in the industry. The four independent directors are courageous in taking on their duties, and they actively participate in and contribute to the operation of the Board of Directors. In addition to exercising a supervisory function over the Board of Directors, the Audit Committee, and the Remuneration Committee, they also established the Nomination Committee in 2022. The Board of Directors and various functional committees all actively participate in project discussions related to the Company's strategies and provide guidance on corporate governance and business strategies, offering their full assistance.

Suggestions	The Company's improvement plan
<p>1. The Company arranged for senior executives to report to the first-time directors on information related to the Company's business and industry overview, submit regulatory advocacy materials that directors need to know to perform their duties, and provide directors with information on continuing education so as to assist first-time directors in familiarizing themselves with the Company's various business items and industry information in a timely manner. It is recommended that a "pre-onboarding orientation program for first-time directors" be formulated in consideration of the overall situation, where a dedicated person will give a briefing, provide regulations and rules in writing, arrange on-site visits to gain understanding, schedule necessary courses, etc. This will allow first-time directors to engage in Board operations more efficiently and smoothly exercise their functions to enhance the synergy of the Board of Directors.</p> <p>2. The Company has not yet established a reporting procedure for major incidents. It is recommended that the Company establish a clear whistleblowing system for incidental material information. The content must include the types of information for reporting, reporting time limits, reporting methods and levels, etc., to ensure that all Board members can swiftly and fully grasp the Company's important intelligence data, supervise the handling of major incidents in real time, and fulfill the Board's responsibility to guide and monitor the Company's operations.</p>	<p>1. The Company has arranged various sessions of regulatory advocacy as well as education and training for new directors, and the director of the Conference Affairs unit has introduced the Company's history, organization, and various business items to the directors. The Company will establish an orientation program based on the recommendations to assist first-time directors in familiarizing themselves with the Company's various business items, industry information and regulatory compliance in a timely manner.</p> <p>2. The Company has formulated the reporting procedures and response plans for major incidents, and will revise the reporting levels as recommended in the future so that all Board members can be informed of important information in a timely manner.</p>
<p>(b) Internal evaluation: The Conference Affairs unit is in charge of this evaluation, which is conducted in the form of questionnaires. The questionnaires are uniformly collected at the end of January every year, then the evaluation content is compiled into an evaluation results report and submitted to the Board meeting of the first quarter.</p>	

The results of the internal evaluation are as follows:

Overall performance evaluation of the Board of Directors		
Evaluation aspect	Score (note)	Evaluation result
Extent of participation in company operations	5	The result of the overall evaluation of the Board of Directors showed that the average score of the five major aspects was 5 points, indicating that the overall performance of the Company's Board of Directors was excellent.
Improving the quality of Board decision-making	5	
Board composition and structure	5	
Selection and continuing education of directors	5	
Internal control	5	

Director performance evaluation		
Evaluation aspect	Score (note)	Evaluation result
Understanding of the Company and awareness of responsibilities	5	The result of the director evaluation showed that the average score in the five major aspects reached 4.99 points, indicating that the overall operation of the Company's Board of Directors was sound.
Extent of participation in company operations	4.97	
Internal relationship management and communication	5	
Professionalism and continuing education of directors	5	
Internal control	5	

Performance evaluation of the Audit Committee		
Evaluation aspect	Score (note)	Evaluation result
Extent of participation in company operations	5	The self-evaluation results of the Audit Committee showed that the average score in the five major aspects was 5 points, indicating that the overall performance of the Company's Audit Committee was excellent.
Awareness of committee responsibilities	5	
Improving the quality of decision-making	5	
Committee composition and member selection	5	
Internal control	5	

Performance evaluation of the Remuneration Committee		
Evaluation aspect	Score (note)	Evaluation result
Extent of participation in company operations	5	The self-evaluation results of the Remuneration Committee showed that the average score in the four major aspects was 5 points, indicating that the overall performance of the Company's Remuneration Committee was excellent.
Awareness of committee responsibilities	5	
Improving the quality of decision-making	5	
Committee composition and member selection	5	

Note: The evaluation score is expressed as a range of 0–5 points, with 5 points being the maximum.

- (6) In order to assist directors in carrying out their duties and to enhance the effectiveness of the board of directors, the Company has established and implemented the "Standard Operating Procedures for Handling Directors' Requests" in accordance with the "Taiwan Stock Exchange Corporation Operation Directions for Compliance with the Establishment of Board of Directors by TWSE Listed Companies and the Board's Exercise of Powers".
- (7) The Company formulated the "Codes of Ethical Conduct" in accordance with the "Guidelines for the Adoption of Codes of Ethical Conduct for TWSE/TPEX Listed Companies", so that the conduct of directors of the Company can be subject to and conform to the ethical standards.
- (8) During the term of office, the directors of the current term continued to participate in the further education courses on the topic of corporate governance organized by the institutions designated by the "Directions for the Implementation of Continuing Education for Directors and Supervisors of TWSE Listed and TPEX Listed Companies".

Note: The actual attendance (participation) rate (%) was calculated based on the number of board meetings held and the number of actual attendance (participation) times of directors during their term of office.

(2) Information on the operational status of the Audit Committee

The purpose of the Audit Committee is to assist the Board of Directors in fulfilling its supervision over the quality and integrity of the Company's implementation of accounting, auditing, financial reporting processes, and financial controls.

1. The functions and powers of the Audit Committee and the annual work focus are set out as follows
 - (1) Assessment of the effectiveness of the internal control system:
 1. Review the Company's internal control policies and procedures.
 2. Review the self-assessment of each unit on the implementation and effectiveness of the internal control system as well as the implementation results of the audit unit's annual audit plan.
 - (2) Review of preparation for accounting statements:

It reviewed the Company's business report, earnings distribution, annual and mid-term financial statements.
 - (3) Appointment of certified public accountants:

It assessed the certified public accountants' independence, professionalism, and suitability, and assessed whether they are related persons, having business dealings or financial interests with the Company.
 - (4) Endorsement or provision of guarantee:

It reviewed the extension of the endorsement and guarantee provided by the Company to the reinvested company.
 - (5) Reviewed in accordance with Article 14-1 of the Securities and Exchange Act:

Review of the Company's amendments to the "Human Resources and Payroll Cycle", "Authority and Responsibility Matrix for Administrative Approvals", and "Research and Development Cycle".
 - (6) Reviewed in accordance with Article 36-1 of the Securities and Exchange Act:

Review of the Company's amendments to the "Procedures for Acquisition or Disposal of Assets" and the "Procedures for Lending Funds to Other Parties".

- (7) Review of the Implementation Rules for Internal Auditing:
Review of the Company's amendments to the "Internal Audit System."
 - (8) Internal audit operation inspection plan:
Deliberate on the Company's 2026 internal audit plan.
 - (9) Review the certified public accountant's provision of non-assurance services:
Advanced deliberation on the non-assurance service items provided by the Company's certified public accountants.
2. In 2025 and as of the date of publication of the annual report, the Audit Committee held 5 meetings, and the attendance or participation of independent directors was as follows:

Title	Name	Actual number of attendance	Attend through proxy	Actual attendance rate (%) (note)	Remark
Independent Director (Convener)	Xiao Min-Zhi	5	0	100%	Re-elected on June 19, 2024.
Independent Director	Liu Vincent	5	0	100%	Re-elected on June 19, 2024.
Independent Director	Yang Yun-Hua	5	0	100%	Re-elected on June 19, 2024.
Independent Director	Chen Wei-Ru	5	0	100%	Newly-assumed on June 19, 2024.

Other matters required to be recorded:

1. The main purpose of the operation of this committee is to supervise the following matters:
 - (1) Fair presentation of the Company's financial statements.
 - (2) Selection (dismissal) and remuneration of certified public accountants.
 - (3) Independence assessment of the certified public accountants.
 - (4) Effective implementation of the Company's internal control.
 - (5) Corporate compliance with relevant laws, regulations, and rules.
 - (6) The management and control of existing or potential risks of the Company.
2. The functions and powers of this committee are as follows:
 - (1) Establish or revise the internal control system in accordance with Article 14-1 of the Securities and Exchange Act.
 - (2) Evaluation of the effectiveness of the internal control system.
 - (3) Formulate or revise the handling procedures for significant financial and business acts of acquiring or disposing of assets, engaging in derivative transactions, lending funds to others, or endorsing or providing guarantees for others in accordance with Article 36-1 of the Securities and Exchange Act.
 - (4) Matters involving the interests of directors themselves.
 - (5) Significant asset or derivative transactions.
 - (6) Significant loans of funds, endorsement or provision of guarantee.
 - (7) Offering, issuance, or private placements of equity securities.
 - (8) Appointment, dismissal, or remuneration of certified public accountants.
 - (9) Appointment and removal of financial, accounting or internal audit supervisors.
 - (10) The annual and mid-term financial reports signed or stamped by the Chairperson, the manager, and the accounting supervisor.
 - (11) Other significant matters stipulated by the Company Act or the competent authority.

3. If the operation of the Audit Committee falls under any of the following circumstances, the date of the meeting of the Audit Committee, the session, the content of the motions, the content of any dissenting or qualified opinion or significant recommendation of the independent directors, the results of the resolutions of the Audit Committee, and the Company's handling of the Audit Committee's comments shall be stated clearly:

(1) Matters specified in Article 14-5 of the Securities and Exchange Act:

Date of Audit Committee meeting (session)	Date of Board meeting (session)	Content of motions and resolution	Objections, reservations, or major suggestions from independent directors	The Company's handling of the Audit Committee's opinions
March 6, 2025 (The 3 rd meeting of the 3 rd term)	March 6, 2025 (The 5 th meeting of the 9 th term)	Motion: 2024 business report and financial statements. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: 2024 earnings distribution. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Appointment, remuneration, and independence assessment of the Company's certified public accountant in 2025. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Pre-approval of the 2025 certified public accountant's provision of non-assurance services. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the Company's "Procedures for Acquisition or Disposal of Assets." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the Company's "Procedures for Lending Funds to Other Parties." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the Company's "Authority and Responsibility Matrix for Administrative Approvals." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: The 2024 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
May 14, 2025 (The 4 th meeting of the 3 rd term)	May 14, 2025 (The 6 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to March 31, 2025. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the "Human Resources and Payroll Cycle." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the "Internal Audit System." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
August 13, 2025 (The 5 th meeting of the 3 rd term)	August 13, 2025 (The 7 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to June 30, 2025. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.

November 12, 2025 (The 6 th meeting of the 3 rd term)	November 12, 2025 (The 8 th meeting of the 9 th term)	Motion: Consolidated financial statements from January 1 to September 30, 2025. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Application for extension of the Company's endorsement and guarantee for its reinvested enterprise in Mainland China. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Revision of the Company's "Research and Development Cycle." Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Internal audit operation inspection plan for 2026. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
March 5, 2026 (The 7 th meeting of the 3 rd term)	March 5, 2026 (The 10 th meeting of the 9 th term)	Motion: 2025 business report and financial statements. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: 2025 earnings distribution. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Appointment, remuneration, and independence assessment of the Company's certified public accountant in 2026. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: Pre-approval of the 2026 provision of non-assurance services by the certified public accountant. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
		Motion: The 2025 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter. Resolution: Passed by all committee members in attendance.	None	Passed by all directors in attendance.
<p>(2) Except for the foregoing matters, other matters that have not been approved by the Audit Committee but have been resolved by two thirds or more of all directors: None.</p> <p>4. For the implementation status of recusal of independent directors from proposals of interests, the name of the independent director, the content of the proposal, the reason for the recusal, and the voting status shall be stated clearly: None.</p> <p>5. Communication status between independent directors and internal audit supervisors and certified public accountants:</p> <p>(1) The certified public accountant shall explain to independent directors at least quarterly at the Audit Committee meeting about the impact on the Company in term of the Company's financial condition audited, as well as revisions and release of IFRSs bulletins.</p> <p>(2) In addition to regularly reporting to the Audit Committee on the implementation status of internal audit, the audit unit also reports to or talks with independent directors irregularly.</p> <p>(3) Independent directors, audit supervisors, and certified public accountants shall communicate directly by e-mail, telephone or other means as necessary.</p>				

(4) Communication status between independent directors and certified public accountants:

Meeting date	Communication focus	Communication results
March 6, 2025	<ul style="list-style-type: none">• Explanation of the financial report for Q4 2023• Replacement of the certified public accountant and assessment of the certified public accountant's independence.• Pre-approval review for the provision of non-assurance services	No comments at this meeting
May 14, 2025	<ul style="list-style-type: none">• Explanation of the financial report for Q1 2025	No comments at this meeting
August 13, 2025	<ul style="list-style-type: none">• Explanation of the financial report for Q2 2025	No comments at this meeting
November 12, 2025	<ul style="list-style-type: none">• Annual planning and related matters• Explanation of the financial report for Q3 2025	No comments at this meeting
March 5, 2026	<ul style="list-style-type: none">• Explanation of the financial report for Q4 2025• The certified public accountant's independence.• Pre-approval review for the provision of non-assurance services	No comments at this meeting

(5) Communication status between independent directors and internal audit director:

Meeting date	Communication focus	Communication results
March 6, 2025	<ul style="list-style-type: none">• Summary report on the implementation results and tracking results of the previous year's audit plan• Report on the implementation status of this year's audit plan• Communication on the audit implementation status of store operations and inventory• 2024 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter	No comments at this meeting
May 14, 2025	<ul style="list-style-type: none">• Report on the implementation status of the audit plan for Q1• Communication on the audit implementation status of store operations and inventory	No comments at this meeting
August 13, 2025	<ul style="list-style-type: none">• Report on the implementation status of the audit plan for Q2• Communication on the audit implementation status of store operations and inventory	No comments at this meeting
November 12, 2025	<ul style="list-style-type: none">• Report on the implementation status of the audit plan for Q3• Communication on the audit implementation status of store operations and inventory• Explanation of 2026 audit plan preparation	No comments at this meeting
March 5, 2026	<ul style="list-style-type: none">• Summary report on the implementation results and tracking results of the previous year's audit plan• Report on the implementation status of this year's audit plan• Communication on the audit implementation status of store operations and inventory• 2025 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter	No comments at this meeting

Note: The actual attendance rate (%) was calculated based on the number of Audit Committee meetings held and the number of actual attendances during their term of office.

(3) The operational status of corporate governance and its differences from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reasons thereof

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
1. Did the Company formulate and disclose its corporate governance best practice principles in accordance with the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies?	✓		The Company has established the “Corporate Governance Practice Principles” with reference to the “Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies”, which provides for the protection of shareholders’ rights and interests, strengthening the duties of the Board of Directors, exercising the roles of functional committees, respecting the rights and interests of stakeholders, and enhancing the transparency of information, etc. The Corporate Governance Best Practice Principles are also published on the Market Observation Post System and the Company’s website.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
2. The Company’s shareholding structure and shareholder equity				
(1) Did the Company formulate internal operating procedures to deal with shareholder suggestions, doubts, disputes and litigation matters, and implement them in accordance with the procedures?	✓		(1) The “Ethical Norms Advocacy and Whistleblowing system for Practitioners” has been announced on the Company’s website, and a dedicated unit has been established to deal with shareholders’ suggestions, doubts, disputes and litigation matters.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
(2) Did the Company have a list of the major shareholders who actually control the Company and the ultimate controllers of the major shareholders?	✓		(2) The Company regularly maintains a list of the top ten shareholders in shareholding.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
(3) Did the Company establish and implemented risk control and firewall mechanisms with affiliated companies?	✓		(3) The Company has established the “Regulations Governing Financial and Business Transactions Between Related Parties and Specific Companies”, “Subsidiary Supervision Procedures”, “Procedures for Acquisition or Disposal of Assets”, “Procedures for Lending Funds to Other Parties”, and “Procedures for Endorsements and Guarantees” as part of its management mechanism for transactions with related parties. The Company has faithfully implemented these procedures to establish a firewall against non-arm’s-length transactions.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
(4) Did the Company formulate internal norms that prohibit company insiders from using unpublished information on the market to buy and sell securities?	✓		(4) The Company has formulated the “Internal Material Information Handling Procedures” as the basis for the Company’s material information processing and disclosure mechanism. The Company also reviews these guidelines from time to time to comply with current laws and regulations as well as to meet practical needs for management, and regularly conducts advocacy to directors (monthly), managers and employees (quarterly) on the prevention of insider trading.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
3. Composition, functions and responsibilities of the Board of Directors (1) Did the Board of Directors formulate a diversity policy, specific management goals and guidelines, and implement them?	✓		(1) Article 20 of the Company’s “Corporate Governance Practice Principles” clearly stipulates that the composition of the Board of Directors shall take into account the policy of diversification. In addition to the basic qualifications, there are also criteria of professional literacy and skills, and management capabilities for the purpose of comprehensive supervision. The Company has effectively achieved its board diversity objectives. The current Board of Directors is composed of nine members, including four independent directors who account for 44% of the total seats—exceeding the established target of one-third (33%). In	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>terms of gender distribution, 78% (seven) of the directors are male and 22% (two) are female. Moving forward, the Company will continue striving to increase the number of female directors in order to achieve the goal of having female representation exceed one-third of the board. Additionally, the professional backgrounds of board members encompass a wide range of core areas, including but not limited to operational judgment, business management, leadership and decision-making, crisis management, risk management, industry knowledge, financial accounting, legal affairs, marketing, and international market insight. Based on a review of the members' key academic and professional experiences, the board has achieved a 100% compliance rate with these core diversity competencies.</p> <ol style="list-style-type: none"> Two directors are aged between 51 and 60; six directors are aged between 61 and 70; one director is aged between 71 and 75. The four independent directors serve on the 4th, 3rd, 2nd, and 1st term of the Board, respectively. In the 9th term of the Company's Board of Directors, in addition to their ability to lead decision-making, crisis management, risk management, international market perspective, etc., each member also possess his/her own expertise in various fields for deep cultivation: The Chairperson Ou Shu-Fang and the director Lin Pi-Jung are both ophthalmologists; the director Chou Tsan-Der had been serving in the education and public affairs system for a long time, and used to be the administrative deputy minister of the Ministry of Education; the director Weng Su-Hei as well as the two independent directors Xiao Min-Zhi, and Liu Vincent are all in the core management team of the enterprise, and they have been specializing in the operations management in the manufacturing and retail industries for a long time, leadership, and efficient decision-making respectively; and the independent director Yang Yun-Hua is a professor at the National Chengchi University College of Law and has a 	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
(2) In addition to the Remuneration Committee and the Audit Committee set up in accordance with the law, Did the Company voluntarily set up other various functional committees?	✓		<p>professional background in law; and the independent director Chen Wei-Ru is an Associate Professor of Strategy at China Europe International Business School (CEIBS) and serves as an Independent Director for several publicly listed companies in Mainland China. All members of the Board of Directors have the necessary capabilities to perform their duties.</p> <p>3. The Company has achieved the specific target of the diversity policy.</p> <p>(2) In addition to the establishment of the Remuneration Committee and the Audit Committee in accordance with the law, the Company also voluntarily establishes the Nominating Committee and Sustainable Development Committee.</p>	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
(3) Did the Company formulate the performance evaluation guidelines and evaluation methods of the Board of Directors, conduct performance evaluations annually and regularly, and report the results of performance evaluation to the Board of Directors, and use them as a reference for the remuneration and nomination of individual directors?	✓		<p>(3) According to the Company's "Board of Directors Performance Evaluation Guidelines", the performance evaluation of the Board of Directors, directors, and various functional committees (Remuneration Committee and Audit Committee) for the previous year shall be completed in the first quarter of each year.</p> <p>1. The evaluation is conducted by the deliberation unit by means of questionnaires. The evaluation report is reported to the Board of Directors after all the evaluation results are compiled.</p> <p>2. The evaluation report has been reported to the Board of Directors on March 5, 2026. The 2025 measurement items and evaluation results are:</p> <p>(1) The measurement items of the self-assessment of the performance of the Board of Directors include the five major aspects: "extent of participation in Company operations," "improving the quality of Board</p>	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>decision-making,” “Board composition and structure,” “selection and continuing education of directors,” and “internal control.” The assessment results indicated that the overall performance of the Company’s Board of Directors was excellent.</p> <p>(2) The measurement items for the self-assessment of board members include the five major aspects: “understanding of the Company and awareness of responsibilities,” “extent of participation in Company operations,” “internal relationship management and communication,” “director’s professionalism and continuing education,” and “internal control.” The assessment results indicate that the overall operation of the Company’s Board of Directors was sound.</p> <p>(3) The measurement items for the self-assessment of the operational performance of the functional committees include the five major aspects: “extent of participation in Company operations,” “awareness of the responsibilities of the Audit Committee and the Remuneration Committee,” “improving the quality of decision-making of the Audit Committee and the Remuneration Committee,” “composition and selection of members of the functional committees,” and “internal control.” The assessment results indicate that the overall performance of the Company’s functional committees was excellent.</p> <p>3. The results of the performance evaluation of the Board of Directors are used as the reference basis for the selection or nomination of directors; the performance evaluation results of individual directors are used as the reference basis for determining their individual remuneration.</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof																					
	Yes	No	Summary description																						
(4) Did the Company regularly assess the independence of the certified public accountant?	✓		<p>(4) The Company's Audit Committee evaluates the independence and competency of its certified public accountants every year. In addition to requiring the certified public accountants to provide the Statement of Independence of Certified Public Accountants and the Audit Quality Indicators (AQIs), it also conducts the evaluation in accordance with the criteria in Note 1 and the AQI indicators in Note 2. It is confirmed that the certified public accountants have no other financial interests and business relationships with the Company except for attestation fees, business and corporate registration fees, and financial and tax service fees and that the accountants' family members also do not violate the independence requirements. By reference to the AQI indicator information, it is also confirmed that numerous indicators are superior compared with the average standard of the peer industry. The evaluation results of the most recent year were discussed and approved by the Audit Committee on March 5, 2026, and submitted to the Board of Directors on March 5, 2026, for a resolution to pass the evaluation of the independence and competency of the accountants.</p> <p>Note 1: Important evaluation items for accountants' independence and suitability</p> <table border="1"> <thead> <tr> <th>Evaluation items</th> <th>Evaluation results</th> <th>Conformed or not</th> </tr> </thead> <tbody> <tr> <td>As of the latest attestation operation, whether the CPAs have not been changed for 7 years</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Whether the CPAs have a material financial interest in the Company</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Whether the CPAs avoid any inappropriate relationship with the Company</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Whether the CPAs ensure the integrity, impartiality, and independence of their assistants</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Whether the CPAs have audited and attested the financial statements of the service organization within 2 years before assuming their position</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Whether the names of the CPAs have been used by others</td> <td>No</td> <td>Yes</td> </tr> </tbody> </table>	Evaluation items	Evaluation results	Conformed or not	As of the latest attestation operation, whether the CPAs have not been changed for 7 years	No	Yes	Whether the CPAs have a material financial interest in the Company	No	Yes	Whether the CPAs avoid any inappropriate relationship with the Company	Yes	Yes	Whether the CPAs ensure the integrity, impartiality, and independence of their assistants	Yes	Yes	Whether the CPAs have audited and attested the financial statements of the service organization within 2 years before assuming their position	No	Yes	Whether the names of the CPAs have been used by others	No	Yes	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
Evaluation items	Evaluation results	Conformed or not																							
As of the latest attestation operation, whether the CPAs have not been changed for 7 years	No	Yes																							
Whether the CPAs have a material financial interest in the Company	No	Yes																							
Whether the CPAs avoid any inappropriate relationship with the Company	Yes	Yes																							
Whether the CPAs ensure the integrity, impartiality, and independence of their assistants	Yes	Yes																							
Whether the CPAs have audited and attested the financial statements of the service organization within 2 years before assuming their position	No	Yes																							
Whether the names of the CPAs have been used by others	No	Yes																							

Evaluation item	Operational status					Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof																						
	Yes	No	Summary description																									
			Whether the CPAs hold shares in the Company and its affiliated companies	No	Yes																							
			Whether the CPAs have any monetary loans with the Company and its affiliated companies	No	Yes																							
			Whether the CPAs have a joint investment or interest-sharing relationship with the Company and its affiliated companies	No	Yes																							
			Whether the CPAs concurrently and regularly work for the Company or its affiliated companies, receive a fixed salary, or serve as directors or supervisors	No	Yes																							
			Whether the CPAs are involved in the management function of the Company or its affiliated companies and can make decisions	No	Yes																							
			Whether the CPAs concurrently operate other businesses that may compromise their independence	No	Yes																							
			Whether the CPAs have the relationship of spouse, direct blood relative, direct relative by marriage, or second degree blood relative with the management personnel of the Company	No	Yes																							
			Whether the CPAs charge any commissions related to the business	No	Yes																							
			As of now, whether the CPAs have been subject to disciplinary action, or have been in circumstances that compromise the principle of independence	No	Yes																							
			<p>Note 2: Assessment Items of the Audit Quality Indicators (AQI Report):</p> <table border="1"> <thead> <tr> <th>Assessment Items</th> <th>Whether Assessed</th> </tr> </thead> <tbody> <tr> <td colspan="2">Dimension 1: Professional Competence</td> </tr> <tr> <td>Indicator 1-1: Audit Experience</td> <td>Yes</td> </tr> <tr> <td>Indicator 1-2: Training Hours</td> <td>Yes</td> </tr> <tr> <td>Indicator 1-3: Staff Turnover Rate</td> <td>Yes</td> </tr> <tr> <td>Indicator 1-4: Professional Support</td> <td>Yes</td> </tr> <tr> <td colspan="2">Dimension 2: Quality Control</td> </tr> <tr> <td>Indicator 2-1: Auditor Workload</td> <td>Yes</td> </tr> <tr> <td>Indicator 2-2: Audit Input</td> <td>Yes</td> </tr> <tr> <td>Indicator 2-3: Engagement Quality Control Review (EQCR) Execution</td> <td>Yes</td> </tr> </tbody> </table>			Assessment Items	Whether Assessed	Dimension 1: Professional Competence		Indicator 1-1: Audit Experience	Yes	Indicator 1-2: Training Hours	Yes	Indicator 1-3: Staff Turnover Rate	Yes	Indicator 1-4: Professional Support	Yes	Dimension 2: Quality Control		Indicator 2-1: Auditor Workload	Yes	Indicator 2-2: Audit Input	Yes	Indicator 2-3: Engagement Quality Control Review (EQCR) Execution	Yes			
Assessment Items	Whether Assessed																											
Dimension 1: Professional Competence																												
Indicator 1-1: Audit Experience	Yes																											
Indicator 1-2: Training Hours	Yes																											
Indicator 1-3: Staff Turnover Rate	Yes																											
Indicator 1-4: Professional Support	Yes																											
Dimension 2: Quality Control																												
Indicator 2-1: Auditor Workload	Yes																											
Indicator 2-2: Audit Input	Yes																											
Indicator 2-3: Engagement Quality Control Review (EQCR) Execution	Yes																											

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof																		
	Yes	No	Summary description																			
			<table border="1"> <tr> <td>Indicator 2-4: Quality Control Support Capability</td> <td>Yes</td> </tr> <tr> <td colspan="2">Dimension 3: Independence</td> </tr> <tr> <td>Indicator 3-1: Non-audit Services</td> <td>Yes</td> </tr> <tr> <td>Indicator 3-2: Client Familiarity</td> <td>Yes</td> </tr> <tr> <td colspan="2">Dimension 4: Supervision</td> </tr> <tr> <td>Indicator 4-1: External Inspection Findings and Disciplinary Actions</td> <td>Yes</td> </tr> <tr> <td>Indicator 4-2: Improvements Required by Competent Authorities</td> <td>Yes</td> </tr> <tr> <td colspan="2">Dimension 5: Innovation Capability</td> </tr> <tr> <td>Indicator 5-1: Innovation Planning or Initiatives</td> <td>Yes</td> </tr> </table>	Indicator 2-4: Quality Control Support Capability	Yes	Dimension 3: Independence		Indicator 3-1: Non-audit Services	Yes	Indicator 3-2: Client Familiarity	Yes	Dimension 4: Supervision		Indicator 4-1: External Inspection Findings and Disciplinary Actions	Yes	Indicator 4-2: Improvements Required by Competent Authorities	Yes	Dimension 5: Innovation Capability		Indicator 5-1: Innovation Planning or Initiatives	Yes	
Indicator 2-4: Quality Control Support Capability	Yes																					
Dimension 3: Independence																						
Indicator 3-1: Non-audit Services	Yes																					
Indicator 3-2: Client Familiarity	Yes																					
Dimension 4: Supervision																						
Indicator 4-1: External Inspection Findings and Disciplinary Actions	Yes																					
Indicator 4-2: Improvements Required by Competent Authorities	Yes																					
Dimension 5: Innovation Capability																						
Indicator 5-1: Innovation Planning or Initiatives	Yes																					
4. Did the TWSE/TPEX listed company have a competent and appropriate number of corporate governance personnel, and appoint a corporate governance supervisor to be in charge of corporate governance related affairs (including but not limited to providing directors and supervisors with the information required for business execution, assisting directors and supervisors in following laws and regulations, handling matters related to the meetings of the Board of Directors and Shareholders Meetings, and making minutes of the Board of Directors and Shareholders Meetings)?	✓		<p>In order to implement corporate governance, protect shareholders' rights and interests as well as strengthen the functions of the Board of Directors, the Company's Board of Directors resolved on March 30, 2022 to appoint Division Head Lien Su-Ping as the Company's full-time corporate governance officer and to establish the "Governance and Sustainable Development Office" as a dedicated corporate governance unit. Division Head Lien is qualified to practice as a CPA and is the manager of the Company.</p> <p>Corporate governance officer's duty scope includes the following matters:</p> <ol style="list-style-type: none"> 1. Conducting meetings of the board of directors and shareholders' meetings in accordance with the law. 2. Preparing minutes of board meetings and shareholders' meetings. 3. Assisting directors in their appointment and continuing education. 4. Providing information necessary for directors to perform their operations. 5. Assisting directors in complying with laws and regulations. 6. Reporting to the Board of Directors on the officer's inspection results regarding whether independent directors' nominations and elections are in compliance with the law and regulations. 7. Handling matters related to director changes. 8. Other matters in accordance with the Company's Articles of Incorporation or contracts or / and corporate governance-related matters. 	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.																		

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof										
	Yes	No	Summary description											
			<p>A summary of business operations for 2025 is as follows:</p> <ol style="list-style-type: none"> Continued to promote the greenhouse gas inventory and verification schedule, with quarterly progress reports submitted to the Board of Directors for monitoring. Continued to promote “ethical corporate management” and “insider trading prevention,” with quarterly training sessions (in January, April, July, and October) on integrity and insider trading prevention. The Company reports to the Board of Directors at least once a year on matters including the implementation of ethical corporate management, sustainability practices, stakeholder engagement, and intellectual property management linked to business goals. These reports were presented to the Board on May 14, 2025. The 2024 Sustainability Report was prepared, with both Chinese and English versions, and was submitted to and approved by the Board of Directors on August 13, 2025. The report was subsequently disclosed on the Market Observation Post System on August 14, 2025, and published on the Company’s website on October 22, 2025. Amended the Ethical Corporate Management Best Practice Principles and the Sustainable Development Practice Principles; these were submitted to and passed by the Board of Directors on August 13, 2025. On November 12, 2025, a report on “Risk Management Operations for 2025” was presented to the Audit Committee and the Board of Directors. Conducted operations related to the 2025 Corporate Governance Evaluation. <p>The following is the status of the corporate governance officer's continuing education for the year 2025:</p> <table border="1"> <thead> <tr> <th>Course Date</th> <th>Organizers</th> <th>Course Name</th> <th>Course hours</th> <th>Total hours</th> </tr> </thead> <tbody> <tr> <td>Feb. 21, 2025</td> <td>Corporate Organization Association</td> <td>Taiwan’s Implementation of Sustainable Development Policies and Securities-Related Laws and Regulations</td> <td>3</td> <td>12</td> </tr> </tbody> </table>	Course Date	Organizers	Course Name	Course hours	Total hours	Feb. 21, 2025	Corporate Organization Association	Taiwan’s Implementation of Sustainable Development Policies and Securities-Related Laws and Regulations	3	12	
Course Date	Organizers	Course Name	Course hours	Total hours										
Feb. 21, 2025	Corporate Organization Association	Taiwan’s Implementation of Sustainable Development Policies and Securities-Related Laws and Regulations	3	12										

Evaluation item	Operational status					Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof	
	Yes	No	Summary description				
			June 30, 2025	Taipei Exchange	Sharing Session on Investor Relationship Management	3	
			Aug. 22, 2025	Chinese National Association of Industry and Commerce	2025 TS Holdings Net Zero Summit	3	
			Sep. 25, 2025	Corporate Organization Association	Corporate Governance and Securities Regulations-Case Study on Corporate Governance and Compliance	3	
5. Did the Company establish communication channels with stakeholders (including but not limited to shareholders, employees, clients, and suppliers), set up a special area for stakeholders on the Company's website, and appropriately respond to important corporate social responsibility issues of concern to stakeholders?	✓		<p>The Company has established a Stakeholder Area, "Contact Us" e-mail box, internal Employee Mailbox, Reporting Mailbox, Customer Service Hotline, etc. on the Company's website to provide communication channels for shareholders, investors, employees, customers, suppliers, competent authorities, communities/social groups, media, banks, etc., and dedicated personnel will respond to the issues of concern to stakeholders. Through appropriate communication with stakeholders, the Company gets to know the reasonable expectations and needs of stakeholders as well as the important corporate social responsibility issues of concern to them, and the Company incorporates these issues into the basis for formulating its future management policies and operational activities.</p> <p>The latest communication status with stakeholders was reported to the Board of Directors on May 14, 2025.</p> <p>The content of important issues related to corporate social responsibility that is of concern to stakeholders is disclosed at the Stakeholders Area on the Company's website. (Please visit https://www.uvb.com.tw/contact/contact_a04/ for details.)</p>				In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
6. Did the Company appoint a professional stock affairs agency to handle affairs of Shareholders Meetings?	✓		The Company appointed Grand Fortune Securities Co., Ltd. Stock Agency Department to be the Company's stock affairs agency and to handle affairs of Shareholders Meetings.				In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
7. Information disclosure				
(1) Did the Company set up a website to disclose financial business and corporate governance information?	✓		(1) The “Investor Relations Area” on the Company’s website discloses information related to finance and accounting, business, shareholder affairs, corporate governance and corporate sustainability. (For details, please visit https://www.uvb.com.tw/investor/).	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
(2) Did the Company adopt other methods of information disclosure (such as setting up an English website, appointing a person to be in charge of the collection and disclosure of company information, implementing the spokesperson system, placing the process of institutional investor conferences on the Company website)?	✓		(2) The Company has set up an English website with dedicated staff to collect and disclose important information about the Company. (For details, please visit https://www.uvb.com.tw/EN/investor/). The Company has implemented a spokesperson system in which a spokesperson or a proxy spokesperson speaks on behalf of the Company and instructs and requires other employees not to disseminate information to the public without authorization. Material information of the Company is announced in both English and Chinese on the Market Observation Post System and the Company’s website under “Investor Relations > Shareholder Information”, and the information and presentation of the investor conferences are also disclosed on the Company’s website for investors’ reference.	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
(3) Did the Company announce and file the annual financial report within two months after the end of the fiscal year, and announce and file the financial report for the first, second and third quarters and the operating conditions of each month before the specified deadline?		✓	(3) The Company reports financial statements and monthly operations in accordance with the “Taipei Exchange Rules Governing Information Reporting by Companies with TPEX Listed Securities”; it has not yet announced and reported annual financial statements within two months after the end of the fiscal year, and has not yet made early announcements before the prescribed deadline.	A public announcement shall be filed by the deadline specified in accordance with the law.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
8. Did the Company have other important information to help understand the governance operation (including but not limited to employee rights, care for employees, investor relations, supplier relations, rights of stakeholders, training of directors and supervisors, risk management policies) and the implementation of risk measurement standards, implementation of customer policies, the Company's purchase of liability insurance for directors and supervisors)?	✓		<p>1. Employee rights and interests, and care for employees: The Company has formulated operating standards in accordance with the relevant provisions of the "Labor Standards Act", and provided labor insurance, national health insurance and labor pensions for employees in accordance with the law to protect the legitimate rights and interests of employees. To ensure gender equality and the personal safety of employees, the Company has established sexual harassment prevention, complaint, and disciplinary measures; a mechanism to prevent unlawful infringement in the workplace; and consultation and complaint channels to prevent workplace violence. The Company has established the Employee Welfare Committee in, through which contributions are jointly allocated by enterprises and employees to implement various employee welfare measures, improve the quality of life of employees, and promote harmony between labor and management.</p> <p>The Company has a Labor-Management Committee to communicate, coordinate and improve employees' various issues, prevent labor disputes, and ensure labor rights and interests. In 2025, 4 labor-management meetings were held on March 26, June 27, September 25, and December 19.</p> <p>2. Investor Relations: The Company has established a spokesperson and an acting spokesperson who are in charge of communicating and coordinating with investors on various issues and proposals. Additionally, the Company holds general shareholders' meetings in accordance with the law and irregular institutional investor conferences (at least once every quarter, with nine sessions held in 2025) to report on the Company's operating performance, future development strategies, etc. The complete audio and video recordings of the institutional investor conferences held on May 26 and October 22, 2025, have been disclosed, and the links are available on the Company's website.</p>	In conformity to the requirements of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>(Please visit https://www.uvb.com.tw/investor/investor_a03_04/ for details.)</p> <p>Furthermore, the Company discloses material financial and business information on the Company's website and the Market Observation Post System to maintain the transparency of the Company's information and to protect the rights and interests of investors.</p> <p>3. Supplier relations: The Company has formulated the Supplier Management Guidelines to establish relevant rules for the development, evaluation, assessment, and quality management of suppliers to ensure that qualified suppliers can provide long-term and stable supplies of quality products and assist in the continuous improvement of product quality. The Company has formulated the Key Points for Supplier Sustainable Development Management to implement sustainable management of supply chains based on the promotion of environmental protection, occupational safety and health, and labor rights. These Key Points serve as a reference, providing responsible units with information on supplier sustainable development management when implementing procurement operations.</p> <p>4. Stakeholder's rights: The Company upholds the business philosophy of integrity, respects the suggestions and guidance of stakeholders, and fulfills its responsibilities of communication and coordination to maintain good interactions and cooperation relationships and protect the legitimate rights and interests of stakeholders. The Company also reports regularly (at least once a year) to the Board of Directors on the communication status with various stakeholders. The most recent report was made to the Board of Directors on May 14, 2025. The Company's website includes a Stakeholders Area, which discloses each stakeholder's issues of concern, communication channels, response methods and communication frequency. (Please visit https://www.uvb.com.tw/contact/contact_a04/ for details.).</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof																																				
	Yes	No	Summary description																																					
			<p>5. Directors and Supervisors' Continuing Education: The directors of the Company have participated in the educational sessions for corporate governance in accordance with the "Directions for the Implementation of Continuing Education for Directors of TWSE Listed and TPEX Listed Companies" promulgated by the Taiwan Stock Exchange. Information on the educational sessions of the Company's directors have been disclosed in the Corporate Governance Area of the Market Observation Post System.</p> <table border="1"> <thead> <tr> <th>Title</th> <th>Course Date</th> <th>Organizers</th> <th>Course name</th> <th>Course hours</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Chairperson-legal person representative Ou Shu-Fang</td> <td>April 10, 2025</td> <td>Corporate Organization Association</td> <td>Corporate Risk and AI Application Risk Management-The Oversight Responsibilities of the Board and Corporate Governance Executives</td> <td>3</td> </tr> <tr> <td>May 15, 2025</td> <td>Corporate Organization Association</td> <td>Strategies for Preventing and Addressing Labor Litigation</td> <td>3</td> </tr> <tr> <td>August 6, 2025</td> <td>Taipei Foundation of Finance</td> <td>Corporate Governance Course</td> <td>6</td> </tr> <tr> <td rowspan="2">Director-legal person representative Lin Pi-Jung</td> <td>August 20, 2025</td> <td>Corporate Organization Association</td> <td>The company's operational weakness or crisis can be told from the financial report</td> <td>3</td> </tr> <tr> <td>September 3, 2025</td> <td>Corporate Organization Association</td> <td>NVIDIA's Three-Trillion Miracle: A New Perspective on the Semiconductor Industry Revolution Behind Artificial Intelligence</td> <td>3</td> </tr> <tr> <td rowspan="2">Director-legal person representative Weng Su-Hei</td> <td>August 8, 2025</td> <td>Securities and Futures Institute</td> <td>Corporate Mergers Regulations and Transaction Practicalities</td> <td>3</td> </tr> <tr> <td>October 7, 2025</td> <td>Taiwan Project Management Association</td> <td>Integrated Generative AI Applications</td> <td>3</td> </tr> </tbody> </table>	Title	Course Date	Organizers	Course name	Course hours	Chairperson-legal person representative Ou Shu-Fang	April 10, 2025	Corporate Organization Association	Corporate Risk and AI Application Risk Management-The Oversight Responsibilities of the Board and Corporate Governance Executives	3	May 15, 2025	Corporate Organization Association	Strategies for Preventing and Addressing Labor Litigation	3	August 6, 2025	Taipei Foundation of Finance	Corporate Governance Course	6	Director-legal person representative Lin Pi-Jung	August 20, 2025	Corporate Organization Association	The company's operational weakness or crisis can be told from the financial report	3	September 3, 2025	Corporate Organization Association	NVIDIA's Three-Trillion Miracle: A New Perspective on the Semiconductor Industry Revolution Behind Artificial Intelligence	3	Director-legal person representative Weng Su-Hei	August 8, 2025	Securities and Futures Institute	Corporate Mergers Regulations and Transaction Practicalities	3	October 7, 2025	Taiwan Project Management Association	Integrated Generative AI Applications	3	
Title	Course Date	Organizers	Course name	Course hours																																				
Chairperson-legal person representative Ou Shu-Fang	April 10, 2025	Corporate Organization Association	Corporate Risk and AI Application Risk Management-The Oversight Responsibilities of the Board and Corporate Governance Executives	3																																				
	May 15, 2025	Corporate Organization Association	Strategies for Preventing and Addressing Labor Litigation	3																																				
	August 6, 2025	Taipei Foundation of Finance	Corporate Governance Course	6																																				
Director-legal person representative Lin Pi-Jung	August 20, 2025	Corporate Organization Association	The company's operational weakness or crisis can be told from the financial report	3																																				
	September 3, 2025	Corporate Organization Association	NVIDIA's Three-Trillion Miracle: A New Perspective on the Semiconductor Industry Revolution Behind Artificial Intelligence	3																																				
Director-legal person representative Weng Su-Hei	August 8, 2025	Securities and Futures Institute	Corporate Mergers Regulations and Transaction Practicalities	3																																				
	October 7, 2025	Taiwan Project Management Association	Integrated Generative AI Applications	3																																				

Evaluation item	Operational status						Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description				
			Director-legal person representative Chou Tsan-Der	March 5, 2025	Securities and Futures Institute	Struggle for the Power of Corporate Operations: An Introduction to Recent Case Studies	3
				June 19, 2025	Securities and Futures Institute	The Explosion in Space Technology: Trends in B5G and 6G Low-Earth Orbit Satellite Technology and Development	3
			Director-legal person representative Chang Hong-Jen	March 13, 2025	Securities and Futures Institute	The Wafer Century War: TSMC's Globally Leading Key Technologies and Business Opportunities	3
				March 25, 2025	Taiwan Project Management Association	Industry Analysis and Enterprise Diagnostics	3
			Independent Director Xiao Min-Zhi	October 23, 2025	Corporate Organization Association	Embracing AI and ESG: The Key to Corporate Innovation and Sustainable Transformation	3
				November 6, 2025	Taiwan Project Management Association	Board of Directors vs. Management Team	3
				December 19, 2025	Taipei Foundation of Finance	Prospects for 2026: An Analysis of Major Landmarks and Trends in Global Politics and Economics	3
			Independent Director Liu Vincent	June 18, 2025	Taiwan Project Management Association	Digital Technology and AI Trends: Risks and Opportunities in Corporate Operations	3
				September 19, 2025	Taiwan Project Management Association	Artificial Intelligence Trend Analysis and Corporate Risk Management Strategies	3
				October 28, 2025	Independent Director Association Taiwan	An Analysis of Commonly-Seen Tricks and Legal Liabilities in Non-Arm's Length Transactions and Related-Party Transactions	3

Evaluation item	Operational status				Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof																	
	Yes	No	Summary description																			
			<table border="1"> <tr> <td rowspan="2">Independent Director Yang Yun-Hua</td> <td>November 27, 2025</td> <td>Corporate Organization Association</td> <td>Promoting Sustainable Development through Risk Management</td> <td>3</td> </tr> <tr> <td>December 11, 2025</td> <td>Corporate Organization Association</td> <td>Corporate Governance and Securities Regulations-Corporate Governance Risks under Securities Regulations---A Prosecutor's Perspective</td> <td>3</td> </tr> <tr> <td rowspan="2">Independent Director Chen Wei-Ru</td> <td>April 11, 2025</td> <td>Taiwan Corporate Governance Association</td> <td>Practical discussion on the latest development trends of artificial intelligence and risk management framework</td> <td>3</td> </tr> <tr> <td>September 26, 2025</td> <td>Taiwan Project Management Association</td> <td>Insights into Generative AI's Commercial Value and Digital Risks</td> <td>3</td> </tr> </table>	Independent Director Yang Yun-Hua	November 27, 2025	Corporate Organization Association	Promoting Sustainable Development through Risk Management	3	December 11, 2025	Corporate Organization Association	Corporate Governance and Securities Regulations-Corporate Governance Risks under Securities Regulations---A Prosecutor's Perspective	3	Independent Director Chen Wei-Ru	April 11, 2025	Taiwan Corporate Governance Association	Practical discussion on the latest development trends of artificial intelligence and risk management framework	3	September 26, 2025	Taiwan Project Management Association	Insights into Generative AI's Commercial Value and Digital Risks	3	
Independent Director Yang Yun-Hua	November 27, 2025	Corporate Organization Association	Promoting Sustainable Development through Risk Management		3																	
	December 11, 2025	Corporate Organization Association	Corporate Governance and Securities Regulations-Corporate Governance Risks under Securities Regulations---A Prosecutor's Perspective	3																		
Independent Director Chen Wei-Ru	April 11, 2025	Taiwan Corporate Governance Association	Practical discussion on the latest development trends of artificial intelligence and risk management framework	3																		
	September 26, 2025	Taiwan Project Management Association	Insights into Generative AI's Commercial Value and Digital Risks	3																		
			<p>6. Implementation status of risk management policies and risk measurement standards:</p> <p>(1) Risk management policies and procedures</p> <p>To ensure stable operation and sustainable development, the Company formulated the Risk Management Policies and Procedures under the supervision of the Audit Committee, and they were approved by the Board of Directors on August 10, 2023. These policies serve as the highest guiding principles for the Company's risk management. Each year, the risk management team regularly coordinates the planning and implementation of risk factor identification for each operating unit to identify relevant risks that may affect the sustainable development of the Company. Then, it selects risk management scopes, monitors potential risks, and implements prevention measures based on the latest developments, standards, and requirements so to strengthen risk management. It formulates risk management policies for various risks, covering management objectives, organizational structure, attribution of powers and responsibilities, risk</p>																			

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>management procedures, and other mechanisms, and implements them to control various risks arising from business activities to within an acceptable range.</p> <p>(2) Risk management organizational structure</p> <ul style="list-style-type: none"> ◆ Board of Directors: The highest governance unit for risk management; approves the Risk Management Policies and Procedures”. ◆ Audit Committee: Assists the Board of Directors in supervising the Company to establish a risk management operation mechanism. ◆ Risk Management Team: The President serves as the convener, gathering management personnel at all levels to jointly participate in the promotion, implementation, and integration of various risk issues. The Risk Management Team is responsible for overall risk-related differentiation, analysis, prevention, and monitoring of major risk management and control issues, and it reports the annual risk assessment and risk management operations to the Board of Directors at least once a year. ◆ Each operating unit: Identifies, analyzes, assesses, and responds to risks within the unit; establishes relevant crisis management mechanisms when necessary; and regularly reports risk management information to risk management promotion and implementation units. <p>(3) Risk management operations in 2025</p> <p>The Company actively promotes the implementation of the risk management mechanism, which is supervised by the Audit Committee. The Risk Management Team reports its operations to the Board of Directors at least once a year. The main operations in the last 2 years were as follows:</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<ul style="list-style-type: none"> ◆ Formulated the Risk Management Policies and Procedures and the organizational structure, submitted them to the Audit Committee for review and supervision. The Risk Management Policies and Procedures were approved by the Board of Directors on August 10, 2023. ◆ In order to reduce the impact and effects of internal and external risks, risks associated with operations-related corporate governance as well as economic, environmental, social, and other issues were identified based on the principle of materiality as well as the Company's business and operating characteristics; relevant management and monitoring measures were planned by assessing various risks faced by the Company, including risk categories, management units, risk content, and management and control mechanisms; response actions in various risk scopes were regularly submitted to the Audit Committee for supervision and reported at Board meetings every year. The most recent report was made at the Board meeting on November 12, 2025. ◆ The Risk Management Area was established on the Company's website to disclose the Risk Management Policies and Procedures and the organizational structure, the risk management operations for the year, and risk management scopes. (Please visit https://www.uvb.com.tw/investor/investor_a02_08 for details.) <p>7. Implementation of customer policy: The Company attaches absolute importance to its commitment to customers and is committed to continuously improving its service quality and software and hardware facilities to meet customer needs. A customer service hotline has been set up to provide consumers or customers with consultation or services, and a mailbox has been established on the Company's website to provide a channel for consumers to contact us.</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>The Company has formulated the “Personal Data Protection Management Regulations” and “Information Security Management Regulations” to protect the privacy of customers by providing proper use and protection of their personal data and by fulfilling the duty of confidentiality of their personal data.</p> <p>In 2025, the Personal Data Protection Act training course was incorporated into the onboarding program for new employees. As of December 31, 2025, a total of 103 participants had completed the training.</p> <p>8. Information on the Company’s liability insurance for directors and supervisors: The Company has purchased liability insurance for directors and managers and regularly evaluates the amount of insurance coverage each year. The latest renewed insurance period is from July 1, 2025 to July 1, 2026, and the insured amount, scope of coverage, and premium rate have been submitted to the board of directors’ meeting on August 13, 2025.</p> <p>9. Implementation status of directors’ recusal of motions due to conflicts of interest: Where directors were involved in motions with conflicts of interest, the Company required all such directors to recuse themselves from voting on such motions.</p> <p>10. Intellectual property management plan and implementation status for the year: The Company has established the “Intellectual Property Management Plan” to create corporate value through the accumulation of intellectual property. In addition to using intellectual property rights to strengthen our competitive advantage, we continue to focus on and study the latest domestic and international intellectual property rights cases and regulatory requirements to address potential operational risks.</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>The Company reports to the Board of Directors on a regular basis (at least once a year) on relevant matters for the current year.</p> <p>The implementation status for 2025 is as follows:</p> <p>(1) The intellectual property management plan and its implementation status are reported to the Board of Directors on a regular basis. The most recent report was presented at the Board meeting on May 14, 2025.</p> <p>(2) The number of patents obtained: 16 (As of the end of December 2025)</p> <p>(3) The number of trademark registrations: 142 (As of the end of December 2025)</p> <p>(4) Business secrets protection measures:</p> <ul style="list-style-type: none"> • When employees join the company, they agree that they have the obligation to keep their respective business and the Company's business secrets, and they shall comply with the obligation to protect the Company's confidential technology or information after they are employed or leave the Company. • For confidential information that needs to be disclosed to the public, the Company shall enter into confidentiality-related documents with the recipient. • The Company's internal computer system is controlled by authorization, and a dedicated unit is responsible for regular information security operations. • In 2025, the Trade Secrets Act training course was incorporated into the onboarding program for new employees. As of December 31, 2025, a total of 92 participants had completed the training. <p>11. Cyber security governance: The responsible unit for the Company's information security is the Information System and Equipment Division, which is staffed by one</p>	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>director and several professional information personnel. It is in charge of formulating internal information security policies, planning and implementing information security operations, promoting and implementing information security policies, and reporting to the Audit Committee on the overview of the Company's information security governance.</p> <p>The supervisory and inspection unit for the Company's information security is the Audit Office, which is staffed by one audit director and several dedicated audit personnel. Responsible for supervising and auditing the implementation of internal cyber security matters. If deficiencies are found during the audit, the audited unit is required to propose relevant improvement plans and specific actions, and to track the improvement results in order to reduce internal cyber security risks.</p> <p>2025 implementation status for the investment of resources into the Information Security Management System is as follows:</p> <ol style="list-style-type: none"> (1) In 2025 (May 15, Oct. 30, Nov. 6, and Nov. 28), carried out the Cybersecurity Awareness Training for Computer Network Information Security Operations, with 409 persons undergoing training. (2) In June 2025, held the Information Security Course in-service training, with 319 persons trained. (3) In December 2025, the Company appointed a Chief Information Security Officer (CISO) and dedicated information security personnel. A budget exceeding NT\$6 million was allocated for software and hardware updates related to cybersecurity. (4) As of December 31, 2025, 91 new incoming employees had taken the 2025 Advocacy of Information Security training. (5) The Company has introduced the ISO/IEC 27001 Information Security Management System and obtained ISO/IEC 27001:2022 	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			<p>third-party certification in August 2025. The certification is currently valid from August 22, 2025 to October 31, 2026. Through the implementation of ISO/IEC 27001, the Company has strengthened its incident response capabilities; safeguarded the confidentiality, integrity, availability, and legal compliance of its information assets; and enhanced personal data protection for customers.</p> <p>(6) Implementation status related to information security in 2025:</p> <ul style="list-style-type: none"> • ISO/IEC 27001 meetings: Convened 14 meetings with related government agencies and consultants. • Information Security Taskforce meeting: Convened 1 Information Security Taskforce meeting. <p>(7) CISO and information security personnel professional development and certifications:</p> <ul style="list-style-type: none"> • CISO: <ul style="list-style-type: none"> ✧ In February 2025, completed 6-hour information security course held by the Taiwan Academy of Banking and Finance. ✧ In June 2025, completed 6-hour ISO/IEC 27001:2022 Information Security Management Systems Internal Auditor training. • Information Security Personnel: <ul style="list-style-type: none"> ✧ In February 2025, completed 6-hour information security course held by the Taiwan Academy of Banking and Finance. ✧ In August 2025, completed 36-hour Industrial Human Resource Investment Plan “Cloud Computing and AI Information Security Course”. 	

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
			The Company's website has an Information Security section, which discloses information security management strategies and structures; information security policy; specific management plans; quantified resources invested in information security management for the year; and ISO/IEC 27001 Information Security Management International Standard certification and effectiveness (see https://www.uvb.com.tw/investor/investor_a05_08).	
<p>9. Please explain what has been improved on the results of the corporate governance evaluation issued by the Corporate Governance Center of Taiwan Stock Exchange Corporation in the most recent year, and propose priority enhancements and measures for those that have not yet improved. The Company has consecutively recognized as ranking among the top 5% for three years in the Ninth, Tenth and Eleventh Corporate Governance Evaluation. The improved items as well as the items yet to be improved and the priority enhancement items and measures are explained as follows:</p> <p>(1) Improvements made in the 11th Corporate Governance Review</p> <ol style="list-style-type: none"> 1. The Company, either by invitation or on its own initiative, held at least one institutional investor conference per quarter or convened separate conferences to report on quarterly operating performance. It disclosed the links to at least two full audio–video recordings, ensuring that the first and last conferences during the evaluated year were held more than 3 months apart. 2. The Company continued to allocate resources in support of domestic cultural development, with a total contribution of NT\$7.37 million in 2024, and disclosed the support methods and outcomes on the Company's website, in the annual report, or in the sustainability report. 3. The Company has disclosed its policy linking senior executives' compensation to ESG-related performance evaluations. 4. The Company has established a greenhouse gas reduction management policy, including reduction targets, implementation measures, and progress status. 5. The Company's sustainability report, compiled in August 2025, was submitted to and approved by the Board of Directors. 6. The Company's Board of Directors approved the "Sustainable Information Management Operating Guidelines" and the "Sustainability Report Preparation and Assurance Procedures" in November 2024, and implemented the measures starting January 1, 2025. <p>(2) Matters and measures for priority improvement this year (2025)</p> <ol style="list-style-type: none"> 1. The Company has formulated a Corporate Value Enhancement Plan, which was submitted to the Board of Directors on November 13, 2025. Related information is disclosed on the Market Observation Post System's Corporate Value Enhancement Plan section. 2. Held a general shareholders meeting on May 26, 2025 (before the end of May). 3. In December 2025, formulated an Environmental Management System, and disclosed the Environmental Management System and its operating status for the year on the Company's website. 4. In December 2025, formulated an Energy Management Plan, and disclosed the Energy Management Plan and its operating status for the year on the Company's website. 				

Evaluation item	Operational status			Difference from the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies, and the reason thereof
	Yes	No	Summary description	
5. In December 2025, introduced Internal Carbon Pricing to estimate the impacts of climate change on the Company's financial business, and disclosed the basis for internal carbon pricing price formulation on the Company's website.				
6. The Company has already formulated a Employee Training and Development Program to Enhance the Career Skills of Employees with Career Potential, and discloses the aspects, scope, and content of the Program in/on the Company's website, annual report, or sustainability report, as well as quantified resources invested into the training program for the year.				
7. The Company already implements periodic employee satisfaction surveys, and discloses the results and implementation status for the year of such surveys on the Company's website, as well as the proposed improvement plan in response to said employee satisfaction survey results.				
8. The Company has already formulated a Personal Data Protection Policy, and discloses said Policy on the Company's website, as well as its scope of applicability and quantified data related to its implementation status for the year.				
9. The Company has already formulated consumer and customer rights protection policies and complaint procedures regarding its products and services with respect to issues such as customer health and safety, marketing, or labeling, and has disclosed such on its website.				
10. The Company established a board-level sustainability committee on August 13, 2025, and discloses the names of all corporate sustainability expertise and abilities that each committee member possesses on the Company website, as well as the composition of the committee, including members' names, duties, operations for the year.				
11. The Company convened an in-person general shareholders meeting supplemented by video conference on May 26, 2025, in order to increase shareholder participation, promote corporate governance, and to provide flexibility in the event of force majeure event, thus ensuring that shareholders' rights and interests are not affected.				

(4) The Composition of Remuneration Committee and Nominating Committee; their functions and operational status:

1. Information on members of Remuneration Committee

January 2, 2026

By identity (Note 1)	Conditions Name	Professional qualification and experience (Note 2)	Status of independence (Note 3)	Number of public companies where the members of the Remuneration Committee are also the members of the Remuneration Committees of these companies
Independent Director (Convener)	Xiao Min-Zhi	Please refer to Schedule 1 “Disclosure of information on the professional qualifications of directors and supervisors, and the independence of independent directors” on page 11.	(1) Not an employee of the Company or any of its affiliates. (2) Not a director or supervisor of the Company or any of its affiliates. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)	0
Independent Director	Liu Vincent			0
Independent Director	Yang Yun-Hua			1
Independent Director	Chen Wei-Ru			0
Other	Chen Yan-Jun	<p>Education Graduate Institute of International Business, National Taiwan University/ R.O.C. CPA License</p> <p>Current position: Chairman of Jun Lin Co., Ltd./ Independent Director, Member of Audit Committee, Member of Remuneration Committee of Yem Chio Co., Ltd./ Independent Director, Member of Audit Committee, Member of Sustainability Committee of Teco Image Systems (TIS) Co., Ltd.</p> <p>Experience: Chairman, President, Chief Strategy Officer of Star Comgistic Capital Co.,</p>	(3) Not a natural-person shareholder who holds shares, together with those held by the person’s spouse, minor children, or held by the person under others’ names, in an aggregate amount of 1% or more of the total number of issued shares of the Company or ranking in the top ten in holdings. (4) Not a manager in preceding subparagraph (1) or a spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship, of any of the persons in the preceding subparagraph (2) and (3). (5) Not a director, supervisor, or employee of a corporate shareholder who directly holds 5% or more of the total number of issued shares of the Company, or that ranks among the top five in	2

		<p>Ltd./ Chairman, CEO, Chief Risk Control Officer, Group Financial President of Tsann Kuen Enterprise Co., Ltd./ Chairman of Star Travel Corp./ Vice Chairman and Chief Strategy Officer of HOLA/ Group Chief Financial Officer, Vice President of Business and Marketing Development Center of Test Rite International Co., Ltd.</p>	<p>shareholdings, or designates its representative to serve as a director or supervisor of the Company under Article 27(1) or (2) of the Company Act. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(6) Not a director, supervisor or employee of other company such that a majority of the Company's director seats or voting shares are controlled by the same person. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(7) The chairperson, president, or a person holding an equivalent position of the Company is not a director (or governor), supervisor, or employee of other company or institution, or are spouses. (Not applicable in cases where the person is an independent director of the Company, its parent company, or any subsidiary as appointed in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(8) Not a director (or governor), supervisor, manager, or shareholder holding five percent or more of the shares, of a specified company or institution that has a financial or business relationship with the Company. (Not applicable in cases where the specified company or institution holds at least twenty percent but not exceeding fifty percent of the total number of issued shares of the Company, and the person is an independent director of the Company, its parent company, or any subsidiary as appointed</p>	
--	--	--	--	--

			<p>in accordance with the Act or with the laws of the country of the parent or subsidiary.)</p> <p>(9) Not a professional, sole proprietorship, partnership, business owner of a company or institution, partner, director, supervisor, manager, and the spouse thereof that provides audit or business, legal, financial, accounting, or other related services for which the cumulative amount of remuneration received in the last two years is less than NT\$500,000 for the Company or its affiliated companies. However, this shall not apply to the members of the Remuneration Committee, the Public Tender Offer Review Committee or the Special Committee on Mergers and Acquisitions who perform their functions and responsibilities in accordance with relevant provisions of the Securities and Exchange Act or the Business Mergers and Acquisitions Act.</p> <p>(10) Not a spouse of or a relative within the second degree of kinship with other directors.</p> <p>(11) There is no situation listed in Article 30 of the Company Act.</p> <p>(12) Not elected as a director on behalf of the government, a legal person, or the representative thereof under Article 27 of the Company Act.</p>	
--	--	--	---	--

Note 1: Please specify in the form the relevant working experience, professional qualifications and experience, and independence of each member of the Remuneration Committee. Please fill in the identity as either independent directors or others respectively (if it is the convener, please add a note).

Note 2: Professional qualifications and experience: Where members of the Remuneration Committee of the Company are independent directors, please refer to Schedule 1 "Disclosure of information on the professional qualifications of directors and supervisors, and the independence of independent directors" on page 11 for that information.

Note 3: Conformity to independence: Please state clearly that the members of the Remuneration Committee meet the conditions of independence, including but not limited to whether the director him/herself, the spouse, or relatives within the second degree of kinship serve as directors, supervisors or employees of the Company or its affiliated companies; the number and percentage of the Company's shares the director him/herself, the spouse, or relatives within the second degree of kinship (or in the name of others) hold; whether the director serves as directors, supervisors or employees of a company that has a specific relationship with the Company (please refer to the provisions of Article 6, Paragraph 1, Subparagraphs 5 to 8 of the Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of a Company Whose Stock is Listed on the Taiwan Stock Exchange or the Taipei Exchange); the amount of remuneration received for providing the Company or its affiliated companies with business, legal, financial, accounting, and other services in the last 2 years.

2. The Remuneration Committee of the Company shall faithfully perform the following functions and powers with the care of good managers, and submit the suggestions to the Board of Directors for discussion:
 - (1) Formulate and regularly review the policies, systems, standards and structures for the performance evaluation and director remuneration and managers of the Company.
 - (2) Regularly evaluate and determine the remuneration of directors and managers.
3. Information on the operational status of the Remuneration Committee

There are 5 members of the Remuneration Committee of the Company. The current term of the members is from June 19, 2024 to June 18, 2027. In 2025 and as of the date of publication of the annual report, the Remuneration Committee held 4 meetings. The member qualifications and attendance status are set out as follows:

Title	Name	Actual number of attendance	Attend through proxy	Actual attendance rate (%) (note)	Remark
Convener	Xiao Min-Zhi	4	0	100%	Re-elected on June 19, 2024.
Member	Chen Yan-Jun	4	0	100%	Re-elected on June 19, 2024.
Member	Liu Vincent	4	0	100%	Re-elected on June 19, 2024.
Member	Yang Yun-Hua	4	0	100%	Re-elected on June 19, 2024.
Member	Chen Wei-Ru	4	0	100%	Newly-assumed on June 19, 2024.

Other matters required to be recorded:

1. If the Board of Directors does not adopt or revise the recommendations of the Remuneration Committee, it shall state the date of the Board of Directors, the session, the content of the proposal, the resolution of the Board of Directors, and the Company's handling of the opinions of the Remuneration Committee (if the compensation and remuneration approved by the Board of Directors is superior to suggestions made by the Remuneration Committee, the differences and reasons shall be stated): The Board of Directors has not failed to adopt or revised the recommendations of the Remuneration Committee.
2. For matters resolved by the Remuneration Committee, if members have objections or reservations and have a record or written statement, the date of the Remuneration Committee, the session, the content of the proposal, the opinions of all members, and the handling of the opinions of the members shall be stated:

Date of meeting (session)	Content of the proposal	Resolution of the Remuneration Committee	Company's Handling of the Remuneration Committee's Opinion
March 6, 2025 (The 3 rd meeting of the 6 th term)	2024 distribution of employee and director remuneration	All the attending members passed the proposal without objection.	Submitted to the Board of Directors for approval.
May 14, 2025 (The 4 th meeting of the 6 th term)	1. Payment of director remuneration. 2. Distribution of remuneration for managers and employees.	All the attending members passed the proposal without objection.	Submitted to the Board of Directors for approval.
December 18, 2025 (The 5 th meeting of the 6 th term)	2025 year-end bonus payment criteria and payment amount for managers.	All the attending members passed the proposal without objection.	Submitted to the Board of Directors for approval.

March 5, 2026 (The 6 th meeting of the 6 th term)	Distribution of 2025 employee remuneration and director remuneration.	All the attending members passed the proposal without objection.	Submitted to the Board of Directors for approval.
--	---	--	---

Note: The actual attendance rate (%) is calculated based on the number of meetings held by the Remuneration Committee and the number of actual attendances during the term of office.

4. Information on Nominating Committee Members and Operation

(1) The Company's Nominating Committee is composed of at least three directors elected by the Board of Directors, of which a majority of independent directors shall participate. The Nominating Committee, with the authority of the Board of Directors, shall faithfully perform the following duties and responsibilities with duty of care, and shall submit its recommendations to the Board of Directors for discussion:

- Nominating candidates for directors, independent directors and managers, and reviewing the diversity of expertise, skills, experience and gender required of board members, independent directors and managers, as well as their independence.
- Organizing and developing the structure of the Board of Directors and the committees, evaluating the performance of the Board of Directors, committees, directors and managers, as well as assessing the independence of independent directors.
- Determining and periodically reviewing directors' continuing education programs and succession plans for directors and managers.
- Other matters that the Board of Directors may direct the Nominating Committee to perform.

(2) Professional Qualifications and Experience of Nominating Committee Members and Operation:

The Company's Nominating Committee consists of 5 members, at least half of whom are independent directors. The term of office of the current members: June 19, 2024 to June 18, 2027. The Nominating Committee held two (A) meetings in the most recent year, and the professional qualifications and experience of the members, their attendance and matters discussed are as follows:

Title	Name	Professional qualification and experience	Actual number of attendance (B)	Attend through proxy	Actual attendance rate (%) (B/A) (note)	Remark
Convener	Xiao Min-Zhi	Please refer to Schedule 1 "Disclosure of information on the professional qualifications of directors and supervisors, and the independence of independent directors" on page 11.	2	0	100%	Re-elected on June 19, 2024.
Member	Liu Vincent		2	0	100%	Re-elected on June 19, 2024.
Member	Yang Yun-Hua		2	0	100%	Re-elected on June 19, 2024.
Member	Chen Wei-Ru		2	0	100%	Newly-assumed on June 19, 2024.

Member	Chen Yan-Jun	<p>Education Graduate Institute of International Business, National Taiwan University R.O.C. CPA License</p> <p>Current position: Chairman of Jun Lin Co., Ltd./ Independent Director, Member of Audit Committee, Member of Remuneration Committee of Yem Chio Co., Ltd./ Independent Director, Member of Audit Committee, Member of Sustainability Committee of Teco Image Systems (TIS) Co., Ltd.</p> <p>Experience: Chairman, President, Chief Strategy Officer of Star Comgistic Capital Co., Ltd./ Chairman, CEO, Chief Risk Control Officer, Group Financial President of Tsann Kuen Enterprise Co., Ltd./ Chairman of Star Travel Corp./ Vice Chairman and Chief Strategy Officer of HOLA/ Group Chief Financial Officer, Vice President of Business and Marketing Development Center of Test Rite International Co., Ltd.</p>	2	0	100%	Re-elected on June 19, 2024.
--------	--------------	--	---	---	------	------------------------------

Other items to be disclosed:

The date, session and contents of the main motions of the Nominating Committee, the contents of the proposals or objections of the Nominating Committee members, the resolution results of the Nominating Committee and the Company's handling of the opinions of the Nominating Committee.

Date of meeting (session)	Content of the proposal	Resolution of the Nominating Committee	Company's Handling of the Nominating Committee's Opinion
August 13, 2025 (The 1 st meeting of the 2 nd term)	<ol style="list-style-type: none"> Revision of the Company's Nominating Committee Charter. Establishment of the Company's Sustainable Development Committee and formulation of the Sustainable Development Committee Charter. Appointment of members of the Company's 1st Sustainable Development Committee. 	All the attending members passed the proposal without objection.	Submitted to the Board of Directors for approval.

March 5, 2026 (The 2 nd meeting of the 2 nd term)	[Note]	Not applicable	Not applicable
[Note] At said meeting, there was only a report (the 2025 Board of Directors and Functional Committee Performance Evaluation Results Report), with no discussion matters.			

Note: The actual attendance rate (%) is calculated based on the number of meetings held by the Nominating Committee and the number of actual attendances during the term of office.

5. Sustainable Development Committee Members and Operating Status

(1) The Company's Sustainable Development Committee shall be no less than 3 people, with at least 1 director participating and overseeing the committee. Based on the authorization given by the Board of Directors, this committee shall faithfully carry out the following duties with the care of a good administrator, and shall provide its advice to the Board of Directors for discussion:

- Formulating and implementing the Company's sustainable development policies, yearly plans, and related strategies.
- Overseeing and inspecting sustainable development implementation status and the effectiveness of such.
- Overseeing the disclosure of sustainability information, and auditing the Company's sustainability reports.
- Overseeing the implementation status of the Company's sustainable development principles.
- Handling other matters related to sustainable development entrusted to the committee by the Board of Directors.

(2) Sustainable Development Committee members' professional qualifications and experience, and operating status of said committee:

The Company's Sustainable Development Committee has 5 members, of whom 4 members are independent directors. The term of the current committee members runs from August 13, 2025 to June 18, 2027. In the most recent year, the committee met 0 times (A). The committee members' professional qualifications and experience, attendance, and matters discussed are as follows:

Title	Name	Professional qualification and experience	Actual number of attendance (B)	Attend through proxy	Actual attendance rate (%) (B/A) (note)	Remark
Convener	Xiao Min-Zhi	Please refer to Schedule 1 "Disclosure of information on the professional qualifications of directors and supervisors, and the independence of independent directors" on page 11.	0	0	NA	Newly-assumed on August 13, 2025.
Member	Liu Vincent		0	0	NA	Newly-assumed on August 13, 2025.
Member	Yang Yun-Hua		0	0	NA	Newly-assumed on August 13, 2025.
Member	Chen Wei-Ru		0	0	NA	Newly-assumed on August 13, 2025.

Title	Name	Professional qualification and experience	Actual number of attendance (B)	Attend through proxy	Actual attendance rate (%) (B/A) (note)	Remark
Member	Chen Yan-Jun	<p><u>Education</u> Graduate Institute of International Business, National Taiwan University/ R.O.C. CPA License</p> <p><u>Current position:</u> Chairman of Jun Lin Co., Ltd./ Independent Director, Member of Audit Committee, Member of Remuneration Committee of Yem Chio Co., Ltd./ Independent Director, Member of Audit Committee, Member of Sustainability Committee of Teco Image Systems (TIS) Co., Ltd.</p> <p><u>Experience:</u> Chairman, President, Chief Strategy Officer of Star Comgistic Capital Co., Ltd./ Chairman, CEO, Chief Risk Control Officer, Group Financial President of Tsann Kuen Enterprise Co., Ltd./ Chairman of Star Travel Corp./ Vice Chairman and Chief Strategy Officer of HOLA/ Group Chief Financial Officer, Vice President of Business and Marketing Development Center of Test Rite International Co., Ltd.</p>	0	0	NA	Newly-assumed on August 13, 2025.

Other items to be disclosed:

The date, session, and contents of the main motions of the Sustainability Development Committee, the contents of the proposals or objections of the Sustainability Development Committee members, the resolution results of the Sustainability Development Committee, and the Company's handling of the opinions of the Sustainability Development Committee: None.

Note: The actual attendance rate (%) is calculated based on the number of meetings held by the Sustainability Development Committee and the number of actual attendances during the term of office.

(5) The implementation status of the promotion of sustainable development and the differences from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reasons thereof:

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
1. Did the Company establish a governance structure to promote sustainable development, and set up a dedicated (concurrently) unit to promote sustainable development, and did the Board of Directors authorize the senior management to handle such matters, and supervise the status?	✓		<p>1. The Board of Directors is the highest governance unit for sustainable development in the Company. In March 2022, the Governance and Sustainable Development Office (formerly known as the “Corporate Governance Group”, and later renamed in June 2022) was established under the Board of Directors. Said office assists in introducing implementation targets and directions, both domestic and international, such as policies, laws, trends, etc. These include sustainability matters related to the environmental, social, and governance aspects. The head of each unit collects internal and external information on sustainable development issues related to the company’s operations, and conducts risk identification and evaluation; regularly reviews the corporate ESG and sustainable development issues; and manages the formulation of management policies, strategies, and goals, as well as their performance and progress.</p> <p>2. The “Governance and Sustainable Development Office” has set up four functional groups, and all departments of the Company shall participate in the operation of each group according to their business and responsibilities. The main responsibilities of each group in promoting sustainability issues are as follows:</p> <p>(1) Environmental Protection: Greenhouse gas inventories; energy management; climate change impacts; ecological effects; supply chain management; etc.</p> <p>(2) Social Responsibility: Human rights and community relations; stakeholder communications; business ethics and legal compliance; customer privacy, rights, and interests; employee compensation/welfare/health/safety/loyalty; diversity and inclusion; etc.</p> <p>(3) Corporate Governance: Maintaining shareholders’ rights and interests and treating shareholders fairly; strengthening Board of Directors structure and functions; enhancing information transparency and implementing sustainable development; etc.</p>	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>(4) Information and Communication Security: Information and communication risk control; data governance; e-business; AI applications; etc.</p> <p>3. The Governance and Sustainable Development Office reports to the Board of Directors at least once a year on the implementation status of sustainable enterprise development, the content of which includes:</p> <p>(1) The risk assessment of environmental, social, and corporate governance issues related to the Company's operations, conducted in accordance with the principle of materiality;</p> <p>(2) Formulation of relevant risk management policies or strategies;</p> <p>(3) Implementation status of sustainable operations.</p> <p>The Board of Directors listens to reports from the management team, supervises the Company to formulate and propose sustainability strategies and review specific actions, and urges the management team to make adjustments when necessary. The most recent report was made to the Board of Directors on May 14, 2025, which has been put on record.</p> <p>4. The Company established a Sustainable Development Committee on August 13, 2025. The committee's primary duties are as follows:</p> <ul style="list-style-type: none"> • Formulating and implementing the Company's sustainable development policies, yearly plans, and related strategies. • Overseeing and inspecting sustainable development implementation status and the effectiveness of such. • Overseeing the disclosure of sustainability information, and auditing the Company's sustainability reports. • Overseeing the implementation status of the Company's sustainable development principles. • Handling other matters related to sustainable development entrusted to the committee by the Board of Directors. <p>The committee has 5 members, 4 of whom are independent directors, and 1 is an expert. All committee members possess corporate sustainability expertise and abilities.</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason						
	Yes	No	Summary description							
2. Did the Company conduct risk assessments on environmental, social and corporate governance issues related to company operations in accordance with the principle of materiality, and formulate relevant risk management policies or strategies? (Note 2)	✓		<p>1. This disclosure of information covers the sustainable development performance of the Company in its main bases from January 2025 to December 2025. The risk assessment boundary is based on the Company’s overall operating activities.</p> <p>2. The Company adheres to the establishment purpose of “the way of great learning consists in manifesting one’s bright virtue, consists in loving the people, consists in stopping in perfect goodness”, and guards each product and service. Adhering to the pursuit of sustainable operation and profitability, incorporating corporate social responsibility, attaching importance to the rights and interests of stakeholders, emphasizing the principles of environmental, social and corporate governance and materiality, for the Company's management policy, operational activities and risk management policies or strategies, so as to achieve the goal of sustainable operations.</p> <p>3. The Company conducted analysis and assessment based on the principle of materiality; determined material ESG issues; formulated risk management policies for risk identification, measurement and assessment, supervision, and control; and adopted specific action plans so as to reduce the impact of relevant risks. Based on the assessed risks, relevant risk management policies or strategies have been formulated as follows:</p> <table border="1"> <thead> <tr> <th>Material Topic</th> <th>Risk Evaluation Items</th> <th>Management policy or strategy</th> </tr> </thead> <tbody> <tr> <td>Environmental</td> <td>Climate risk</td> <td>1. Greenhouse Gas (GHG) Inventory: The Company has set 2020 as the base year, and has begun voluntarily conducting and disclosing its greenhouse gas (GHG) emissions. Aligning with Taiwan’s 2050 Net-Zero Emissions pathway, the Company has established a 2030 carbon reduction target of 30% compared to the baseline.</td> </tr> </tbody> </table>	Material Topic	Risk Evaluation Items	Management policy or strategy	Environmental	Climate risk	1. Greenhouse Gas (GHG) Inventory: The Company has set 2020 as the base year, and has begun voluntarily conducting and disclosing its greenhouse gas (GHG) emissions. Aligning with Taiwan’s 2050 Net-Zero Emissions pathway, the Company has established a 2030 carbon reduction target of 30% compared to the baseline.	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Material Topic	Risk Evaluation Items	Management policy or strategy								
Environmental	Climate risk	1. Greenhouse Gas (GHG) Inventory: The Company has set 2020 as the base year, and has begun voluntarily conducting and disclosing its greenhouse gas (GHG) emissions. Aligning with Taiwan’s 2050 Net-Zero Emissions pathway, the Company has established a 2030 carbon reduction target of 30% compared to the baseline.								

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>As of 2024, a cumulative reduction of 29.01% has been achieved. In accordance with the Sustainable Development Roadmap, the roadmap will apply to the Company at Stage 3 (i.e., the inventory will be completed in 2026 and the verification will be completed in 2028). Following the inventory timeline specified by the Financial Supervisory Commission, the Company has set a Greenhouse Gas Emission Intensity target of 5% per year as the quantified management target, and this target has already been reached in 2025.</p> <p>2. Climate Risk Implementation: Due to physical risks of natural disasters caused by global warming (such as floods and droughts), and transition risks arising from government regulations and international initiatives (such as rising electricity prices in Taiwan and increased costs from the use of renewable energy), the Company conducts annual identification of climate risks and opportunities based on the Task Force on Climate-related Financial Disclosures (TCFD) framework and takes corresponding actions regarding climate change, including governance, strategy, climate risk and opportunity analysis, climate scenario analysis, risk management, and metrics and targets, which are disclosed on the Company's website and in the Sustainability Report.</p>

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			Energy Risk	<ol style="list-style-type: none"> 1. Energy Inventory: Electricity is primarily purchased from Taiwan Power Company. In 2025, electricity consumption was 752,474 kWh, an increase of 39.38% compared to 539,868 kWh in 2024. Water is mainly supplied by Taiwan Water Corporation. In 2025, water consumption was 3,676 metric tons, an increase of 12.07% compared to 3,280 metric tons in 2024. The increases were mainly due to an 3.88% growth in the parent company's revenue, the addition of 3 new stores, and changes in the scope of inventories beginning in 2025. 2. Energy-saving Investment: The Company continued to invest in the retrofit of energy-saving air conditioning equipment in retail stores, with an investment of NT\$9.211 million in 2025 and NT\$7.444 million in 2024. 3. Energy Conservation and Carbon Reduction Policy: Equipment replacement policies have been implemented to address energy saving, water conservation, and electricity efficiency. Store renovations have gradually adopted energy-saving LED lighting, inverter-type air conditioning equipment, and the use of green building materials and environmentally friendly materials. In 2025, the Company formulated and disclosed an Energy Management Plan, as well as its operating status for the year.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>4. Promotion of Energy Conservation and Carbon Reduction: In 2025, company-wide awareness campaigns were held (on April 18, July 14 and October 1), focusing on energy conservation, GHG emissions, carbon footprint labeling, and net-zero sustainable living.</p>	
			<p>Resource and Waste Management Risk</p> <p>1. Waste reduction: The Company continues to reduce the potential environmental impact of waste by avoiding excessive product packaging, improving the efficiency of resource utilization, and classifying various types of waste for recycling.</p> <p>2. New Product with Environmentally Friendly Packaging: The gift box design of the newly launched 2024 Jin Run Ming lutein product not only serves the purpose of product placement and display but also complies with regulations on limiting excessive packaging. The product box clearly indicates that its packaging materials meet the environmental standards of the FSC (Forest Stewardship Council), one of the world's most recognized international forest certification standards, underscoring the brand's commitment to environmental sustainability.</p> <p>3. E-commerce Packaging Reduction: The Targets and Implementation Methods for Restriction of Internet Shopping Packaging were issued by the Ministry of Environment in July 2023, and beginning that same month, all of the Company's packaging materials</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>complied with the regulations and underwent assurance by a certified public accountant. Since 2024, the Company encourages customers to pick up their purchases in person at stores, reducing overall packaging by 28.6% and thus already meeting the regulated 25% reduction. In 2025, total packaging reductions reached 30.3%, again reaching the regulated 30% reduction.</p>
			<p>Social</p> <p>Occupational risk</p>	<p>1. Improvement of occupational safety management: In order to optimize job responsibilities and planning timelines for occupational health and safety management, in March 2025, the Company amended 21 occupational health and safety management documents, including occupational health and safety policies, management plans, organizational design, planning and implementation, etc. In 2025, the Company continued to conduct monthly advocacy of occupational safety, on-the-job education and training for new employees, as well as related drills and environmental safety inspections.</p> <p>2. Disaster response plan: The emergency response plans for earthquakes, typhoons and torrential rains, power outages, and fire protection are periodically reviewed, including preventive measures, response actions during incidents, and operating procedures.</p> <ul style="list-style-type: none"> • Head office: A fire drill was conducted on November 6, 2025. 1 occupational safety and health

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>supervisor completed initial training (duration 42 hours), and another completed retraining (duration 6 hours); 2 fire prevention managers completed initial training (duration 12 hours).</p> <ul style="list-style-type: none"> • Retail stores: As of the end of December 2025, self-defense fire organization (emergency response) training was provided for 136 participants. Each session lasted 4 hours, for a total of 544 training hours. <p>3. Implementation of contractor management: For cooperative clinics and store renovation contractors, relevant regulations are established in accordance with labor safety, hygiene, and environmental protection laws, and are included in the subcontracting agreements. During project execution, unscheduled inspections are conducted to verify whether contractors are complying with the required education and implementation. On January 3, 2025, a supplier meeting was held to conduct occupational safety and health training and promote ESG sustainability among suppliers.</p> <p>4. Employee physical and mental health: Employee health checkups were conducted from June to September 2025, employee travel subsidies were provided in 2025, and birthday celebrations were held monthly.</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>Labor-Management risk</p> <ol style="list-style-type: none"> 1. Labor-Management communication channels: Labor-management meetings were held quarterly in 2025 (on March 26, June 27, September 25, and December 19) to establish communication channels and an employee grievance mechanism, aiming to promote harmonious labor relations. 2. Protection of friendly workplace: Strengthen management measures for the collection, processing, and use of personal data; continuously perfect the rules in writing; and respect the rights and interests of employees (parties to the case concerned). 3. Selection, cultivation, and retention system: Strengthen the diverse channels and equality of personnel recruitment, the planning and implementation of education and training, as well as the fair and appropriate performance evaluation and promotion system. 4. Compliance with labor laws and regulations: Ensure that human resource management procedures and related administrative operations comply with legal requirements. 	
			<p>Corporate Governance</p> <p>Strategy risk</p> <ol style="list-style-type: none"> 1. Business report: The management team proceeds with the report, communication, and discussion based on its business strategy and operational overview prior to each Board meeting. 2. Board supervision: Board members make suggestions on the content of the management team's report based on 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>their profession or areas of expertise. If the goals and strategies involve items that could possibly cause significant operational risks, the Board of Directors will prioritize such items on the watch list.</p> <p>3. Subsidiary Operating Strategy: Beginning in 2024, the government in China implemented healthcare insurance reforms. The tightening of the healthcare insurance fund affected reimbursement amounts for cataract surgeries. In 2025, market demand continued its involution as a result the US Reciprocal Tariffs 2.0 policy and China's internal demand, resulting in slugging consumption.</p> <p>Response measures:</p> <p>(1) In 2025, the Company closed the self-operated Linping Eye Hospital and terminated the cooperation with Xiaoshan Hospital's ophthalmology outpatient department. This reversed the loss trend, to reach break-even in the near-term.</p> <p>(2) Continue to transform sizable self-operated clinics and partner hospitals to focus on self-paid medical services, in order to mitigate the risk of reduced cataract reimbursement from healthcare insurance.</p>
			Operating risk	<p>Each unit manages its annual business plan and performance goals through operational meetings.</p> <p>1. Customer relations: Establish standards and customer complaint channels for products, services, personal data protection and other matters concerning consumer rights</p>

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>and interests, and conduct customer service training.</p> <p>2. Product Safety: A Product Safety Monitoring system has been established. Internal guidelines have been formulated and external regulations followed for product development, evaluation, performance assessment, and quality management to enhance the safety and quality of products and services.</p> <p>3. Supply chain management: Prudently evaluate and actively develop new material sources, strengthen strategic supply chain partnerships; establish safety stock and expiry date controls to flexibly respond to market demand, grasp market conditions through business information collection or market research so as to respond in advance.</p> <p>4. Technology trends: Get a good understanding of customer and terminal application demand, product applications and equipment upgrades, and other technological developments so as to respond to rapid changes in the external environment; grasp the changes and dynamics of the peer industry, markets, industries, and customers in order to respond and to serve as a reference for the direction of services, technology, and product development.</p>

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>Financial risk</p> <ol style="list-style-type: none"> 1. Interest rate risk: Monitor changes in the interest rate market, grasp capital demand and conditions, maintain good relationships with banks, and strive for the best financing and deposit interest rates. 2. Exchange rate risk: Mainly due to conversion adjustments in foreign currencies for long-term foreign investment positions. Accounts receivable and accounts payable generated from operations are currently mainly based on receipts and payments in New Taiwan dollars from local market transactions and purchases through agents rather than direct import/export and export sales; therefore, the impact of exchange rate risk is relatively small. 3. Credit risk: The accounts collectible are from brand-authorized cooperative clinics (monitored using monthly receivable statements) and customers of self-operated eyeglasses stores (monitored using daily cash/credit card statements). 4. Financial changes: Regularly monitor the financial structure, solvency, operating capabilities, profitability, cash flow, etc. using financial statements. 	
			<p>Information security risk</p> <ol style="list-style-type: none"> 1. Information security protection mechanism: In August 2025, the Company obtained certification for the transition to ISO/IEC 27001:2022 information security protection measures; and conduct vulnerability risk assessment and improvement for 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>hosts/networks/applications; establish file encryption mechanisms and plan secure cloud services to reduce the risk of confidential and sensitive data leakage; regularly inspect the vulnerability of the external service system, perform penetration testing, and use network risk detection tools; make timely improvements to ensure the security of the external service system; regularly conduct disaster recovery drills, strengthen the data security backup mechanism, and establish incident response capabilities to ensure the Company's continuous operations.</p> <p>2. Information Security Policy: A total of more than 20 rules such as the Information Security Policy and related implementation procedures have been formulated, revised, and announced in the Company's document management system to facilitate compliance. The Personal Data Protection Management Guidelines have been formulated and revised to protect and manage personal information, and the Information and Human Resources departments are in charge of relevant protective measures. The Legal department also implements trade secret protection to ensure the implementation of confidentiality obligations. In 2025, a total of 92 new employees participated in training sessions on the Trade Secrets Act.</p>

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
				<p>3. Information Security Risk Awareness: Improve employee information security risk awareness through advocacy and education. As of 2025, 409 attendees have completed the training on Information Security Advocacy, 319 attendees have completed the training on Information Security Courses, and 119 attendees have completed social engineering drills.</p>
			Legal compliance risk	<p>1. Implementation of ethical corporate management: The Company has formulated the Code of Ethical Corporate Management, the Code of Ethical Conduct, and the Advocacy of Employee Code of Ethics and Whistleblowing system to regularly advocate the values and corporate culture of ethical corporate management and guide colleagues' conduct to be in line with ethical standards so as to avoid involvement in unlawful activities.</p> <p>2. Internal control and internal audit operation: The internal control process controls the Company's transactions, projects, risks, and dispute cases; enables timely discovery; and tracks improvements through internal audits.</p> <p>3. Support in legal affairs: Provide legal consultation and suggestions to deal with issues on regulatory compliance, disputes and litigation, investment as well as mergers and acquisitions, intellectual property management, and other matters.</p>

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			4. Contract Seal and Intellectual Property: Manage the signing status of various types of business contracts and control relevant risks through the contract system; supervise and manage the creation, issuance, use, abolishment, and other matters of the Company's seals through the seal management system to reduce the Company's Overall legal risks; formulate the Intellectual Property Rights Management Guidelines; and conduct regular inventory of intellectual property rights to confirm validity. As of the end of December 2025, the Company held 142 trademarks and 16 patents.	
3. Environmental issues (1) Did the Company establish an appropriate environmental management system according to its industrial characteristics?	✓		<p>(1) Environmental Management System: In accordance with laws formulated by the Air Pollution Control Act, the Water Pollution Control Act, the Waste Disposal Act, the Toxic and Concerned Chemical Substances Control Act, etc.), the Company has established an Environmental Management System and formulated management regulations for environmental safety and health. The headquarters implements environmental management activities at the various stores and operating sites, in order to comply with the goals of "protecting natural resources" and "lowering the risk of hazardous substances". The Company discloses the environmental management targets, scope of applicability, regulations, and 2025 implementation status on its website. For related content, please see the Environmental Management System section (https://www.uvb.com.tw/investor/investor_a05_16).</p> <p>Greenhouse Gas Control: According to the Sustainable Development Roadmap for TWSE/TPEX Listed Companies released by the Financial Supervisory Commission in March 2022, the Company shall apply the greenhouse gas inventory at Stage 3 (i.e., the inventory must be completed in 2026 and the verification must be completed in 2028). The Company reported to the Board of Directors on June 23, 2022, and March 27, 2023, regarding the</p>	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(2) Is the Company committed to improving energy efficiency and using recycled materials with low impact on the environment?	✓		<p>“parent company’s greenhouse gas inventory and verification schedule planning” and the “greenhouse gas inventory and verification schedule planning of subsidiaries listed in the consolidated financial statements”, and it will continue to report the progress of control and implementation on a quarterly basis.</p> <p>Energy-saving and carbon-reduction policies: The Company has no manufacturing and production activities, and is not an energy-intensive and major energy-consuming industry. It is not a source of greenhouse gas emissions that shall be regulated by the Ministry of Environment of the Executive Yuan, and is therefore at low risk of being regulated by the “Climate Change Response Act” and other relevant laws and regulations. However, as climate change has become a global challenge, mitigating the impact of climate change is a matter of great urgency. The Company continues to focus on the changes in relevant domestic and international regulations and actively conducts greenhouse gas inventory, emission control and implements energy-saving and carbon-reduction policies in order to fulfill its corporate responsibilities and obligations in environmental protection.</p> <p>(2) The Company has implemented equipment retirement policies focusing on energy saving, water saving, and power saving, and is committed to improving the utilization efficiency of various resources, managing all types of waste and recycled resources, and making continuous improvements to reduce the impact on the environment.</p> <ol style="list-style-type: none"> Energy-saving investment: The Company has successively improved lighting devices and air conditioning used in all of its stores by using energy-saving LED lighting devices and variable frequency air conditioning equipment. The amount invested in energy-saving equipment during the past 2 years was NT\$9,211 thousand in 2025 and NT\$7,444 thousand in 2024. Carbon reduction advocacy: The Company has progressively used green building materials or environmentally friendly building materials for store renovations; continued to promote energy conservation and carbon reduction on April 18, July 14, and October 1, 2025; and actively educated all colleagues to participate in energy-saving actions, develop 	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason																																			
	Yes	No	Summary description																																				
			<p>behavior that is more environmentally friendly, set the indoor air conditioning temperature as advised, turn off the lights during the lunch break, and turn off the lights and air conditioning after work, so as to achieve energy conservation and carbon reduction.</p> <p>3. ESG procurement: The Company has promoted “ESG sustainable procurement” and prioritized procurement from suppliers with ESG practices and green label products (environmental protection labels, energy saving labels, water saving labels, carbon footprint labels, etc.).</p> <p>4. Energy Management Plan: Doing the utmost to implement energy savings and carbon reduction, the Company continues implementing the three major Self-Managed Electricity Use, Reduced Electricity Consumption, and Rational Electricity Usage programs at all optical stores and brand-authorized partner clinics. The Company has formulated an energy efficiency enhancement plan, to create low-carbon-emission operating sites. For more information about the targets and implementation status for 2025’s Energy Management Plan, see the Energy Management Plan section of the Company’s website (https://www.uvb.com.tw/investor/investor_a05_17).</p> <p>5. The power consumption for the recent years is as follows:</p> <table border="1"> <thead> <tr> <th>Year</th> <th>Head office</th> <th>Stores</th> <th>Total (kWh)</th> <th>Annual Decrease Rate %</th> </tr> </thead> <tbody> <tr> <td>2020</td> <td>158,026</td> <td>630,277</td> <td>788,303</td> <td>Base year</td> </tr> <tr> <td>2021</td> <td>109,596</td> <td>587,528</td> <td>697,124</td> <td>-11.57%</td> </tr> <tr> <td>2022</td> <td>97,687</td> <td>549,364</td> <td>647,051</td> <td>-7.18%</td> </tr> <tr> <td>2023</td> <td>101,730</td> <td>431,976</td> <td>533,706</td> <td>-17.52%</td> </tr> <tr> <td>2024</td> <td>90,527</td> <td>449,341</td> <td>539,868</td> <td>+1.15%</td> </tr> <tr> <td>2025</td> <td>149,644</td> <td>602,830</td> <td>752,474</td> <td>+39.38%</td> </tr> </tbody> </table> <p>Note: 1. The above statistics are for the parent company only. 2. The head office includes the Nangang Office, Xizhi Warehouse, Zhongli Warehouse, Northern Lens Grinding Center, and E-commerce Center.</p>	Year	Head office	Stores	Total (kWh)	Annual Decrease Rate %	2020	158,026	630,277	788,303	Base year	2021	109,596	587,528	697,124	-11.57%	2022	97,687	549,364	647,051	-7.18%	2023	101,730	431,976	533,706	-17.52%	2024	90,527	449,341	539,868	+1.15%	2025	149,644	602,830	752,474	+39.38%	
Year	Head office	Stores	Total (kWh)	Annual Decrease Rate %																																			
2020	158,026	630,277	788,303	Base year																																			
2021	109,596	587,528	697,124	-11.57%																																			
2022	97,687	549,364	647,051	-7.18%																																			
2023	101,730	431,976	533,706	-17.52%																																			
2024	90,527	449,341	539,868	+1.15%																																			
2025	149,644	602,830	752,474	+39.38%																																			

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(3) Did the Company assess the current and future potential risks and opportunities of climate change for the Company, and take measures to the related issues?	✓		<p>(3) With the Board of Directors as the highest organization for climate change management, the Company has designated the “Governance and Sustainable Development Office” as a dedicated unit under the Board of Directors, supervised by the “Sustainability Development Committee”, to annually review the Company’s climate change strategies and objectives, manage climate change risks and opportunities, review implementation status and discuss future plans, and report to the Board of Directors.</p> <p>In accordance with the “Task Force on Climate-related Financial Disclosures (TCFD)” framework, the Company identifies the impact of climate change risks/opportunities on the Company’s operations and finances, and proposed countermeasures and solutions, which are publicly disclosed on the Company’s website and in the Sustainability Report.</p> <ol style="list-style-type: none"> 1. We have adopted the Task Force on Climate-related Financial Disclosures (TCFD) framework issued by the Financial Stability Board (FSB) to disclose the four core elements of governance, strategy, risk management and indicators and targets as well as climate management key results and development objectives. 2. We have developed a TCFD materiality matrix to analyze the physical and transformation risks that may occur in the short, medium, and long term, as well as the related climate opportunities, which are 9 in total. The Company has further elaborated mitigation and adaptation measures to strengthen the climate resilience of the Company. 3. Based on our analysis of risk categories and the identification of risks and opportunities for climate change, we have identified action plans: such as measures to address risks such as energy shortages and increased product costs, and opportunities for new demand for eye health products and services due to high temperatures and strong light in extreme climates. <p>For related content, please refer to the TCFD climate disclose in the Sustainability Report and on the company’s website. (Please refer to https://www.uvb.com.tw/investor/investor_a05_09)</p>	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason																																																	
	Yes	No	Summary description																																																		
(4) Did the Company calculate the greenhouse gas emissions, water consumption and total weight of waste in the past two years, and formulated policies for greenhouse gas reduction, water consumption reduction or other waste management policies?	✓		<p>(4) The Company actively responds to the global climate change issue, puts emphasis on energy management, supports the government's policy of environmental protection and energy saving, and implements energy saving and carbon reduction measures, with the aim of enhancing energy use efficiency and controlling and reducing greenhouse gas emissions. The relevant management policies have been disclosed in the sustainability report. The statistics cover all operations of the Company, including the head office (Nangang Office, Xizhi Warehouse, Zhongli Warehouse, Northern Lens Grinding Center, E-commerce Center, etc.) and all retail stores.</p> <p>1. Greenhouse gas emissions: The Company's greenhouse gas emissions inventory is a voluntary disclosure of self-management system to facilitate understanding of the current trend and early response, and has not been externally third-party verified. Greenhouse gas emissions statistics for the most recent years are as follows</p> <table border="1"> <thead> <tr> <th>Year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> <th>2025</th> </tr> </thead> <tbody> <tr> <td>Category 1 (Direct Emissions)</td> <td>63.73</td> <td>67.37</td> <td>78.86</td> <td>76.49</td> <td>70.27</td> <td>239.73</td> </tr> <tr> <td>Category 2 (Indirect Emissions)</td> <td>395.73</td> <td>354.84</td> <td>320.29</td> <td>263.65</td> <td>255.90</td> <td>356.67</td> </tr> <tr> <td>Total (Tons/CO₂e)</td> <td>459.46</td> <td>422.21</td> <td>399.15</td> <td>340.14</td> <td>326.17</td> <td>596.40</td> </tr> <tr> <td>Emission Intensity (per million sales)</td> <td>0.2828</td> <td>0.2144</td> <td>0.1497</td> <td>0.1050</td> <td>0.0928</td> <td>0.1634</td> </tr> <tr> <td>Emission intensity_targeted 5% reduction per year</td> <td>—</td> <td>0.2686</td> <td>0.2552</td> <td>0.2425</td> <td>0.2303</td> <td>0.2188</td> </tr> <tr> <td>Whether the 5% annual reduction target is achieved or not</td> <td>Base year</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> </tr> </tbody> </table> <p>Note: The above statistics are for the parent company only.</p>	Year	2020	2021	2022	2023	2024	2025	Category 1 (Direct Emissions)	63.73	67.37	78.86	76.49	70.27	239.73	Category 2 (Indirect Emissions)	395.73	354.84	320.29	263.65	255.90	356.67	Total (Tons/CO₂e)	459.46	422.21	399.15	340.14	326.17	596.40	Emission Intensity (per million sales)	0.2828	0.2144	0.1497	0.1050	0.0928	0.1634	Emission intensity_targeted 5% reduction per year	—	0.2686	0.2552	0.2425	0.2303	0.2188	Whether the 5% annual reduction target is achieved or not	Base year	Achieved	Achieved	Achieved	Achieved	Achieved	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Year	2020	2021	2022	2023	2024	2025																																															
Category 1 (Direct Emissions)	63.73	67.37	78.86	76.49	70.27	239.73																																															
Category 2 (Indirect Emissions)	395.73	354.84	320.29	263.65	255.90	356.67																																															
Total (Tons/CO₂e)	459.46	422.21	399.15	340.14	326.17	596.40																																															
Emission Intensity (per million sales)	0.2828	0.2144	0.1497	0.1050	0.0928	0.1634																																															
Emission intensity_targeted 5% reduction per year	—	0.2686	0.2552	0.2425	0.2303	0.2188																																															
Whether the 5% annual reduction target is achieved or not	Base year	Achieved	Achieved	Achieved	Achieved	Achieved																																															

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>With 2020 as the base year and a 5% annual reduction in greenhouse gas emission intensity as the quantitative management target, the Company's policy on climate change or greenhouse gas management is to</p> <ol style="list-style-type: none"> (1) Promote and implement energy saving and carbon reduction measures, and communicate the policy to employees, suppliers, customers and other stakeholders. (2) Strengthen the advocacy and encourage all employees to develop the habit of saving energy and resources. (3) Turn off lighting in unoccupied areas in a timely manner, and turn off lights in office areas during lunch breaks to save energy. (4) Establish an electronic form system to reduce the use of paper. (5) Promote carpooling to reduce the number of vehicle trips and reduce fuel consumption. (6) Establish greenhouse gas emission inventory, regular inventory, and control emissions. (7) Replaced outdated air conditioning systems at retail stores, upgrading 60% of the units to Level 1 energy efficiency products. (8) Formulated the Environmental Management System and Energy Management Plan, and have disclosed the implementation status of each for the year. <p>2. Water Management: The Company is not a manufacturing industry and does not discharge wastewater from production processes or laboratories. The water consumption of the head office (including Nangang Office, Xizhi Warehouse, Zhongli Warehouse, Northern Lens Grinding Center, E-commerce Center, etc.) and all retail stores is relatively small, and there is no significant ecological impact on water resources. However, as environmental protection and sustainable development are our responsibility and commitment, we are still proactively promoting our water conservation policy to our employees.</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason																																			
	Yes	No	Summary description																																				
			<p>With a base year of 2020 and a quantitative management goal of a 5% annual reduction in water consumption intensity, the Company's water consumption statistics for the most recent years are as follows</p> <table border="1"> <thead> <tr> <th>Year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> <th>2025</th> </tr> </thead> <tbody> <tr> <td>Total water consumption (metric tons)</td> <td>4,755.33</td> <td>3,526.67</td> <td>4,704.92</td> <td>3,074.62</td> <td>3,279.86</td> <td>3,675.82</td> </tr> <tr> <td>Water consumption intensity (per million sales)</td> <td>2.9268</td> <td>1.7905</td> <td>1.7649</td> <td>0.9488</td> <td>0.9335</td> <td>1.0072</td> </tr> <tr> <td>Water consumption intensity_targeted 5% annual reduction</td> <td>—</td> <td>2.7805</td> <td>2.6414</td> <td>2.5094</td> <td>2.3839</td> <td>2.2647</td> </tr> <tr> <td>Whether the 5% annual reduction target is achieved or not</td> <td>Base Year</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> <td>Achieved</td> </tr> </tbody> </table> <p>Note: The above statistics are for the parent company only.</p> <p>3. Waste management: The Company continuously endeavors to reduce the possible impact of waste on the environment by taking various voluntary actions to avoid over-packaging of products and to fulfill the responsibility of being environmentally friendly. The Company also enhances the efficiency of resource utilization by classifying and recycling various types of waste.</p> <p>(1) Paper Saving</p> <ul style="list-style-type: none"> ◆ We promote convenient and paperless services such as online trading platform and electronic payment. ◆ We have introduced electronic forms and processes for corporate documents to reduce paper and toner usage. ◆ We use 70P photocopy paper, encourage double-sided printing, and set up waste paper recycling bins. 	Year	2020	2021	2022	2023	2024	2025	Total water consumption (metric tons)	4,755.33	3,526.67	4,704.92	3,074.62	3,279.86	3,675.82	Water consumption intensity (per million sales)	2.9268	1.7905	1.7649	0.9488	0.9335	1.0072	Water consumption intensity_targeted 5% annual reduction	—	2.7805	2.6414	2.5094	2.3839	2.2647	Whether the 5% annual reduction target is achieved or not	Base Year	Achieved	Achieved	Achieved	Achieved	Achieved	
Year	2020	2021	2022	2023	2024	2025																																	
Total water consumption (metric tons)	4,755.33	3,526.67	4,704.92	3,074.62	3,279.86	3,675.82																																	
Water consumption intensity (per million sales)	2.9268	1.7905	1.7649	0.9488	0.9335	1.0072																																	
Water consumption intensity_targeted 5% annual reduction	—	2.7805	2.6414	2.5094	2.3839	2.2647																																	
Whether the 5% annual reduction target is achieved or not	Base Year	Achieved	Achieved	Achieved	Achieved	Achieved																																	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>(2) E-commerce Packaging Reduction: In response to the Targets and Implementation Methods for Restriction of Internet Shopping Packaging, issued by the Ministry of Environment in July 2023, the Company began that same month to inventory packaging materials and methods for e-commerce orders. All of the Company's packaging materials complied with the regulations and underwent assurance by a certified public accountant. Since 2024, the Company encourages customers to pick up their purchases in person at stores, reducing overall packaging by 28.6% and thus already meeting the regulated 25% reduction. In 2025, total packaging reductions reached 30.3%, again reaching the regulated 30% reduction.</p> <p>(3) New Product with Environmentally Friendly Packaging: The gift box design of the newly launched 2024 lutein product Jin Run Ming not only serves the purpose of product placement and display but also complies with regulations on limiting excessive packaging. The product box clearly indicates that its packaging materials meet the environmental standards of the FSC (Forest Stewardship Council), one of the world's most recognized international forest certification standards, underscoring the brand's commitment to environmental sustainability.</p> <p>(4) Waste statistics: The general waste of the head office and retail stores is uniformly managed by the Building Management Committee and cannot be calculated effectively, thus the total weight of waste cannot be provided. Waste from product scrapping: The Company is not in the manufacturing industry and is not required to distinguish the total weight of hazardous waste from that of non-hazardous waste. The Company's statistics on the total weight of waste from product scrapping in recent years are as follows:</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>In addition, in order to fulfill our corporate social responsibility and protect the basic human rights of our employees, customers and stakeholders, we respect internationally recognized basic human rights in accordance with the principles set forth in the “United Nations Universal Declaration of Human Rights”, “the United Nations Guiding Principles on Business and Human Rights”, “the United Nations Global Compact” and “the United Nations International Labor Organization”. We also adhere to the labor laws and regulations of the countries in which we operate and develop human rights policies and specific management programs.</p> <ul style="list-style-type: none"> · Diversity inclusiveness and equal opportunity · Prohibition of forced labor and child labor · Providing fair and reasonable wages and working conditions · Providing a safe, sanitary and healthy working environment · Respect of employees’ freedom of assembly and association <p>The Company implements diversity and equality in the workplace, selects and retains employees without discrimination on the basis of gender, religion, race or political stance, and employs people based on their qualifications through an open recruitment process.</p> <p>In 2025, female employees accounted for 54% of all employees at the Company and 63% of all employees at the subsidiaries listed in the consolidated financial statements; female managers accounted for 49% of management positions at the Company and 57% at the subsidiaries listed in the consolidated financial statements, indicating no significant difference in terms of gender.</p>	

Implementation item	Implementation status			Summary description	Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason																																																
	Yes	No																																																			
				<table border="1"> <thead> <tr> <th colspan="2">Company type</th> <th colspan="4">The Company</th> <th colspan="4">The Company and the subsidiaries listed in the consolidated financial statements</th> </tr> <tr> <th colspan="2">Gender</th> <th>Female</th> <th>Male</th> <th>Total</th> <th>Percentage of female</th> <th>Female</th> <th>Male</th> <th>Total</th> <th>Percentage of female</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Rank</td> <td>Management Position</td> <td>39</td> <td>41</td> <td>80</td> <td>49%</td> <td>73</td> <td>56</td> <td>129</td> <td>57%</td> </tr> <tr> <td>Non-managerial position</td> <td>161</td> <td>129</td> <td>290</td> <td>56%</td> <td>304</td> <td>163</td> <td>467</td> <td>65%</td> </tr> <tr> <td>Total</td> <td>200</td> <td>170</td> <td>370</td> <td>54%</td> <td>377</td> <td>219</td> <td>596</td> <td>63%</td> </tr> </tbody> </table> <p>Note: Percentage of female employees = number of female employees / total number of employees</p> <p>In addition, pursuant to the implementation of the fixed quota employment for people with disabilities, as of the end of December 2025, the Company hired four people (including two persons with severe disabilities). The Company will continue to offer job opportunities to recruit people with disabilities so that they can give full play to their strengths, integrate into society, and arouse the recognition of their work abilities from the general public in society and corporate employers.</p> <p>In 2025, the difference between the average monthly salary of female managers and the overall average monthly salary was 4.57% for the Company and 7% for the subsidiaries listed in the consolidated financial statements; the difference between the average monthly salary for female employees in non-management positions and the overall average monthly salary was 4.54% for the Company and 7.86% for the subsidiaries in consolidated financial statements; this indicates that there was no significant difference in average monthly salary between management positions and non-management positions in terms of gender.</p>	Company type		The Company				The Company and the subsidiaries listed in the consolidated financial statements				Gender		Female	Male	Total	Percentage of female	Female	Male	Total	Percentage of female	Rank	Management Position	39	41	80	49%	73	56	129	57%	Non-managerial position	161	129	290	56%	304	163	467	65%	Total	200	170	370	54%	377	219	596	63%	
Company type		The Company				The Company and the subsidiaries listed in the consolidated financial statements																																															
Gender		Female	Male	Total	Percentage of female	Female	Male	Total	Percentage of female																																												
Rank	Management Position	39	41	80	49%	73	56	129	57%																																												
	Non-managerial position	161	129	290	56%	304	163	467	65%																																												
	Total	200	170	370	54%	377	219	596	63%																																												

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason																																							
	Yes	No	Summary description																																								
(2) Did the Company formulate and implement reasonable employee welfare measures (including remuneration, vacation and other benefits, etc.), and	✓		<table border="1"> <thead> <tr> <th colspan="2">Company type</th> <th colspan="4">The Company</th> <th colspan="4">The Company and the subsidiaries listed in the consolidated financial statements</th> </tr> <tr> <th colspan="2">Gender</th> <th>Female</th> <th>Male</th> <th>All</th> <th>Difference (%)</th> <th>Female</th> <th>Male</th> <th>All</th> <th>Difference (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Average monthly salary (NTD)</td> <td>Management position</td> <td>110,702</td> <td>121,057</td> <td>116,009</td> <td>4.57%</td> <td>96,881</td> <td>113,689</td> <td>104,177</td> <td>7.00%</td> </tr> <tr> <td>Non-managerial position</td> <td>62,681</td> <td>69,375</td> <td>65,659</td> <td>4.54%</td> <td>49,706</td> <td>61,859</td> <td>53,948</td> <td>7.86%</td> </tr> </tbody> </table> <p>Note: Difference (%) = (average monthly salary of all employees – average monthly salary of female employees) / average monthly salary of all employees</p> <p>In addition, the Company is committed to providing an equal and friendly workplace. Taking non-management Company positions in Taiwan as an example, the average monthly salary in 2025 was 2.3 times the basic salary (the monthly basic salary in Taiwan in 2025 was NT\$28,590); it was 2.4 times for men and 2.2 times for women, regardless of gender, age, race, nationality and other factors.</p> <p>(2) 1. Implementation Status of Employee Salary Structure and of Policy to Reflect Business Performance or Results in Employee Remuneration The Company sets the compensation system according to the characteristics of the industry, market conditions and future development. We also provide appropriate incentives according to the achievement of the company’s operational goals and the performance assessment results of departments and employees in order to motivate our employees to jointly create operational performance and long-term value with the Company and to realize our establishment purpose, vision and mission and sustainable management.</p>	Company type		The Company				The Company and the subsidiaries listed in the consolidated financial statements				Gender		Female	Male	All	Difference (%)	Female	Male	All	Difference (%)	Average monthly salary (NTD)	Management position	110,702	121,057	116,009	4.57%	96,881	113,689	104,177	7.00%	Non-managerial position	62,681	69,375	65,659	4.54%	49,706	61,859	53,948	7.86%	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Company type		The Company				The Company and the subsidiaries listed in the consolidated financial statements																																					
Gender		Female	Male	All	Difference (%)	Female	Male	All	Difference (%)																																		
Average monthly salary (NTD)	Management position	110,702	121,057	116,009	4.57%	96,881	113,689	104,177	7.00%																																		
	Non-managerial position	62,681	69,375	65,659	4.54%	49,706	61,859	53,948	7.86%																																		

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
appropriately reflect operating performance or results on employee compensation?			<p>(1) Establishment of the Remuneration Committee: It is responsible for the policy, system, standard and structure of salary and compensation. The salary standard is in accordance with the classification of the position. The salary, license allowance, and promotion of positions shall not discriminate on the basis of gender, age, race, nationality, and other factors.</p> <p>(2) Performance evaluation: Performance evaluation shall be carried out twice a year, and the evaluation results shall be used as the basis for promotion, salary adjustment, bonus payment and compensation payment.</p> <p>(3) Bonus distribution: monthly or quarterly operational bonus, year-end bonus, employee remuneration distribution, project incentive bonus, etc. The total year-end bonus for the past 3 years ranged from 3–7% of net profit before tax for the year, and was distributed according to the appraisal criteria.</p> <p>2. Employee Remuneration Policy</p> <p>(1) Articles of Incorporation: In accordance with the Company’s Articles of Incorporation, the Company shall distribute 1% to 10% of the profit for the year as employee compensation, and within said employee compensation, no less than 10% shall be distributed as non-executive employee compensation. However, if the Company still has accumulated losses, it shall make up for the loss. Employee compensation may be in stock or cash, and the recipients of the stock or cash may include employees of subordinate companies who meet certain conditions. The distribution of employee remuneration (including the proportion distributed as non-executive employee compensation) must first be reviewed by the Remuneration Committee, then submitted to the Board of Directors for resolution and reported to the shareholders.</p> <p>(2) Non-Executive Employee Compensation Policy and Actual Distribution Status:</p> <ul style="list-style-type: none"> • Year-end bonuses: The Company distributes year-end bonuses to encourage all employees to strive together toward the Company’s goals. Non-executive employees 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(3) Did the Company provide employees with a safe and healthy working environment, and conduct regular safety and health education for employees?	✓		<p>accounted for 61% of the total value of 2025 year-end bonuses distributed in January 2026.</p> <ul style="list-style-type: none"> Employee compensation: On March 5, 2026, the Board of Directors made a resolution on the 2025 employee compensation proposal. The actual value of employee compensation distributed in June 2026 by the Company was approximately 3% of the profit for 2025, of which approximately 30% was distributed to non-executive employees. <p>The Company has established and implemented reasonable welfare measures (including salary, vacation and other benefits) and appropriately reflects the operational performance or results in employee compensation. Please refer to the explanations on page 169.</p> <p>(3) The Company has promulgated the “Occupational Health and Safety Management Manual”, “Human-caused Hazards Prevention Plan”, and “Abnormal Workload Disease Prevention Implementation Plan”, etc. The Company has also established regulations pertaining to labor safety and health measures, covering accidents, fire safety, electrical work safety, machine and equipment work safety, first aid and rescue, preparation, maintenance and use of protective equipment, accident notification and reporting, etc. and conducts regular education and training to ensure a good working environment and the protection of employees’ physical and mental well-being.</p> <ol style="list-style-type: none"> Improvement of occupational safety management: In order to optimize job responsibilities and planning timelines for occupational health and safety management, in March 2025, the Company amended 21 occupational health and safety management documents, including occupational health and safety policies, management plants, organizational design, planning and implementation, etc. Fire incident control: There were no fire cases, deaths, or injuries in 2025. The Company has formulated the “Safety and Health Work Code”, which clearly stipulates fire safety 	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>instructions. It has also formulated the “Directions on Fire Alarm Response Handling” in accordance with the “Emergency Response Management Guidelines”, stipulating the measures to be taken in the event of a fire alarm, how to activate the self-defense firefighting grouping and organization in the event of a fire, etc., which serves to comprehensively reduce workplace fire risks.</p> <p>3. Disaster response plan: The emergency response plans for earthquakes, typhoons and torrential rains, power outages, and fire protection are periodically reviewed, including preventive measures, response actions during incidents, and operating procedures.</p> <ul style="list-style-type: none"> • Head office: A fire drill was conducted on November 6, 2025. 1 occupational safety and health supervisor completed initial training (duration 42 hours), and another completed retraining (duration 6 hours); 2 fire prevention managers completed initial training (duration 12 hours). • Retail stores: As of the end of December 2025, self-defense fire organization (emergency response) training was provided for 136 participants. Each session lasted 4 hours, for a total of 544 training hours. <p>4. Fire escape drills: Fire escape drills are conducted regularly for employees to strengthen their safe escape concepts. During the past 2 years, fire drills were conducted on November 6, 2025, and October 4, 2024.</p> <p>5. Fire safety inspection: Fire safety inspections, filings, and reinspections by the fire brigade, etc., were successively completed at the head office in April and October 2025, and at each retail store from April to May and October to November 2025. Self-defense firefighting grouping drills were also conducted according to plan.</p> <p>6. Work environment safety inspection: The Company commissioned qualified fire protection companies and architects to conduct fire equipment inspection filings, and safety inspections and filings of fire prevention and evacuation facilities in buildings. The head office and stores implement 24-hour access control security management.</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(4) Did the Company establish an effective career development training program for employees?	✓		<p>7. Occupational safety and health education and training: On March 26, 2025, the Company held occupational safety and health training for retail staff, with 40 participants. For new employees, occupational safety and health training is implemented in accordance with the law upon onboarding. In 2025, 103 attendees completed the training (8.5 hours per person), totaling 875.5 hours.</p> <p>8. Health examination and healthcare benefits: Employee health examinations were held from June to September 2025, with a total of 210 participants; in April, August, and November 2025, employees received three discounts on healthcare products and spectacle lenses.</p> <p>9. Employee physical and mental health: The Company held monthly birthday parties, provided annual department employee travel subsidies, and held a 2025 year-end party, etc., to care for the physical and mental health of employees, unite staff teams, and build a sense of belonging so all employees can continue to work hand in hand with one heart to make progress together.</p> <p>10. Occupational disaster management and control: In 2025, the total number of working hours was 714,624, with 1 occupational disaster cases. The Company continued to strengthen awareness of occupational disasters on a monthly basis, and no occupational diseases or suspected cases were found through health examinations.</p> <p>11. Advocacy of occupational safety: Occupational safety advocacy information was shared monthly in 2025, for a total of 12 times.</p> <p>(4) The Company has established the “Education and Training Regulations” and the “Education and Training Procedures” to provide professional and managerial training courses for various categories of employees in order to achieve the goal of sustainable development and to enrich the knowledge and skills of employees.</p> <p>1. Aspects, scope, and content of training program:</p> <ul style="list-style-type: none"> For new employees: The Company’s history, organization overview, rules and regulations, and future outlook, as well as the correct understanding of the organization and a sense of belonging. 	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<ul style="list-style-type: none"> • In-service personnel: On-the-job training plans have been formulated based on the Company's business philosophy and policies, the training requirements and development goals of each unit, as well as the job responsibilities and professional fields of each position. The scope of training includes internal training, outsourced training, and supplier training. The training methods include online learning, physical courses, external training, and on-the-job training. • Management: The Company provides professional, regulatory, and management-related cultivation and training for the Company's supervisors and professional managers in accordance with the Company's business development strategy and corporate sustainability thinking so as to enhance supervisors' professionalism and leadership management knowledge and skills. <ul style="list-style-type: none"> ✧ Five-Year Growth Strategy Camp: This was held January 22, 2025. Supervisors in every division and department report, in a bottom-up way, their operating targets and strategic orientations; and the Chairperson and President provide top-down guidance. Attendees include the Chairperson, Chief Technology Officer, President, and supervisors at the division, department, and section levels, totaling 39 participants. ✧ 2025 ESG Kick-off Meeting: This was held December 22, 2025. The training course covered topics such as sustainability development trends, sustainability report disclosure frameworks, material topic assessment, and ESG assessment indicators. Attendees included the General Manager, division-level supervisors, department managers, section chiefs, and specialists, totaling 35 participants. 2. Optometrist professional functions grading cultivation and training: <ul style="list-style-type: none"> • The Company has carried out staffing as well as cultivation and training planning by professional functions grading for optometrists in accordance with the Training Blueprint 2.0, and has continuously developed professional courses according to the plan to provide optometrists with systematic on-the-job professional training that meets their practical needs. 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(5) Did the Company comply with relevant laws and international standards, and formulate relevant consumer or customer rights protection policies and grievance procedures for issues such as customer health and safety, customer privacy, marketing and labelling of products and services?	✓		<ul style="list-style-type: none"> • Licensing subsidies: In 2025, subsidies were given to a total of 154 optometrists/optical technicians for initial and ongoing professional association membership fees, totaling NT\$510,000. <ol style="list-style-type: none"> 3. General education courses: The Company has provided all personnel with relevant education and training on information security, personal data management, trade secret laws, etc. in accordance with the Company's information security rules, with the hope of strengthening colleagues' awareness of information security risks so as to ensure information security. 4. Quantified resources invested for the year's training program: In 2025, training fees were NT\$1,656,000, for a total of 8,186 hours of training. <p>(5) The Company has formulated a Consumer Rights and Interests Protection Policy, in order to put in place systematic management and protections for matters such as customer health and safety with products and services, customer privacy, marketing and labeling management, and consumer complaint handling.</p> <ol style="list-style-type: none"> 1. Product safety monitoring <ul style="list-style-type: none"> • The Company has established the "product safety control" system. For product development, evaluation, assessment, and quality management, the Company has formulated the Supplier Management Guidelines, the Purchase Requisition, Purchase, and Acceptance of Products Guidelines, the Adverse Drug Reaction Notification Guidelines, the Recall Mechanism and Handling Guidelines, and other rules so as to enhance the safety and quality of products and services. • The Company has regularly maintained the GDP (Good Distribution Practice) license for Western medicines and medical equipment. The strict quality management spirit covers the entire life cycle of medicines and medical equipment so as to ensure that the quality and package integrity will be maintained throughout the course of product storage and transportation. 	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<ul style="list-style-type: none"> • The Company' sales focus is on ophthalmic pharmaceuticals and consumables as well as optical products, primarily targeting cooperative clinics and optical store customers. The product names, external boxes, package inserts, and labeling of the products purchased and sold are fully in compliance with the Regulations for Registration of Medicinal Products. The Company has a dedicated unit in place to collect and analyze domestic and international medical material and drug regulations, and to proceed with the application, change of registration, extension of medical material and drug sales licenses, and the product quality inspection and certification. <ol style="list-style-type: none"> 2. Marketing and customer relations The Company has formulated the Media Procurement Operation Regulations, which are aimed at distributing information about the Company's products, and protecting the corporate image and other such information. The regulations require that all marketing and advertising comply with the Pharmaceutical Affairs Act, Medical Care Act, the Act Governing Food Safety and Sanitation, and other regulations. Before promoting the Company's products, business employees must undergo sufficient training to supply partner clinics and optometry customers with greater expert information and to maintain good interactions and relationships. 3. Complaint channels and complaint procedures The Company has established the "Customer Service Handling Regulations" to effectively handle customer inquiries and complaints. A customer service hotline and a contact mailbox have been set up on the Company's website to provide a channel and process for consumer inquiries or complaints, and all cases have been properly handled and documented. The Company has established a toll-free 0800 telephone number to directly respond to inquiries from the general public, and has complied with the relevant provisions of the Personal Data Protection Act to safeguard the rights of both parties. For more information, please visit the Customer Health and Safety section of the Company's website. (https://www.uvb.com.tw/investor/investor_a05_15) 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>4. Personal data protection policy and implementation status</p> <ul style="list-style-type: none"> • Personal data protection policy: The Company cares a great deal about Customer Privacy Protection. In compliance with the Personal Data Protection Act, the Company has established a Privacy Protection Policy, and formulated the Personal Data Protection Management Regulations and the Security and Maintenance Plan for the Protection of Personal Data Files and a Guideline on Disposing Personal Data Following a Business Termination. These provide customers with contact channels about their privacy rights, and provide them with ways to request inquiries, review, correction, suspension of collection, and deletion of their data. These are strict personal data privacy security management and protection measures. The Company also puts in place data governance systems, implementing data access permission controls and data ownership review mechanisms, to ensure that data access and sharing receive appropriate governance and protection, as well as to ensure data accessibility, completeness, and confidentiality. The scope of application covers the Company headquarters, operating sites, customers, and suppliers. • Personal data protection implementation status <ul style="list-style-type: none"> ✧ We strictly abide by the contents of customer contracts and confidentiality commitments, and all information, documents and data that are commercially confidential and related to our customers are uploaded to our internal system for strict control, and we are required to use account passwords to log into the system and browse documents online. ✧ Personal Data Protection Act, Trade Secrets Act, and Advocacy of Information Security training courses have been included in the onboarding program for new employees. As of December 31, 2025, 103 participants have completed training on the Personal Data Protection Act, 92 have completed training on the Trade Secrets Act, and 91 have completed training on the Advocacy of Information Security. ✧ Management personnel are assigned to be responsible for planning, formulating, 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(6) Did the Company formulate a supplier management policy, requiring suppliers to follow relevant norms on issues such as environmental protection, occupational safety and health, or labor rights, and their implementation status?	✓		<p>amending, and implementing matters related to personal data security maintenance and the disposal of personal data following business terminations. Approximately NT\$200,000 is allocated each year for the implementation budget for such.</p> <p>For more information on customer privacy protection policies and regulations, the customer service hotline, the privacy reporting email address, and the implementation status for the year, please see the Personal Data Protection Policy and Implementation Status section of the Company's website (https://www.uvb.com.tw/investor/investor_a05_14).</p> <p>(6) The Company has formulated the Supplier Management Guidelines to establish relevant rules for supplier development, evaluation, assessment, and quality management to ensure that qualified suppliers can provide long-term and stable supplies of quality products and to assist in the continuous improvement of product quality. The Company has formulated the Key Points for Supplier Sustainable Development Management to implement sustainable management of the supply chains based on the promotion of environmental protection, occupational safety and health, and labor rights, and to provide responsible units with information on supplier sustainable development management when implementing procurement operations for reference.</p> <p>Sustainability implementation status of suppliers in 2025:</p> <p>(1) International supply chain</p> <p>The Company has integrated procurement resources and achieved the most competitive supply chain value through strategic cooperation. All the global supply chain companies are quite well-known and most of them are listed companies in their own countries. They must meet ESG requirements in terms of products, financial performance, corporate governance or corporate sustainability, and other aspects to comply with local government regulations for publicly listed companies.</p> <p>The Company regularly holds procurement meetings with international suppliers and</p>	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>works with relevant units to identify risks related to the time of delivery, quality management, or supply chain interruptions for the product; it also holds training sessions and forums from time to time to move hand in hand toward sustainable operations through various forms of communication.</p> <p>(2) Localized supply The Company has continued to diversify and localize supply, deepen its influence through long-term strategic partnerships with domestic suppliers to jointly build a green supply chain, paying attention to issues such as environmental friendliness, occupational safety and health, and labor rights. In terms of store openings and development at each business location, the Company focuses on the occupational safety of the contractor for the renovation engineering and holds Supplier Conferences every year (the two most recent sessions were on January 16, 2026, and January 3, 2025) to advocate occupational safety and health management rules, construction protection, personal protective equipment, etc.; in addition, rules have been formulated in accordance with labor safety, health, environmental protection, and other laws and regulations to be included in the contractor agreement. Suppliers are checked from time to time during construction to see whether the contractor has carried out advocacy and implementation in accordance with the rules. If a supplier is involved in the violation of social policies with a significant impact on the environment and society, the contract may be terminated or cancelled at any time.</p> <p>(3) Advocacy of sustainable supply chain In order to promote suppliers' improvement of their economic, social, and environmental performance and establish a sustainable supply chain, the Company has prepared the "Supplier Sustainability Statement", which stipulates environmental protection, safety, health, human rights, ethical code, government requirements, social responsibility, and other relevant issues. Additionally, the Company has advocated domestic suppliers' compliance with relevant rules so to jointly fulfill corporate social responsibilities. The</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>Company's top ten purchases account for 80% or more of its total purchases; therefore, it has carried out advocacy and encouraged the top twenty suppliers in four categories: optical products, pharmaceutical consumables, instruments and equipment, and renovation engineering. As of the end of 2025, the Company has completed its advocacy for 80 domestic and foreign suppliers, and the advocacy rate (the purchase amount of the advocated suppliers as a percentage of total purchase amount) has reached 97.3%. In the future, the Company will gradually advocate for this statement to be extended to the domestic and foreign suppliers of subsidiaries' purchasing units so as to complete the management of suppliers.</p> <p>(4) ESG sustainable supplier and procurement The Company has proactively implemented sustainable procurement and pursued economic benefits while taking into account environmental friendliness and human rights protection, and it continued to advocate the concept of "ESG procurement" to purchasing units. When making purchasing decisions, purchasing units prioritize suppliers that implement ESG results to serve as strategic partners. Under the premise of ensured quality and reasonable price, the Company strives to purchase environmentally friendly materials certified by the Green Label and incorporate green energy-saving specifications into purchasing options. The Company encourages suppliers to not only protect the environment, but also contribute to ESG practices in aspects of social inclusion and corporate governance so as to achieve sustainable development in the supply chain. In recent years, the purchase amount from ESG sustainable suppliers as a percentage of net purchases has all exceeded 80% (81% in 2022, 82% in 2023, 84% in 2024, and 81% in 2025), demonstrating the performance of the ESG sustainable supply chain.</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
5. Did the Company refer to the internationally accepted reporting preparation standards or guidelines to prepare reports such as sustainability reports that disclose non-financial information of the Company? Did the foregoing disclosure report obtain the assurance or assurance opinion of the third-party verification unit?	✓		<p>The Company compiled the Sustainability Report in accordance with the GRI Guidelines issued by the Global Reporting Initiative, the SASB Standards issued by the Sustainability Accounting Standards Board, the guidelines for the TCFD climate-related financial disclosures, and the Taipei Exchange Rules Governing the Preparation and Filing of Sustainability Reports by TPEX Listed Companies. The Company then posted the report on the Market Observation Post System and announced it on the Company’s website. The Chinese version was uploaded on August 14, 2025, and the English version was uploaded on October 22, 2025.</p> <p>The content disclosed in the Company’s sustainability report complies with the AA1000 Assurance Standard v3 Type 1 and has obtained an independent assurance opinion statement issued by Great Certification, a third-party verification unit.</p>	In conformity to the requirements of the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
6. If the Company has its own code of sustainable development in accordance with the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, please clearly describe the difference between its operations and the stipulated code: No difference.				
7. Other important information that helps to understand the implementation status of sustainable development: The Company was founded on the principle of “the way of great learning consists in manifesting one’s bright virtue, consists in loving the people, consists in stopping in perfect goodness.” It is committed to the management concept of “See Clear, See Comfort, See the Future” for the public, and to building a map of eye health for the UNIVERSAL VISION. In addition to actively achieving our operational goals, the Company is also integrating corporate sustainability ESG (Environmental, Social, and Governance) into its corporate strategy and operations so to gradually promote various ESG tasks.				

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>The Company is deeply aware of its corporate responsibility and mission to society. By actively participating in the activities of public welfare organizations and investing resources to care for the underprivileged, attaching importance to talent cultivation and community motivation, and supporting domestic cultural development, the Company's strength will be appropriately exerted to bring about change and impact society.</p> <p>Important information on the implementation status of sustainable development in 2025 is summarized as follows:</p> <p>(1) Social welfare services</p> <ol style="list-style-type: none"> In Taiwan, the Company assisted its cooperative clinics in conducting a total of 55 sessions of community vision health charity activities (including 24 sessions with the Taoyuan City Government telemedicine project and 7 sessions of Taiwan Taxi eye-care promotion and public welfare screenings). With 260 staffs participating, these sessions served a total of 2,893 people. 22 campus vision care sessions were held at 10 kindergartens, 7 universities/colleges, and 5 community elder-care centers in Taipei City and New Taipei City, with eye-care activities and talks. 52 staffs participated, serving a total of 3,185 people. 23 sessions of community vision health charity activities were also conducted in remote areas of Chiayi, with 106 staffs participating, and serving 837 people. A total of 100 sessions of the aforementioned community activities were held in 2025, with 418 total staffs and a total of 6,915 people served. In Mainland China, the Company conducted public welfare screenings at the campuses of more than 151 schools, providing vision health screening services for more than 557,609 children and adolescents. The Company responds annually to the Neihu Technology Park Blood Donation Campaign, organized by Taipei's Neihu Technology Park. The Chairperson personally led employees to donate blood, taking passionate action to save lives (February 2025). Participated in Uni-President Social Welfare Foundation's "Love Mama, Love You So Much" Mother's Day public welfare event. 10 groups joined hands to show care for families of children undergoing early intervention. 400 children, mothers, and other family members were invited to attend. UVB joined with partner clinics to give 103 people vision screenings (April 2025). The Company joins in the Taipei Technology Cup Love Earth Charity Road Run Event every spring and fully subsidizes employees' registration fees. The Chairperson personally led the event, and a total of 92 employees participated in the charity run (April, 2025). Participated in the 2025 Taipei 101 Run Up, taking real action to show care about public health and welfare. Made donation of NT\$400,000 to Taipei 101's designated public welfare organizations, with 17 employees forming a team to compete; won 2nd place among corporate public welfare teams (May, 2025). 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(2) Charity Care Donation				
			<ol style="list-style-type: none"> 1. Made public welfare donations of 3600 pairs of eyeglasses to Taoyuan City Government, Hsinchu County Government, Taichung City Government, and others, helping protect local families in remote villages and in 2. In cooperation with the Global Views - Commonwealth Education Foundation, the Company participated in the Sowing the Seeds of Reading – Giving Children a Big Future campaign by donating a 1-year subscription of <i>Global Kids</i> magazine to 12 elementary schools in rural areas of Chiayi, benefiting a total of 35 classes with 35 subscriptions. The Company similarly donated 3 <i>Global Kids Junior Monthly</i> magazine subscriptions to 3 classes in Shanmei Elementary, in a remote village in Chiayi County. The Company also donated a set of SDGs sustainable book boxes to the same 13 schools, with one copy of each title for a total of 221 books (May, 2025). 3. Participated in the “2025 Love You, Love Me: June 19 Global Kindness Day”, organized by the GFCBW. This campaign donated ambulances and rescue vehicles to fire departments in various counties and cities, as well as in remote regions and outlying islands. By so doing, the campaign will help enhance emergency rescue and disaster response capacity (June, 2025). 4. Made donations to help disaster recovery following the Matai’an River barrier lake disaster in Hualien County. The donation recipients were Hualien County Government and the Global Federation of Chinese Business Women of Taipei City and Chairwomen Chapters, which received a total of NT\$60,000 (November, 2025). 5. Sponsored the 2025 “Healthy Kids: Reading for Fun” healthy children picture book series. This benefits the health of children all around Taiwan; the donation recipient was the Hway Hsen Medical Foundation (December, 2025). 	
(3) Eye Care and Health Education Promotion				
			<ol style="list-style-type: none"> 1. The Company assisted its partner clinics in promoting eye care and health education, especially in the areas of myopia prevention and control for children, vision correction for the middle-aged, and presbyopia and cataract care for older adults. The Company has provided in-person and online eye care education talks, speeches, and eye care knowledge to jointly protect people’s eye health. 2. The Company was invited to participate in health-related radio, television, and online programs or podcasts, such as Health Media Network, UFO Radio, NOW Health, HEHO Health, News98, ETtoday, IC Broadcasting, Pop Radio, TVBS Health 2.0, USTV Finance, Off-Duty Economics, Health Classmates Club, and Health Roll Call, giving lectures on eye care and health education. 3. Joined hands with supply chain partner Brighten Optix to hold the “A Family Eye-Venture: Having Fun with Eyecare Together” event at the Taipei Zoo. At the event, Teacher Tadpole, an eco-Youtuber, shared fun trivia about animals’ vision; and the Ocean Family kids performance group put on a dance and singing interactive performance. Together, they helped kids learn how to control myopia, and provided adults with vision care knowledge (May, 2025). 	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
			<p>4. The Company, together with supply chain partner Essilor, hosted two sessions of the Vision Planet Challenge at the National Taiwan Science Education Center. With a space exploration theme, children and parents were invited, with 120 people participating to explore five vision-themed “planets” through interactive games. The activity introduced the causes of myopia, preventive measures, and myopia control in an engaging and easy-to-understand way (August, 2025).</p> <p>5. The Company launched the customer engagement program Universal Magic Academy, which is a series of interactive family events designed to raise awareness of visual health. Activities included sports competitions, parent-child eco-bag painting, and a magic stamp rally game. Vision health professionals were invited to deliver information about proper eye care, localizing vision health education for every household. In 2025, three sessions were held across Taiwan (one in Taipei/New Taipei, one in Taoyuan/Hsinchu, and one in Southern Taiwan), with 220 total participants.</p> <p>6. The Company participated in the 2nd Healthy Aging Industry Expo, co-organized by the Development Center for Biotechnology, the Industrial Development Administration, the Administration for Digital Industries, and the National Health Research Institutes. At the expo, the Company provided eye health education materials and information on cataracts and presbyopia for older adults. A total of 288 participants were served (August, 2025).</p> <p>7. Invited to attend the Children’s Vision Protection Campaign, organized by Zeiss. Together with many ophthalmology specialists, bore witness to how protection for children’s vision is moving toward a “New Seen-tury of Vision” (December, 2025).</p> <p>8. The Company participated in the 2025 Taiwan Healthcare+ Expo and responded to the “Taiwan’s Largest Health Party” theme. Integrated expert consulting services on elder presbyopia and multi-focal prescriptions and vision health solutions; provided health education on eye health and common eye diseases. All this helped enhance public recognition of vision health and preventive medicine, serving 616 persons (December, 2025).</p> <p>(4) Product and Service Innovation</p> <p>1. Store service awarded: Universal Optical’s Tainan Minsheng and Taoyuan Zhongli branches were honored by the Taiwan Chain Stores and Franchise Association at the 12th TCFA Service Angel awards (April, 2025).</p> <p>2. New products on the market: Introduced the new EVO implantable collamer lens (ICL) technology from STAAR Surgical (a Swiss company). This technology uses minimally-invasive techniques to implant the anterior chamber-type ICL, providing the population with moderate to severe myopia with a new choice in correction. The products advantages include that it is minimally invasive; it is reversible; it uses new implantable lens with central hole technology; it uses the patented Collamer material, with high compatibility with eye tissues; and that it obtained US FDA certification in 2022, and then initial Taiwan FDA certification in 2025 (July, 2025).</p>	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
3.			New optometry services: Universal Optical joined hands with Hoya, Japan’s leading optical brand, to launch the new Dual-Expert Precision for Progressive Lenses optometry model. This integrates the Smart Multi-Focal Real Lens Experience, to enhance wearers’ grasp of multi-focal lens technology. This provides members of the public who are troubled by presbyopia with personalized smart-prescription multi-focal eyeglasses, to precisely enhance their vision quality (July, 2025).	
4.			International medical certification: With assistance from the Company, the Xinnan partner eye clinic passed Joint Commission International (JCI) Accreditation in 2025. This marks the sixth time that the Xinnan clinic has received this honor (2010, 2013, 2016, 2019, 2022, and 2025).	
5.			AI service innovation: Joined in the Taiwan Chain Stores and Franchise Association’s “2025 TCFA Chill Go Joint Initiative”. The initiative’s primary focus was using AI to enhance localized service and create a new everyday of machine-assisted living. Through technological assistance, optometry can focus on warm interactions, and thus creating service models that allow for both AI efficiency and personalized experiences (November, 2025).	
6.			New product development: There is an increasing use of digital devices and prolonged screen time, which leads to fatigue and dryness. In response, the Company has launched the new stronger SOS Jin Run Ming (enhanced hydration formula) Lutein product, which offers a complete eye-nourishing solution with crystal clarity and moisture. This product was honored in the 28th Symbol of National Quality (SNQ) awards (December, 2025).	
(5)			Talent Cultivation and Community Participation	
1.			Industry–university cooperation plan: To support education at local science and technology universities, increase students’ practical work experience, and reduce the risk of manpower shortages, the Company has actively carried out industry–university and cooperative education with the colleges and universities adjacent to each of its stores and arranged for students to receive practical work training. This includes signing industry–university and constructive education contracts with seven universities and colleges, providing students with internship placements and workplace experience opportunities, and inviting teachers and students from partner schools to visit. In 2025, there were 199 industry–university cooperation participants and 39 optometry (store) internship participants.	
2.			Optometry talent development: President Kenneth Lu attended a signing ceremony for the Industry–University Cooperation Plan at Jenteh Junior College of Medicine, Nursing and Management. The Company has invested in industry-academia collaboration for a long time, using a scholarship system to assist students by lightening their study burdens. This helps them to focus on the professional training and preparing for certifications. Then, after graduation, they can smoothly connect with the Company. This enhances practices in clinics and stores, strengthens specialist service quality in optometry, and works toward forming the development chain for the next generation of optometry talent. Together, the Company and Jenteh are laying a more solid talent foundation for Taiwan’s optometry industry (November, 2025).	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
3.			Supporting higher education: In response to the National Taiwan University’s promotion of school affairs development and industry–university cooperation to celebrate the 100th anniversary of the school’s founding, the Company has pledged to donate NT\$2 million per year to National Taiwan University for a period of 5 years (from 2023–2027) totaling NT\$10 million, to be used exclusively for coordinating industry–university development (July, 2025).	
4.			Universal Eyeglasses Short Video Program: With employee optometrists as the main subjects and eyecare knowledge as the central theme, producing short, eye-catching, podcast-style videos. These videos incorporate popular trends and real-life situations, connecting with viewers emotionally, and encouraging interaction and sharing of eye health concepts. (2.33 million views, 10,000 likes, and 5,000 interactions to date.) In 2025, 69 videos were released featuring 38 participating optometrists. The 2025 Universal Golden Eye Awards was also held to recognize outstanding optometrists and store teams for their creative content. By combining creativity and professionalism, the program not only brought eye health knowledge closer to the public but also inspired store colleagues, becoming a catalyst for internal culture and injecting fresh energy into the brand while spotlighting employees, improving their self-worth, and encouraging growth.	
5.			International exchange and visits: Serge Zins, VP Asia Pacific at Hoya Vision Care, and George Kwan, Managing Director of Hoya Vision Care Taiwan, came for a visit and exchange (March, 2025); University of Geneva Faculty of Medicine Professor Farhad Hafezi did a visit and exchange (April, 2025); Company representatives visited Xi’an People’s Hospital (Xi’an Fourth Hospital) and Youyue Ophthalmology clinics, and attended the announcement of the new Stellest brand (June, 2025); Leon Adler, Executive Assistant to the Chief Commercial Officer at Carl Zeiss Meditec, paid a visit for exchange (November, 2025); CooperVision invited global vision control authority Dr. Kate Gifford to engage in exchanges with physicians in the partner clinic system, focusing on recent evidence for controlling myopia, children’s prescription safety, and trends in soft contact lenses (November, 2025); and then-President Prof. Filomena Ribeiro, then President-elect Prof. Burkhard Dick, and Elected Council Member Prof. Thomas Kohnen, all of the European Society of Cataract and Refractive Surgeons (ESCRS), came for visits and exchange (December, 2025).	
6.			Supporting Domestic Cultural Development: The Company has actively invested in domestic performing groups, arts and cultural organizations, and the creation of artistic works, focusing on the production, broadcasting, exhibition, and performance of movies, TV, music, and dramas. The Company also collaborates with local cultural institutions and other arts and cultural venues through support and sponsorship of arts and cultural activities, hoping to drive the development of Taiwan’s overall cultural and creative industry so as to fulfill its corporate social responsibilities. In 2025, the total amount of sponsorships and related resource investments in activities such as traditional folk customs, music exhibitions and performances, drama creations, arts and cultural creations, art venues, film and television promotions and productions, events to promote reading habits, and more reached NT\$5.02 million. The items, time, amount, and activities where resources have been invested are disclosed in the Support Domestic Cultural Development section of the Company’s website. (Please visit https://www.uvb.com.tw/investor/investor_a05_11 for details.)	

Implementation item	Implementation status			Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	

Note 1: If you tick “Yes” for the implementation status, please specify the important policies, strategies and measures adopted and the implementation status; if you tick “No” for the implementation status, please fill in the “Difference from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, and the reasons” field to explain the circumstances and reasons for the differences, and describes the plans to adopt relevant policies, strategies and measures in the future.

Note 2: The principle of materiality refers to those issues which have a significant impact on the Company’s investors and other stakeholders related to environmental, social and corporate governance.

(6) Climate-related information of TWSE/TPEX listed companies

1. Implementation status of climate-related information

Item	Implementation status
1. Describe clearly the supervision and governance of climate-related risks and opportunities by the Board of Directors and management.	<p>Supervision and governance by the Board of Directors:</p> <p>The Company's Board of Directors is the highest governance unit to promote the sustainable development of the enterprise. Based on the principle of ethical corporate management and safeguarding the rights and interests of shareholders, the Board of Directors oversees a wide range of environmental risks and opportunities, including the impacts related to climate change. The Company's Board of Directors has reviewed the progress of greenhouse gas inventory and verification every quarter since 2022, and the latest report was made on December 18, 2025, which has been put on record. In addition, the Board of Directors reviews the Company's risk management operating status at least once per year, including categories, content, and control mechanisms of responses to climate risk. The latest report was made on November 12, 2025, and is on file.</p> <p>Supervision and governance by the management:</p> <p>In order to implement the sustainable development of the enterprise, the Board of Directors passed the Sustainable Development Practice Principles and established the Governance and Sustainable Development Office to carry out various sustainable actions, including climate risk assessment, greenhouse gas inventory, etc., and is in charge of the Company's coordination and promotion of climate issues, goal setting, action planning and implementation.</p>

Item	Implementation status			
2. Describe clearly how the identified climate risks and opportunities affect the Company's business, strategy, and finance (short-term, medium-term, long-term).	The Governance and Sustainable Development Office uses the TCFD framework to identify climate risks and opportunities every year based on the Company's own business characteristics, and generates TCFD material issues to analyze the physical risks that may occur in the short-, medium-, and long-term, the extent of impacts and the financial impact, and further formulate response measures so as to strengthen corporate climate resilience.			
	Physical risk Risk description	Severe rainfall and drought Severe rainfall results in logistical interruptions, warehouse flooding, and damage to pharmaceuticals and consumables.	Typhoon Strong typhoons damage the supply chain, stores cease business, and transport is delayed.	Average temperature rise Long-term high temperatures increase energy consumption for air conditioning, risks to employee health, and the worsening of pharmaceutical and consumable storage conditions.
	Impact timeline	Short-term to midium-term	Short-term to midium-term	Midium-term to Long-term
	Impact level	Midium to high	High	Medium
	Financial Impact	Damage to warehouses; increased logistical costs; rising insurance premiums.	Damage to assets; operational interruptions; increased costs from emergency response.	Energy costs rise; employee productivity decreases; cold chain equipment investment increases.
	Response measures	1. Strengthen infrastructure engineering (such as flood control facilities for stores) and implement water conservation. 2. Purchase property insurance related to climate on a yearly basis.	1. Reinforce store architectural structures. 2. Strengthen disaster response and store anti-typhoon measures (removing signage, etc.). 3. Supplier's long-term supply as strategic partner.	1. Set air conditioning at 28°C in offices and operating locations. 2. Change air conditioning and lighting equipment to high energy efficiency classes to conserve energy.

Item	Implementation status			
3. Describe clearly the financial impact of extreme climate events and transition actions.	Transition risk	Market uncertainty	Change in customer behavior	Regulatory changes
	Risk description	Transformation to the low-carbon economy results in fluctuating demand (such as demand for environmentally-friendly eyeglass frames increased, while traditional products move more slowly).	Consumer preferences turns toward low-carbon products; if the Company is unable to respond in a timely manner, market share will be lost. High temperatures and strong light in extreme climates may trigger new transitional demands related to cataracts, dry eye syndrome, and polarized lenses.	Carbon fees beginning to be assessed increase operating costs; if unable to reduce carbon, the Company will face penalties or weaker competitiveness. With regulatory requirements for greenhouse gas inventories, verifications, etc., human resources costs, verification fees, and operating costs for climate-related information disclosures.
	Impact timeline	Medium-term	Medium-term	Medium-term
	Impact level	Medium	Medium	Medium
	Financial Impact	Warehousing pressures; increased investment in new product development.	Operating and profit structure changes. Brand value affected.	Rising carbon fee expenditures; product price competitiveness declines. Increase in operating expenses
	Response measures	<ol style="list-style-type: none"> 1. Product grouping adjustments. 2. Building an agile supply chain management system. 3. Energy conservation and carbon reduction activities are implemented in the offices and operating bases to implement green procurement. 	<ol style="list-style-type: none"> 1. Developing low-carbon frames and environmentally-friendly packaging. 2. Strengthening green marketing and customer communications. 3. Developing new products or services. 	<ol style="list-style-type: none"> 1. Introduce carbon inventories and carbon reduction plans. 2. Low-carbon requirements for the supply chain.

Item	Implementation status
<p>4. Describe clearly how climate risk identification, assessment, and management processes are integrated into the overall risk management system.</p>	<p>The Company has integrated climate risks into the risk management system, established an effective risk management mechanism, and assessed and monitored risk-taking capabilities and risk management status. The Board of Directors has passed the Risk Management Policies and Procedures as the Company’s highest guiding principle for risk management, integrating and managing various strategic, operational, financial, and hazardous (including climate change, etc.) potential risks that may affect operations and profits. The Company also carries out risk warning and takes appropriate preventive measures to maintain operational activities when an accident occurs.</p> <ol style="list-style-type: none"> 1. Risk content: Greenhouse gases, carbon emission management, energy use, and other related issues in response to issues related to climate change and natural disasters, as well as the risks that may affect the Company due to the need to comply with international norms and local government laws and regulations. 2. Control mechanism: <ol style="list-style-type: none"> (1) Climate-related implementation: The physical risks of natural disasters (such as floods and droughts) caused by global warming will expose enterprises to operational pressures and impacts, as well as the transition risks of increasing the proportion of renewable energy use due to government regulations and international initiatives (Taipower will raise electrical expense and the use percentage of renewable energy will lead to higher electricity costs). The Company conducts annual climate risk and opportunity identification and climate change-related response actions based on its own business characteristics and as recommended by TCFD, including governance, strategies, climate risks and opportunities analysis, climate scenario analysis, risk management, indicators, and goals. (2) Carbon emission management: Regularly establish carbon inventories and carbon emission estimates, as well as specific reduction indicators. Promote electricity and energy-saving programs and set carbon reduction performance indicators to facilitate carbon emission management. (3) Implementation of “ESG procurement”: Advocate ESG management key points to suppliers, set ESG supply chain performance indicators (such as the number of companies for advocating ESG and percentage of ESG procurement), and respond to the international initiative of sustainable development goals (SDGs). (4) Disclosure through sustainability reports to explain climate risk response and effectiveness.
<p>5. If scenario analysis is used to assess resilience to climate change risks, please explain the scenarios, parameters, assumptions, and analysis factors used as well as the main financial impact.</p>	<p>The Company uses the Worst-case Scenario to analyze the impact of climate change on operations in accordance with the recommendations of the TCFD guidelines. It incorporates the analysis results into the risk management process, and takes appropriate adaptation actions.</p> <ol style="list-style-type: none"> 1. Analysis of physical risks of climate change <p>Set the baseline scenario and 2°C scenario to identify and analyze the short-, medium-, and long-term climate risks and opportunities in the Company’s operating scope and the entire life cycle of its assets. In terms of transition risks, the baseline scenario and the 2°C scenario refer to the RCP8.5 and RCP 2.6 climate scenarios of the United Nations Intergovernmental Panel on Climate Change (IPCC) respectively, and risk assessments are conducted on immediate physical risks and long-term physical risks.</p>

Item	Implementation status
	<p>(1) Immediate Physical Risks: The increasing frequency and severity of typhoons have led to risks of damage to facilities, equipment, or inventory caused by strong winds and heavy rain. In 2025, four typhoons — Danas, Podul, Ragasa, and Fung-wong — along with multiple torrential downpours struck Taiwan. These affected seven operating locations, with estimated financial losses of approximately NT\$200,000 due to repairs to exteriors and signage. (In 2026, with the expansion to 36 business locations across Taiwan, and an estimated 3–5 typhoons expected to strike, losses from typhoon-related damages are projected at NT\$200,000–500,000 due to the increased number and size of operating locations.)</p> <p>(2) Long-term physical risks: The average temperature continues to rise, resulting in increased energy consumption and increased operating costs.</p> <ul style="list-style-type: none"> ● Under the scenario of RCP 8.5, Taiwan’s TCCIP research pointed out that Taiwan’s average temperature will increase by 0.90°C from 2021–2040, 1.65°C from 2041–2060, 2.53°C from 2061–2080, and 3.37°C. from 2081–2100. It can be found that the average temperature in Taiwan will continue to rise. Assuming that the Company’s power demand remains unchanged and remains at the electricity consumption in 2025 (annual electricity consumption of 752,474 kWh); the average temperature across Taiwan increases by 1 degree, resulting in an increase of 6% in electricity consumption; and that the average electricity price per kWh remains unchanged at NT\$5, it is therefore expected that by 2040, Universal Vision’s electricity bill will increase by NT\$203,000 per year. Under these assumptions, it will increase to NT\$372,000 by 2060; NT\$571,000 by 2080; and NT\$761,000 by 2100. ● Under the scenario of RCP2.6, Taiwan’s TCCIP research pointed out that Taiwan’s average temperature will increase by 1.02°C from 2021–2040, 1.35°C from 2041–2060, 1.31°C from 2061–2080, and 1.2°C. from 2081–2100. It can be found that Taiwan’s average temperature will reach its peak from 2041–2060, and then continue to cool. Assuming that the Company’s power demand remains unchanged and remains at the electricity consumption in 2025 (annual electricity consumption of 752,474 kWh); the average temperature across Taiwan increases by 1 degree, resulting in an increase of 6% in electricity consumption; and that the average electricity price per kWh remains unchanged at NT\$5, it is therefore expected that by 2040, the Universal Vision’s electricity bill will increase by NT\$230,000 per year. Under these assumptions, it will increase to NT\$305,000 by 2060; NT\$296,000 by 2080; and NT\$271,000 by 2100. <p>2. Climate change transition risk analysis</p> <p>The Company does not belong to an energy-intensive industry. Nevertheless, it still pays close attention to global climate-related measures and analyze the possible financial impact caused by transition risks. According to the assessment results, this transition risk will not have a significant impact on operations in the short- to medium-term. In order to reduce the impact of transition risks, the Company will continue to promote various energy-saving measures and seek various possible carbon reduction actions and new product business opportunities in extreme climates.</p> <p>In August 2024, the Ministry of Environment of the Executive Yuan announced three carbon fee regulations, officially marking Taiwan’s entry into the era of carbon pricing. Starting in 2025, carbon emissions will be formally included in the calculation of carbon fees. Beginning in 2026, entities subject to the fee—those in the electricity, gas supply, and manufacturing sectors with</p>

Item	Implementation status								
	<p>annual greenhouse gas emissions of 25,000 metric tons of CO₂e or more—will be charged a general rate of NT\$300 per metric ton of carbon dioxide equivalent. The Company does not belong to a high carbon leakage risk industry and is currently not subject to carbon fee collection.</p> <p>The Company’s carbon risk assessments are planned out based upon the scientific conclusions and policy scenarios in the UN Intergovernmental Panel on Climate Change (IPCC) Sixth Assessment Report (AR6) Climate Change 2023: Synthesis Report. That report states that internalized carbon cost mechanisms such as carbon pricing, carbon fees, etc. are key policy tools to achieving the temperature targets established by the Paris Agreement.</p> <p>Based on related research by the IPCC, International Energy Agency (IEA), and International Monetary Fund (IMF), by 2030, carbon pricing standards are suggested to rise to c. US\$50–100 per ton CO₂e; prices are expected to continue rising in the medium to long term. The Company includes these long-term carbon pricing trends within the assumptions for climate risk assessments, in order to strengthen management of transformational risk.</p> <p>Based on the Company’s annual greenhouse gas emissions for 2025, it is estimated that the maximum value for the long-term potential risk of carbon fees beginning to be assessed will be an additional NT\$1,789 thousand per year (calculated as US\$100 per ton, equivalent to NT\$3,000/ton, × 596.40 tons, = NT\$1,789 thousand).</p>								
<p>6. If there is a transition plan in response to the management of climate-related risks, please describe the content of the plan, and the indicators and goals used to identify and manage physical risks and transition risks.</p>	<p>The Company conducts risk identification for climate change, including analysis of risks and opportunities caused by direct or indirect impacts due to extreme weather, transition impacts of regulations, technology, or market demand, and other humanistic and social aspects on the Company’s operating activities. A risk management strategy plan is established based on the analysis results to serve as the core of climate change response actions, and relevant opportunities are identified to reduce risks and to seize business opportunities. The assessment results are summarized as follows:</p> <table border="1" data-bbox="465 906 2152 1425"> <thead> <tr> <th data-bbox="465 906 654 1018">Risk categories</th> <th data-bbox="654 906 918 1018">Climate change risk identification</th> <th data-bbox="918 906 1279 1018">Climate change opportunity identification</th> <th data-bbox="1279 906 2152 1018">The Company’s response measures</th> </tr> </thead> <tbody> <tr> <td data-bbox="465 1018 654 1425">Energy source</td> <td data-bbox="654 1018 918 1425">Demand for clean energy / insufficient power supply / shortage of water.</td> <td data-bbox="918 1018 1279 1425"> <ul style="list-style-type: none"> When adding new equipment, comply with government energy conservation and carbon reduction policies. Promote the electronic management system. </td> <td data-bbox="1279 1018 2152 1425"> <ul style="list-style-type: none"> Support colleagues to use public transportation or bicycles to come to work, as well as office planting and greening to reduce carbon emissions. Advocate green consumption for office and daily purchases of products primarily with green procurement label. Establish an electronic management system to ensure the operation of low-carbon activities at all stages and to improve efficiency. When purchasing office equipment, purchase air conditioning, lighting, and water-saving equipment that meet the requirements for energy-saving subsidies. </td> </tr> </tbody> </table>	Risk categories	Climate change risk identification	Climate change opportunity identification	The Company’s response measures	Energy source	Demand for clean energy / insufficient power supply / shortage of water.	<ul style="list-style-type: none"> When adding new equipment, comply with government energy conservation and carbon reduction policies. Promote the electronic management system. 	<ul style="list-style-type: none"> Support colleagues to use public transportation or bicycles to come to work, as well as office planting and greening to reduce carbon emissions. Advocate green consumption for office and daily purchases of products primarily with green procurement label. Establish an electronic management system to ensure the operation of low-carbon activities at all stages and to improve efficiency. When purchasing office equipment, purchase air conditioning, lighting, and water-saving equipment that meet the requirements for energy-saving subsidies.
Risk categories	Climate change risk identification	Climate change opportunity identification	The Company’s response measures						
Energy source	Demand for clean energy / insufficient power supply / shortage of water.	<ul style="list-style-type: none"> When adding new equipment, comply with government energy conservation and carbon reduction policies. Promote the electronic management system. 	<ul style="list-style-type: none"> Support colleagues to use public transportation or bicycles to come to work, as well as office planting and greening to reduce carbon emissions. Advocate green consumption for office and daily purchases of products primarily with green procurement label. Establish an electronic management system to ensure the operation of low-carbon activities at all stages and to improve efficiency. When purchasing office equipment, purchase air conditioning, lighting, and water-saving equipment that meet the requirements for energy-saving subsidies. 						

Item	Implementation status			
	Products and services	Low carbon products and services.	Promote low-carbon products and services in response to climate change.	<ul style="list-style-type: none"> • When purchasing products and equipment, introduce suppliers that pay attention to ESG sustainable development. • Establish an energy-saving and carbon-reducing work environment, and provide lower carbon emission-intensive services to the public.
		Seek new business opportunities.	The international community continues to attach importance to environmental awareness and care for life on earth.	<ul style="list-style-type: none"> • High temperatures and strong light in extreme climates may trigger new transitional demands related to cataracts, dry eye syndrome, and polarized lenses.
Climate management results and development goals				
TCFD aspects	Climate management key results			Development goals
Governance	<ul style="list-style-type: none"> • The Board of Directors is the highest governance unit that oversees climate change risks and opportunities, and is in charge of decision-making and supervision of climate-related issues and matters. • The Governance and Sustainable Development Office, subordinate to the Board of Directors, is a dedicated unit for climate change management. It is in charge of drafting strategies, assessing, supervising and implementing climate-related issues and matters, and reporting on the ESG implementation status, review of the results, strategic objectives, and revision of relevant rules and systems of the Company's sustainable development to the Board of Directors at least once a year. 			<ul style="list-style-type: none"> • Continue to improve the Board of Directors' and the management's knowledge of low carbon, relevant scientific knowledge, and international climate-related issues or initiatives. • Strengthen the Board of Directors' and the management's supervision of the Company's continued low-carbon transition plan.
Strategy	<ul style="list-style-type: none"> • Commit to promoting a green supply chain in the hope of driving environmental awareness in the biotechnology industry and achieving the goal of effectively reducing greenhouse gas emissions. • Low carbon products and services. 			<ul style="list-style-type: none"> • Continue to promote low-carbon products and services. • List net-zero emissions as the Company's long-term development goal.

Item	Implementation status		
	Risk management	<ul style="list-style-type: none"> The Governance and Sustainable Development Office identifies and measures physical and transition risks, develops relevant response measures and opportunities, and establishes indicators and control mechanisms for major risks/opportunities to promote the achievement of specific environmental goals. 	<ul style="list-style-type: none"> Strengthen the negotiation mechanism with upstream and downstream suppliers and customers to enhance the Company's influence on the low-carbon transformation of the biotechnology industry.
	Metrics and targets	<ul style="list-style-type: none"> Set and achieve carbon reduction goals for our own operations. The proportion of ESG procurement in the Company's product purchases. 	<ul style="list-style-type: none"> Set the Company's greenhouse gas reduction goals and regularly disclose phased results. The reduction target of "total greenhouse gas emissions" in 2030 is 30% compared with the base year 2020. Net-zero emissions by 2050.
7. If internal carbon pricing is used as a planning tool, please explain the basis for setting the price.	<p>In order to strengthen autonomous carbon reduction management, beginning in 2025, and using the initial carbon fee pricing of Taiwan's Ministry of Environment as a basis, the Company (parent entity) formulated an internal carbon pricing (ICP) mechanism of NT\$300/ton CO₂e. The ICP's initial phase will primarily be applied when converting stores' electricity usage to ICP. Establishing carbon pricing as an operating cost concept will help realize future compliance with carbon reduction and management targets. Later on, the Company will also include assessments and ICP within management statements, to track changes in greenhouse gas emissions.</p> <p>Details on the Company and each store's carbon costs are disclosed in the Internal Carbon Pricing (ICP) section of the Company's website. (Please visit https://www.uvb.com.tw/investor/investor_a05_18 for details.)</p>		

Item	Implementation status																					
<p>8. If climate-related targets are set, please explain the information such as the activities covered, greenhouse gas emission scope, schedule planned, and annual achievement progress; if carbon offsets or renewable energy certificates (RECs) are used to achieve relevant targets, information such as the source and number of carbon reduction credits or the number of renewable energy certificates (RECs) being redeemed.</p>	<p>The Company uses 2020 as the base year to reveal the quantitative management target and achievement status of reducing greenhouse gas emission intensity by 5% annually from 2021–2025:</p>																					
	<table border="1"> <thead> <tr> <th data-bbox="450 276 846 316">Item</th> <th data-bbox="846 276 1064 316">Year</th> <th data-bbox="1064 276 1254 316">2020</th> <th data-bbox="1254 276 1433 316">2021</th> <th data-bbox="1433 276 1612 316">2022</th> <th data-bbox="1612 276 1787 316">2023</th> <th data-bbox="1787 276 1966 316">2024</th> <th data-bbox="1966 276 2145 316">2025</th> </tr> </thead> </table>	Item	Year	2020	2021	2022	2023	2024	2025	Actual value	0.2828	0.2144	0.1497	0.1050	0.0928	0.1634						
	Item	Year	2020	2021	2022	2023	2024	2025														
	<table border="1"> <tbody> <tr> <td data-bbox="450 316 846 355" rowspan="3">Greenhouse gas emission intensity (revenue in NT\$1 million)</td> <td data-bbox="846 316 1064 355">Target value</td> <td data-bbox="1064 316 1254 355">—</td> <td data-bbox="1254 316 1433 355">0.2686</td> <td data-bbox="1433 316 1612 355">0.2552</td> <td data-bbox="1612 316 1787 355">0.2425</td> <td data-bbox="1787 316 1966 355">0.2303</td> <td data-bbox="1966 316 2145 355">0.2188</td> </tr> <tr> <td data-bbox="846 355 1064 395">Achievement status</td> <td data-bbox="1064 355 1254 395">Base year</td> <td data-bbox="1254 355 1433 395">Achieved</td> <td data-bbox="1433 355 1612 395">Achieved</td> <td data-bbox="1612 355 1787 395">Achieved</td> <td data-bbox="1787 355 1966 395">Achieved</td> <td data-bbox="1966 355 2145 395">Achieved</td> </tr> </tbody> </table>	Greenhouse gas emission intensity (revenue in NT\$1 million)	Target value	—	0.2686	0.2552	0.2425	0.2303	0.2188	Achievement status	Base year	Achieved	Achieved	Achieved	Achieved	Achieved	Target value	—	0.2686	0.2552	0.2425	0.2303
Greenhouse gas emission intensity (revenue in NT\$1 million)	Target value		—	0.2686	0.2552	0.2425	0.2303	0.2188														
	Achievement status		Base year	Achieved	Achieved	Achieved	Achieved	Achieved														
	Achievement status	Base year	Achieved	Achieved	Achieved	Achieved	Achieved															

 Target value | — | 0.2686 | 0.2552 | 0.2425 | 0.2303 | 0.2188 || | | | | | | | | | |--|--------------------|-----------|----------|----------|----------|----------|----------| | Greenhouse gas emission intensity (revenue in NT\$1 million) | Achievement status | Base year | Achieved | Achieved | Achieved | Achieved | Achieved | |--|--------------------|-----------|----------|----------|----------|----------|----------| | Achievement status | Base year | Achieved | Achieved | Achieved | Achieved | Achieved |
 Achievement status | Base year | Achieved | Achieved | Achieved | Achieved | Achieved | Note: The above statistics are for the parent company only. || Mid- to long-term goals: | The Company has set 2020 as the base year, and has begun voluntarily conducting and disclosing its greenhouse gas (GHG) emissions. Aligning with Taiwan’s 2050 Net-Zero Emissions pathway, the Company has established a 2030 carbon reduction target of 30% in Total Scope 1 + Scope 2 Greenhouse Gas Emissions. As of 2024, a cumulative reduction of 29.01% has been achieved. In accordance with the Financial Supervisory Commission’s Sustainable Development Roadmap, the roadmap will apply to the Company at Stage 3 (i.e., the inventory will be completed in 2026 and the verification will be completed in 2028). Following the specified inventory timeline, the Company has set a Greenhouse Gas Emission Intensity target of 5% per year as the quantified management target, and this target has already been reached in 2025. |
| 9. Greenhouse gas inventory and assurance status, reduction targets, strategies and specific action plans (fill in 1-1 and 1-2 separately). | The Company’s greenhouse gas inventory and assurance status, reduction targets, strategies, and specific action plans are separately filled in 1-1 and 1-2. |

1-1 The Company's greenhouse gas inventory and assurance status in the last 2 years

1-1-1 Information on greenhouse gas inventory

Describe clearly the emissions (metric tons CO₂e), intensity (metric tons CO₂e/ NT\$1 million) and data coverage of greenhouse gases in the past 2 years.

The Company's greenhouse gas emissions are mainly caused by the liters of refueling of company vehicles and refrigerant leakage sources from air conditioners, water dispensers, and company vehicles in Scope 1, and the electricity consumption in Scope 2 of Taipower's electricity.

The Company's greenhouse gas inventory boundary is the head office in Nangang and each branch store. The electricity consumption is based on the carbon emission coefficient of electricity announced by Taipower Corporation, the carbon emission coefficient of fuel oil announced by the Ministry of Environment of the Executive Yuan, and the emission factors for refrigerant leakage sources. The converted total emissions are as follows:

Greenhouse gas emission statistics are as follows:

Year	2020	2021	2022	2023	2024	2025
Scope 1 (direct emissions)	63.73	67.37	78.86	76.49	70.27	239.73
Scope 2 (indirect emissions)	395.73	354.84	320.29	263.65	255.90	356.67
Total (metric tons/CO₂e)	459.46	422.21	399.15	340.14	326.17	596.40
Emission intensity (/ 1 million revenue)	0.2828	0.2144	0.1497	0.1050	0.0928	0.1634

Note: The above statistics are for the parent company only.

1-1-2 Information on greenhouse gas emissions assurance

Describe clearly the assurance status in the most recent 2 years as of the publication date of the annual report, including the scope of the assurance, the assurance institution, the assurance criteria, and the assurance opinion.

In accordance with the Sustainable Development Roadmap for TWSE/TPEX Listed Overseas Companies released by the Financial Supervisory Commission in March 2022, the Company is a company with a paid-in capital of no more than NT\$5 billion; therefore, the parent company should be applicable at Stage 3 (i.e., the inventory will be completed in 2026 and the verification will be completed in 2028), and the subsidiaries in the consolidated financial statements should be applicable at Stage 4 (that is, the inventory will be completed in 2027 and the verification will be completed in 2029).

The Company's greenhouse gas emissions inventory is self-managed and voluntarily disclosed to facilitate understanding of current trends and early response. It has not yet been assured by an external third-party verification institution.

1-2 Greenhouse gas reduction targets, strategies, and specific action plans

Describe clearly the greenhouse gas reduction base year and its data, reduction targets, strategies, specific action plans and achievement status of reduction targets.

Short-term reduction targets:

Using 2020 as the base year, the Company reveals its annual quantitative management targets and achievement status of reducing greenhouse gas emission intensity by 5% from 2021–2025:

Item	Year	2020	2021	2022	2023	2024	2025
Greenhouse gas emission intensity (1 million revenue)	Actual value	0.2828	0.2144	0.1497	0.1050	0.0928	0.1634
	Target value	—	0.2686	0.2552	0.2425	0.2303	0.2188
	Achievement status	Base year	Achieved	Achieved	Achieved	Achieved	Achieved

Note: The above statistics are for the parent company only.

Mid- to long-term targets:

The Company has set 2020 as the base year, and has begun voluntarily conducting and disclosing its greenhouse gas (GHG) emissions. Aligning with Taiwan's 2050 Net-Zero Emissions pathway, the Company has established a 2030 carbon reduction target of 30% in Total Scope 1 + Scope 2 Greenhouse Gas Emissions. As of 2024, a cumulative reduction of 29.01% has been achieved, thus meeting the phased targets.

In accordance with the Financial Supervisory Commission's Sustainable Development Roadmap, the roadmap will apply to the Company at Stage 3 (i.e., the inventory will be completed in 2026 and the verification will be completed in 2028). Following the specified inventory timeline, the Company has set a Greenhouse Gas Emission Intensity target of 5% per year as the quantified management target, and this target has already been reached in 2025.

The Company's greenhouse gas emissions are mainly indirect emissions, and the emission sources mainly come from the electricity required for air conditioning, equipment, and lighting. The impact of climate change on the global environment is becoming increasingly significant. The Company complies with environmental protection laws and regulations, continues to promote energy conservation and carbon reduction measures, operates sustainably, and fulfills its corporate responsibilities. The specific action plan is as follows:

1. Promote and implement energy conservation and carbon reduction measures, and communicate policies to employees, suppliers, customers, and other stakeholders.
2. Strengthen advocacy and encourage all employees to develop the habit of saving energy and resources.
3. Turn off lighting equipment in vacant areas in a timely manner and turn off lights in office areas during lunch breaks to save energy.
4. Establish an electronic form system to reduce paper usage.
5. Promote company car sharing to reduce the number of vehicle trips and reduce fuel consumption.
6. Establish a greenhouse gas emission inventory, carry out regular inventory inspections, and control emissions.
7. The air-conditioning systems in stores will be replaced with new ones, and 60% of the air-conditioning equipment will be replaced with energy-efficiency Level 1 products.
8. Formulated the Environmental Management System and Energy Management Plan, and have disclosed the implementation status of each for the year.

(7) Implementation status of performing ethical corporate management and the difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reasons thereof:

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
<p>1. Formulation of policies and plans for ethical corporate management</p> <p>(1) Did the Company formulate an ethical corporate management policy approved by the Board of Directors, and express the policy and practice of ethical corporate management in its regulations and external documents, as well as the commitment of the Board of Directors and senior management to actively implement the management policy?</p> <p>(2) Did the Company establish an assessment mechanism for the risk of ethical behavior, regularly analyzes and evaluates the business activities with high risk of ethical behavior within the business scope, and formulate a plan for preventing ethical behavior based on it, which at least covers the preventive measures for the behaviors in</p>	<p>✓</p> <p>✓</p>		<p>(1) The Company takes integrity and responsibility as the basis of its operating policies, and has formulated the Company's Code of Ethical Corporate Management with reference to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies. The Company's Code of Ethical Corporate Management was approved by the Board of Directors on March 31, 2011, which clearly stipulates the Company's ethical corporate management policies and practices that the Board of Directors and the management shall commit to actively implement, and they shall establish good corporate governance and risk control mechanisms accordingly so as to create a business environment for sustainable development. The most recent revision made by the Board of Directors was on March 23, 2020.</p> <p>(2) The Company's "Ethical Corporate Management Best Practice Principles" covers the preventive measures for the behaviors described in Paragraph 2 of Article 7 of the "Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies". The Company has also established the "Ethics Advocacy and Whistleblowing system for Employees" and "Work Rules" to stipulate that employees who violate laws and regulations or commit fraud and misappropriation shall be subject to verbal warning, reprimand, demerit, major demerit, demotion or dismissal (discharged) depending on the severity of the case, and those who are criminally liable shall be brought to justice to prevent the occurrence of the above-mentioned cases by strengthening the internal control system.</p>	<p>In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.</p> <p>In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.</p>

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
<p>the subparagraphs of Paragraph 2, Article 7 of the “Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies”?</p> <p>(3) Did the Company clearly define operating procedures, behavior guidelines, punishment and appeal systems for non-compliance in the plan for preventing ethical behavior, and implement it, and regularly review and revise the plan before disclosure?</p>	✓		<p>(3) The Company has established the “Ethical Corporate Management Best Practice Principles”, which requires directors and managers to set an example by adhering to the principles of honesty and integrity and establishing a corporate culture of integrity and truthfulness. In addition, the Company has set up the “Ethics Advocacy and Whistleblowing system for Employees” and the “Work Rules”, which describe the disciplinary and complaint system for non-compliance. The Company regularly reviews the aforementioned programs and revises them in accordance with the operational situation.</p>	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.
<p>2. Implementation of ethical corporate management</p> <p>(1) Did the Company evaluate the integrity record of its counterparties and specify the terms of integrity in its contracts with counterparties?</p>	✓		<p>(1) The Company has established the “Ethical Corporate Management Best Practice Principles”, and shall conduct its business activities in a fair and transparent manner based on the principle of integrity. The purchase contract specifies the terms and conditions of integrity, including the absolute prohibitions, such as the prohibition of illegal acts, the prohibition of commission, and the prohibition of fake products</p> <p>The key information of communication with suppliers shall be kept in written documents such as “meeting minutes” or Email. In addition to the verbal notification and Email notification, the prohibitions shall also be stipulated in the “Purchase Contract” or recorded in the Memorandum of Understanding.</p>	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(2) Did the Company set up a dedicated unit for promoting corporate ethical corporate management under the Board of Directors, and report regularly (at least once a year) to the Board of Directors on its ethical corporate management policy and plan to prevent ethical behavior and supervise the implementation?	✓		(2) In order to improve the management of integrity management, the Company has designated the “Governance and Sustainable Development Office” as a dedicated unit under the Board of Directors, which is responsible for formulating and supervising the implementation of policies and prevention programs for integrity management and ensuring that all operational activities are in compliance with laws and regulations. This unit reports the implementation status to the Board of Directors on an annual basis, with the most recent report to the Board of Directors on May 14, 2025. The promotion results are summarized in the table below.	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.
(3) Did the Company have a policy to prevent conflicts of interest, provide appropriate channels for representation, and implement it?	✓		(3) The Company has established the “Ethical Corporate Management Best Practice Principles”, which stipulates that interested parties shall recuse themselves from any matters in which they have a conflict of interest and shall not obtain any improper benefits through their positions in the Company. Any person or his or her representing legal entity who has a conflict of interest with the Company’s interests may present his or her opinion and answer questions on the proposals set forth in the Board of Directors’ meeting, but shall not join in the discussion or vote, and shall recuse himself or herself from the discussion or vote, and shall not exercise his or her voting rights on behalf of other directors. The Company’s website has a “Stakeholder Area” to provide various channels for stakeholders to file complaints. The Company continues to promote integrity and ethical behavior within the Company and encourages employees to report violations of laws and regulations or dishonest behavior to the reporting unit when they are discovered.	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(4) Did the Company establish an effective accounting system and internal control system for the implementation of ethical corporate management, and the internal audit unit formulate relevant audit plans based on the results of the assessment of the risk of ethical behavior, and checked the compliance of the plan to prevent ethical behavior based on it, or appoint a public certified accountant to perform the audit?	✓		(4) The accounting system of the Company is established in accordance with the regulations of the competent authorities and other relevant laws and regulations, and is determined in accordance with the nature of accounting affairs, actual business conditions and development and management needs. For internal control, it is clearly stated that each business shall be performed by each functional department, so as to achieve the purpose of division of labor and reconciliation of functions. When conducting transactions, we follow the Company's internal rules and the external regulations, comply with the operational procedures, and clarify the related powers and responsibilities. Conflicting duties are not performed by or on behalf of each other in order to prevent fraud. In addition, each unit shall conduct its own audits and the audit unit shall conduct internal audits in order to achieve the purpose of internal control.	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.
(5) Did the Company regularly hold internal and external education and training on ethical corporate management?	✓		(5) The Company shall promote the "Ethical Corporate Management Best Practice Principles", "Guidelines for the Adoption of Codes of Ethical Conduct", and "Ethics Advocacy and Whistleblowing system for Employees" on a quarterly basis (January 22, April 17, July 14 and October 1, 2025), and provide channels for employees to report violations of laws and regulations and ethics requirements or engage in dishonest behavior. In 2025, the number of people instructed was 432, with 0.1 hours per session, totaling 43.2 hours. In addition, the "Ethical Corporate Management Best Practice Principles" is included in the training course for new employees. In 2025, the number of trainees was 91, with 0.2 hours per session, totaling 18.2 hours.	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
<p>3. Operational status of the Company whistleblowing system</p> <p>(1) Did the Company formulate a specific reporting and reward system, establish a convenient reporting channel, and assign appropriate personnel in charge of the report to the counterparty?</p>	✓		<p>(1) 1.The Company has formulated the Working Rules, the Advocacy of Employee Code of Ethics and Reporting System, the Code of Ethical Corporate Management, and related management operations for stakeholders, and has established a reporting and complaint area on the Company’s website to handle employee opinions and complaints. In case of violation of ethical corporate management, the violating person will be subject to discipline in accordance with the rules; in addition, pursuant to the reward system in Article 5.8.2 of the Working Rules, it is clearly stipulated that an employee with specific deeds, including being alert and vigilant at work, proactively discovering errors, and detecting violations of laws and regulations, that prevent the Company from incurring losses, shall be commended and given a bonus calculated at 1/18 of the basic salary for the month.</p> <p>2. When internal or external parties discover that the Company’s employees have violated laws and regulations, ethical code, or acted dishonestly, the reporting channels and handling system are as follows:</p> <ul style="list-style-type: none"> ◆ Spokesperson: Accept reporting from shareholders, investors and other stakeholders. Company phone number: (02)2655-8000 - 210 E-mail address:jay.liu2@eyecenter.com.tw ◆ Audit director: Accept reporting from colleagues within the Company and customers, suppliers, contractors, etc. Company phone number: (02)2655-8000 - 805、806 Mobile phone:0980-937-888 E-mail address:sophie.lin@eyecenter.com.tw 	<p>In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.</p>

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(2) Did the Company establish the standard operating procedures for the investigation of reported matters, the follow-up measures to be taken after the investigation is completed, and the relevant confidentiality mechanism?	✓		<ul style="list-style-type: none"> ◆ Customer service: Accept consumer complaints. Customer service hotline: 0800-747-488 E-mail address: service@eyecenter.com.tw (2) The Company has announced the Advocacy of Employee Code of Ethics and Whistleblowing system on its website, which includes the complaint process and related confidentiality mechanisms for accepting reporting, and regulates the reporting channels and handling system when internal and external personnel discover that the Company's employees have violated laws and regulations, ethical code, or acted dishonestly. ◆ Principle of accepting the reporting: For named reporting, sufficient information must be provided to facilitate verification (including the name, unit, and job title of the person involved, date of the occurrence, and description of the incident); for anonymous reporting, the accepting unit may also launch an internal preliminary investigation if the documentary or physical evidence has been provided, with the circumstances, the name of the parties involved, time, location, related persons, etc. having been clearly spelled out. ◆ Investigation procedure: If the reported incident has been verified to be true, it will be reported to the general manager and handled in accordance with the relevant internal disciplinary rules of the Company. Before making a disciplinary decision, the Company should provide the person being reported with an opportunity to state his/her opinions or appeal; during the internal investigation stage, if any unlawful circumstances are discovered, they will be reported to the Chairperson and, if necessary, transferred to the judicial authority for criminal investigation; if the reported incident involves any directors or senior management, it will be reported to the independent directors. ◆ Confidentiality mechanism: The Company will keep confidential and protect whistleblowers or persons involved in investigations to prevent them from unfair treatment or retaliation. In the event of unfair 	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
(3) Did the Company take measures to protect whistleblowers from being mistreated due to whistleblowing?	✓		<p>treatment, retaliation, or similar circumstances due to reporting or participating in an investigation, it must be reported to the original accepting unit.</p> <p>The Company has announced the Advocacy of Employee Code of Ethics and Whistleblowing system on its website. For relevant content, please refer to the Whistleblowing System section. (Please visit https://www.uvb.com.tw/investor/investor_a02_07)</p> <p>(3) Article 5.17.1.6 of the Company's Code of Ethical Corporate Management clearly stipulates the measures to protect whistleblowers from being improperly dealt with due to whistleblowing. In addition, Subparagraph 7, Paragraph 2, Article 8 of the Advocacy of Employee Code of Ethics and Whistleblowing system clearly stipulates that the Company shall keep confidential and protect whistleblowers or personnel involved in investigations to prevent unfair treatment or retaliation. In the event of unfair treatment, retaliation, or similar circumstances due to reporting or participating in an investigation, it must be reported to the original accepting unit.</p> <p>The number of reported cases accepted by the Company in 2025 was 0.</p>	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.
<p>4. Strengthen information disclosure</p> <p>(1) Did the Company disclose the content of its Ethical Corporate Management Best Practice Principles and promote its effectiveness on its website and Market Observation Post System?</p>	✓		<p>(1) The Company has disclosed the Code of Ethical Corporate Management on its website and the Market Observation Post System, and disclosed its promotion results in its annual report and the Company's website. For relevant content, please refer to the Implementation of Ethical Corporate Management Area on the Company's website. (Please visit https://www.uvb.com.tw/investor/investor_a02_09)</p>	In conformity to the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies.

Evaluation item	Operational status			Difference from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, and the reason
	Yes	No	Summary description	
5. If the Company has its own Ethical Corporate Management Best Practice Principles in accordance with the “Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies”, please describe the difference between its operation and the established code: there is no major difference.				
6. Other important information that helps to understand the integrity of the Company’s business operations:				
<ol style="list-style-type: none"> 1. The Company places great importance on integrity in its business operations, and when entering into contracts with others, the contents include compliance with the “Ethical Corporate Management Best Practice Principles” policy. 2. In addition to considering the legitimacy of agents, suppliers, customers or other business counterparties, the Company also pays attention to whether they have a record of dishonest behavior in order to further urge our business partners to emphasize integrity management. 3. The Company attaches importance to integrity management, including employees shall abide by the Company’s ethical regulations and business standards, not to violate the law, not to be partial, to perform their duties appropriately, to protect customer privacy, to truthfully inform customers of their rights and interests, and never to deceive and conceal, etc., in order to regularly evaluate the employees’ compliance with integrity management. 4. The Company regularly arranges for directors and managers to participate in corporate governance courses to enhance their ability to supervise and manage the Company in order to improve the effectiveness of corporate governance and the implementation of integrity management. 				

(8) Other important information sufficient to enhance the understanding of the operation of corporate governance: Market Observation Post System and our official website.

(9) Implementation Status of Internal Control System:

1. Internal Control Statement: Please refer to Market Observation Post System > Single Company > Corporate Governance > Company Rules > Internal Control > Internal Control Statement Announcement
(Website: <https://mops.twse.com.tw/mops/#/web/t06sg20>)
2. If a CPA is appointed to review the internal control system: None

(10) Important resolutions of the shareholders meeting and the Board of Directors in the most recent year and as of the publication date of the annual report:

Important resolutions and implementation status of the shareholders' meeting	
May 26, 2025	<p>The Company's 2025 general shareholders meeting was held at the Taipei Head Office on May 26, 2025. The matters passed and the implementation status of the shareholder resolutions in attendance during the meeting are as follows:</p> <ol style="list-style-type: none">1. Acknowledge the 2024 business report and financial statements. Implementation status: Resolution passed.2. Acknowledge the 2024 earnings distribution statement. Implementation status: Resolution passed. The cash dividend distribution was approved by a special resolution of the Board of Directors on March 6, 2025, for which the Chairperson also authorized to set April 1, 2025, as the ex-dividend base date, and pay cash dividends on April 21, 2025 (distribution at NT\$7.5 per share).3. Revision of the Company's "Articles of Incorporation." Implementation status: Resolution passed. Registration was approved by the Ministry of Economic Affairs on July 31, 2025, and the revised version has been announced on the Company's website.4. Revision of the Company's "Procedures for Acquisition or Disposal of Assets." Implementation status: Resolution passed. The revised version has been announced on the Company's website and handled in accordance with the revised procedures.5. Revision of the Company's "Procedures for Lending Funds to Other Parties." Implementation status: Resolution passed. The revised version has been announced on the Company's website and handled in accordance with the revised procedures.6. Revision of the Company's "Rules of Procedure for Shareholders' Meetings." Implementation status: Resolution passed. The revised version has been announced on the Company's website and handled in accordance with the revised procedures.
Important resolutions of the Board of Directors	
March 6, 2025	<ol style="list-style-type: none">1. 2024 distribution of employee and director remuneration2. 2024 business report and financial statements.3. 2024 earnings distribution.4. Matters related to the Company's ex-dividend in 2025.5. Appointment, remuneration, and independence assessment of the Company's certified public accountant in 2025.6. Pre-approval of the 2025 certified public accountant's provision of non-assurance services.7. Proposal for short-term credit line set by the financial institution.8. Establishment of the branch.9. Revision of the Company's "Articles of Incorporation."10. Revision of the Company's "Procedures for Acquisition or Disposal of Assets."11. Revision of the Company's "Procedures for Lending Funds to Other Parties."12. Revision of the Company's "Rules of Procedure for Shareholders' Meetings."13. Revision of the Company's "Authority and Responsibility Matrix for Administrative Approvals."14. The 2024 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter.15. Convening the Company's 2025 general shareholders meeting.

Important resolutions of the Board of Directors	
May 14, 2025	<ol style="list-style-type: none"> 1. Consolidated financial statements from January 1 to March 31, 2025. 2. Proposal for short-term credit line set by the financial institution. 3. Revision of the “Human Resources and Payroll Cycle.” 4. Revision of the “Internal Audit System.” 5. Payment of director remuneration. 6. Distribution of remuneration for managers and employees. 7. Change of the branch.
August 13, 2025	<ol style="list-style-type: none"> 1. Consolidated financial statements from January 1 to June 30, 2025. 2. Proposal for short-term credit line set by the financial institution. 3. Establishment of the branch. 4. Change of the branch. 5. The Company’s 2024 Sustainability Report. 6. Revision of the Company’s Corporate Governance Practice Principles. 7. Revision of the Company’s Sustainable Development Practice Principles. 8. Revision of the Company’s Nominating Committee Charter. 9. Establishment of the Company’s Sustainable Development Committee and formulation of the Sustainable Development Committee Charter. 10. Appointment of members of the Company’s 1st Sustainable Development Committee.
November 12, 2025	<ol style="list-style-type: none"> 1. Consolidated financial statements from January 1 to September 30, 2025. 2. Proposal for short-term credit line set by the financial institution. 3. Application for extension of the Company’s endorsement and guarantee for its reinvested enterprise in Mainland China. 4. Establishment of the branch. 5. Ministry of Economic Affairs Company Major Seal safekeeper proposal. 6. Revision of the Company’s “Research and Development Cycle.” 7. Internal audit operation inspection plan for 2026.
December 18, 2025	<ol style="list-style-type: none"> 1. 2026 operating plan. 2. Establishment of the branch. 3. 2025 year-end bonus payment criteria and payment amount for managers.
March 5, 2026	<ol style="list-style-type: none"> 1. Distribution of 2025 employee remuneration and director remuneration. 2. 2025 business report and financial statements. 3. 2025 earnings distribution. 4. Matters related to the Company’s ex-dividend in 2026. 5. Appointment, remuneration, and independence assessment of the Company’s certified public accountant in 2026. 6. Pre-approval of the 2026 provision of non-assurance services by the certified public accountant. 7. Proposal for short-term credit line set by the financial institution. 8. Establishment of the branch. 9. The 2025 Internal Control System Effectiveness Assessment and Internal Control System Statement Letter. 10. Convening the Company’s 2026 general shareholders meeting.

(11) Adverse opinions from directors or supervisors over important resolution of the Board in the most recent year as of the date of publication of the annual report with records or written declaration, and the contents of such opinion: None.

4. Disclosure of the CPAs' fee

(1) Fee information of CPAs

Amount unit: NT\$ thousand

Accounting Firm	Names of CPAs	Duration of Audit	Auditing fee	Non-Auditing fee	Total	Note
Deloitte & Touche	Liao Wan-I	January 1, 2025- December 31, 2025	2,990	1,580	4,570	
	Tsai Tsung-Yuan	January 1, 2025- December 31, 2025				

1. If there is a change in the accounting firm, and the audit fees paid for the fiscal year in which the change took place are lower than those paid for the fiscal year immediately preceding the change, the amount for the professional audit fee before and after the replacement and the reason shall be disclosed: None
 2. When the audit fees paid for the current fiscal year are lower than those paid for the immediately preceding fiscal year by 10% or more, the amount and percentage of and reason for the reduction in audit fees shall be disclosed: None
- (2) The audit fees mentioned in the preceding paragraph refer to the fees paid by the Company to the certified public accountants for the audit and review of the financial statements, while the non-audit fees refer to the fees for tax attestation, English translation of financial statements, and commercial services.

5. Changes in public certified accountants during the past 2 years and subsequent periods

(1) Regarding the Former Certified Public Accountant

Date of Change:	March 6, 2025		
Reason and Explanation for the Change:	In accordance with the internal rotation policy of Deloitte & Touche, the Company has changed its signing CPA from Kuo Nai-Hua to Liao Wan-I, and its co-signing CPA from Chen Chung-Chen to Tsai Tsung-Yuan starting from 2025.		
Whether the Termination or Non-renewal Was Initiated by the Client or the CPA:	Involved Party	CPA	Client
	Situation		
	Voluntary termination of engagement	Not applicable	Not applicable
	Declined to accept (or continue) engagement	Not applicable	Not applicable
Audit Opinions Other Than Unqualified Opinions Issued in the Past 2 Years and Their Reasons	None.		
Whether There Were Any Disagreements with the Issuer	Yes		Accounting principles or practices
			Disclosure in financial reporting
			Scope or procedures of audit
			Others
	No	✓	
	Explanation: Not applicable.		
Other Matters for Disclosure (Items that must be disclosed pursuant to Subparagraphs 4 to 7, Paragraph 6, Article 10 of the Regulations)	None.		

(2) Regarding the Successor Certified Public Accountant

Firm Name	Deloitte & Touche
Names of Certified Public Accountants	Liao Wan-I, Tsai Tsung-Yuan
Date of Appointment	March 6, 2025
Consultation Prior to Appointment Regarding Accounting Treatment or Principles for Specific Transactions and the Resulting Possible Audit Opinions	None.
Written Opinion from the Successor CPA Regarding Disagreements with the Former CPA	None.

(3) Response from the Former CPA Regarding Subparagraph 1 and Subparagraph 2-3, Item 5, Article 10 of the Regulations: None.

6. The Chairperson, president, managers in charge of financial or accounting affairs of the Company, who have worked in the firm or affiliated company of the certified public accountant within the last year, shall disclose their names, professional titles, and the period of employment in the certified public accountant's firm or its affiliated company: None.

7. In the most recent year as of the date of publication of the annual report, the directors, supervisors, managerial officers and the shareholders holding more than 10% of the shares in the transfer of shares and pledge of shares under lien, and any change thereof.

(1) Changes in equity transfer and equity pledge of directors, supervisors, managers and major shareholders:

Unit: shares

Title	Name	2025		As of March 30, 2026	
		Increase (decrease) in No. of Shares	Increase (decrease) in No. of Pledged Shares	Increase (decrease) in No. of Shares	Increase (decrease) in No. of Pledged Shares
Chairperson	Quny Development Enterprise Co., Ltd.	-	-	-	-
	Representative: Ou Shu-Fang	-	-	-	-
Director	Quny Development Enterprise Co., Ltd.	-	-	-	-
	Representative: Lin Pi-Jung	-	-	-	-
Director	Quny Development Enterprise Co., Ltd.	-	-	-	-
	Representative: Chou Tsan-Der	-	-	-	-
Director	Quny Development Enterprise Co., Ltd.	-	-	-	-
	Representative: Weng Su-Hei	-	-	-	-
Director	Quny Development Enterprise Co., Ltd.	-	-	-	-
	Representative: Chang Hong-Jen	-	-	-	-
Independent Director	Xiao Min-Zhi	-	-	-	-
Independent Director	Liu Vincent	-	-	-	-
Independent Director	Yang Yun-Hua	-	-	-	-
Independent Director	Chen Wei-Ru	-	-	-	-
Shareholders holding more than 10% of the shares	Lin Pi-Jung	-	-	-	-
Managerial officer	President	Lu Kenneth	(158,644)	-	-
	Chief financial and accountant	Sun Yu-Chiao	-	-	-
	Director of Governance and Sustainable Development Office	Lien Su-Ping	-	-	-

(2) Information on the counterparties to the transactions of equity transfer or equity pledge with directors, supervisors, managers and major shareholders that are related parties: None.

8. Information on shareholders among the top 10 by proportion of shareholding who are related parties to one another or spouse, kindred within the 2nd degree of kinship

March 30, 2026

Name	Own shareholdings		Shares held by Spouse & minor children Number of shareholding		Shares held through nominees		If there are related parties, spouses, kindred within the 2nd degree of kinship among the top 10 shareholders, give the names and affiliations of such shareholders		Remark
	Number of Shares	Rate of shareholding	Number of Shares	Rate of shareholding	Number of Shares	Rate of shareholding	Name	Relation	
Lin Pi-Jung	19,274,713	22.75%	2,895	-	-	-	Ou Shu-Fang Lin Ting-Yu	Spouse, father and daughter	-
Rui Li Investment Co., Ltd. Representative: Lin Pi-Jung	7,626,084	9.00%	-	-	-	-	-	-	-
Quny Development Enterprise Co., Ltd. Representative: Lin Pi-Jung	7,515,138	8.87%	-	-	-	-	-	-	-
Core Capital Co., Ltd. Representative: Ou Shu-Fang	3,280,000	3.87%	-	-	-	-	-	-	-
	2,895	-	19,274,713	22.75%	3,280,000	3.87%	Lin Pi-Jung Lin Ting-Yu	Spouse, Mother and daughter	-
Chuang Ming-Lang	2,823,000	3.33%	-	-	-	-	-	-	-
Hsin Shi Investment Co., Ltd. Representative: Lin Ting-Yu	2,545,000	3.00%	-	-	-	-	-	-	-
	247	-	-	-	-	-	Lin Pi-Jung Ou Shu-Fang	Father and daughter, Mother and daughter	-
FUSION GLOBE INC. Representative: Chuang Ming-Lang	742,000	0.88%	-	-	-	-	-	-	-
Wide Emerging Markets Share Fund Investment Account under HSBC (Taiwan)	733,020	0.87%	-	-	-	-	-	-	-
Chang Fu Investment Co., Ltd. Representative: Lin Pi-Jung	556,787	0.66%	-	-	-	-	-	-	-
Standard Chartered Bank Business Department in custody for special account of Vanguard Total International Stock Index Fund, a series of Vanguard Star Funds	506,580	0.60%	-	-	-	-	-	-	-

Note: All the top ten shareholders should be listed. For legal person shareholders, the name of the legal person shareholder and the name of the representative should be listed separately.

9. The number of shares held by the Company, the Company's directors, supervisors, managers and enterprises directly or indirectly controlled by the Company in the same reinvested enterprise, and the comprehensive shareholding ratio:

December 31, 2025; Unit: thousand shares; %

Investee (note)	Investment made by the Company		Investment made by directors, supervisors, managerial official and direct or indirect subsidiaries		Combined investment	
	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding	Number of Shares	Rate of share-holding
Taixue Investment Holdings Co., Ltd.	15,000	100%	-	-	15,000	100%
Taixue Jinghua Co., Ltd.	-	-	600	100%	600	100%
Taixue Jhongdou Co., Ltd.	-	-	6,000	100%	6,000	100%
Eyeseer Medical Inc.	-	-	2,500	100%	2,500	100%
Taixue Jhongke Co., Ltd.	-	-	3,500	58.33%	3,500	58.33%
Taixue Chongde Co., Ltd.	-	-	1,000	16.67%	1,000	16.67%
Taixue Keelung Co., Ltd.	-	-	1,000	16.67%	1,000	16.67%
UNIVERSAL GROUP (BVI) INC.	23,159	100%	-	-	23,159	100%
UNIVERSAL GROUP HOLDING CO., LTD	-	-	23,209	100%	23,209	100%
UNIVERSAL INTERNATIONAL (SAMOA)CO., LTD	-	-	23,000	100%	23,000	100%
Universal Vision Biotechnology (Shanghai) Co., Ltd.	-	-	USD 23,000	100%	USD 23,000	100%
Taixue (Jiangsu) Investment Co., Ltd.	-	-	RMB 143,000	100%	RMB 143,000	100%
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	-	-	RMB 150,000	70%	RMB 150,000	70%
Kunshan Universal Trading Co., Ltd.	-	-	RMB 59,140	70%	RMB 59,140	70%
Taixue (Jiangsu) Glasses Co., Ltd.	-	-	RMB 9,800	70%	RMB 9,800	70%
Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	-	-	RMB 12,000	70%	RMB 12,000	70%
Taixue (Jiangsu) Medical Investment Management Co., Ltd.	-	-	RMB 30,500	70%	RMB 30,500	70%
Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	-	-	RMB 22,900	70%	RMB 22,900	70%
Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	-	-	RMB 19,500	70%	RMB 19,500	70%
Suzhou Haiweishi Ophthalmic Clinic (LP)	-	-	RMB 14,300	70%	RMB 14,300	70%
Taixue (Hangzhou) Glasses Co., Ltd.	-	-	RMB 4,000	70%	RMB 4,000	70%
Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd.	-	-	RMB 1,500	70%	RMB 1,500	70%

Note: it refers to the long-term investment of the company using the equity method.

III. Capital Overview

1. Capital and shares

(1) Sources of Capital Stock

Unit: NT\$ thousand / thousand shares

Period	Price of issuance	Authorized capital stock		Paid in capital stock		Remarks		
		Number of shares	Amount	Number of shares	Amount	Sources of capital stock	Property other than cash is paid by subscribers	Other
Aug. 1994	10	100	1,000	100	1,000	Registration of establishment	—	Note 1
Sep. 1998	10	2,500	25,000	2,500	25,000	Cash capital increase \$24,000	—	Note 2
Dec. 2001	10	10,000	100,000	10,000	100,000	Cash capital increase \$75,000	—	Note 3
Aug. 2002	10	20,000	200,000	20,000	200,000	Cash capital increase \$100,000	—	Note 4
Sep. 2004	10	40,000	400,000	22,000	220,000	Capital increase by earnings recapitalization \$20,000	—	Note 5
Aug. 2005	10	40,000	400,000	27,895	278,959	Capital increase by earnings recapitalization \$58,959	—	Note 6
Mar. 2006	10	40,000	400,000	31,399	313,959	Cash capital increase \$35,000	—	Note 7
Aug. 2006	10	40,000	400,000	34,669	346,698	Capital increase by earnings recapitalization \$32,739	—	Note 8
Nov. 2007	10	100,000	1,000,000	40,165	401,650	Capital increase by earnings recapitalization \$54,952	—	Note 9
Sep. 2008	10	100,000	1,000,000	40,176	401,764	Transferred from corporate bond \$114	—	Note 10
July 2009	10	100,000	1,000,000	40,218	402,180	Transferred from corporate bond \$416	—	Note 11
Oct. 2009	10	100,000	1,000,000	45,204	452,040	Transferred from corporate bond \$49,860	—	Note 12
Jan. 2010	10	100,000	1,000,000	45,273	452,735	Transferred from corporate bond \$695	—	Note 13

Period	Price of issuance	Authorized capital stock		Paid in capital stock		Remarks		
		Number of shares	Amount	Number of shares	Amount	Sources of capital stock	Property other than cash is paid by subscribers	Other
Mar. 2011	10	100,000	1,000,000	46,081	460,818	Transferred from corporate bond \$8,083	—	Note 14
July 2011	10	100,000	1,000,000	46,554	465,540	Transferred from corporate bond \$4,722	—	Note 15
Dec. 2011	10	100,000	1,000,000	66,554	665,540	Cash capital increase \$200,000	—	Note 16
Oct. 2012	10	100,000	1,000,000	66,180	661,800	Cancellation of treasury stock \$3,740	—	Note 17
Feb. 2013	10	100,000	1,000,000	66,123	661,230	Cancellation of treasury stock \$570	—	Note 18
Apr. 2017	10	100,000	1,000,000	76,123	761,230	Cash capital increase \$100,000	—	Note 19
July 2019	10	200,000	2,000,000	76,123	761,230	Authorized capital \$1,000,000	—	Note 20
Sep. 2022	10	200,000	2,000,000	79,929	799,292	Capital increase by earnings recapitalization \$38,062	—	Note 21
Sep. 2023	10	200,000	2,000,000	84,725	847,249	Capital increase by earnings recapitalization \$47,957	—	Note 22

Note 1: The Company was established by the approval with No. Chien-yi-tzu-ti 878467 on August 3, 1994.

Note 2: The registration of change was approved with the official letter No. Chien-yi-tzu-ti 87323841 on September 16, 1998.

Note 3: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 09101014950 on January 16, 2002.

Note 4: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 09101334830 on August 16, 2002.

Note 5: The registration of change was approved with the official letter No. Fu-chien-shang-tzu-ti 09319574210 on September 15, 2004.

Note 6: The registration of change was approved with the official letter No. Fu-chien-shang-tzu-ti 09417198300 on August 22, 2005.

Note 7: The registration of change was approved with the official letter No. Fu-chien-shang-tzu-ti 09574766110 on March 30, 2006.

Note 8: The registration of change was approved with the official letter No. Fu-chien-shang-tzu-ti 09582261000 on August 25, 2006.

Note 9: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 09691337920 on November 15, 2007.

Note 10: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 09789062000 on September 22, 2008.

Note 11: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 09886602610 on July 30, 2009.

Note 12: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 09889563600 on October 14, 2009.

Note 13: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 09892229410 on January 15, 2010.

Note 14: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 10082855000 on April 25, 2011.

Note 15: The registration of change was approved with the official letter No. Fu-chan-yeh-shang-tzu-ti 10085562200 on July 13, 2011.

Note 16: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 10101002800 on January 5, 2012.

Note 17: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 10101208420 on October 5, 2012.

Note 18: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 10201029820 on February 20, 2013.

Note 19: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 10601063020 on May 18, 2017.

Note 20: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 10801084780 on July 12, 2019.

Note 21: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 11101189510 on September 30, 2022.

Note 22: The registration of change was approved with the official letter No. Ching-shou-shang-tzu-ti 11230183770 on September 20, 2023.

Unit: thousand shares

Type of Shares	Authorized capital stock			Remark
	Outstanding shares	Unissued stock	Total	
Ordinary shares	84,725	115,275	200,000	Shares of TPEX listed company

Shelf registration system information: None

(2) List of Major Shareholders

If there are fewer than ten shareholders with a stake of five percent or greater, the names of shareholders, their numbers of shares, and the stake held by each shareholder ranking in the top ten in terms of shareholding percentage shall be listed:

March 30, 2026			Unit: share; %
Shares	Number of Shares	Ratio of Shareholding	
Name of major shareholder			
Lin Pi-Jung	19,274,713	22.75%	
Rui Li Investment Co., Ltd.	7,626,084	9.00%	
Quny Development Enterprise Co., Ltd.	7,515,138	8.87%	
Core Capital Co., Ltd.	3,280,000	3.87%	
Chuang Ming-Lang	2,823,000	3.33%	
Hsin Shi Investment Co., Ltd.	2,545,000	3.00%	
FUSION GLOBE INC.	742,000	0.88%	
Wide Emerging Markets Share Fund Investment Account under HSBC (Taiwan)	733,020	0.87%	
Chang Fu Investment Co., Ltd.	556,787	0.66%	
Standard Chartered Bank Business Department in custody for special account of Vanguard Total International Stock Index Fund, a series of Vanguard Star Funds	506,580	0.60%	

(3) The Company's dividend policy and implementation status:

1. The Company's dividend policy:

The Company's annual final accounts, if there is any surplus, shall first be appropriated for tax purposes, to make up for prior years' losses, and then appropriate 10% of the remaining balance to the legal reserve, except that the legal reserve may no longer be appropriated when the legal reserve has reached the amount of paid-in capital; and the special reserve shall be appropriated or reversed in accordance with the law. If there is any remaining earnings in the current year, along with the accumulated undistributed earnings of the previous years, the Board of Directors shall prepare a proposal for the distribution of earnings and submit it to the shareholders' meeting for approval.

If the Company distributes all or part of the dividends and bonuses or legal reserve and capital surplus in the form of cash, the Board of Directors is authorized to do so with the presence of at least two-thirds of the directors and the approval of a majority of the directors present, and to report to the shareholders' meeting.

The Company shall take into account the environment and growth stage of the Company, its future capital requirements and long-term financial planning, as well as the need to maintain stable dividend payments, and shall appropriately distribute stock dividends or cash dividends in an amount not less than 30% of the current year's distributable earnings, with cash dividends not less than 30% of the total dividends.

2. Proposed dividend distribution for the current year:

The Company's 2025 earnings distribution proposal was passed by a special resolution of the Board of Directors on March 5, 2026. Cash dividends totaling NT\$656,617,968 (NT\$7.75 per share) will be distributed from the earnings to shareholders, with the distribution scheduled to occur on April 22, 2026.

3. If a significant change in dividend policy is expected, it shall be stated as follows:
There is no significant change in dividend policy.

(4) Effect upon operating performance and earnings per share of any free-gratis dividends distribution proposed or adopted at the most recent shareholders' meeting: Not applicable

(5) Employees' and directors' remuneration

1. The percentage or scope of employees' and directors' remuneration as stated in the Company's Articles of Incorporation:
 - (1) The employees remuneration will be allocated at 1% to 10% of the profit for the year, and not less than 10% of the said employee compensation will be distributed to non-executive employees.
 - (2) The director remuneration will be allocated at not more than 3% of the profit for the year.
2. The estimation basis for the estimated amounts of employee remuneration and director remuneration for the current period, the calculation basis for the number of shares distributed as employee remuneration in the form of stocks, and the accounting treatment if the actual distribution amount is different from the estimated amount: If the aforementioned estimated amount is different from the distribution amount resolved by the Board of Directors, it will be treated based on changes in accounting estimates, and it will be adjusted and recorded in the year of the Board of Directors' resolution.

3. The distribution of remuneration approved by the Board of Directors:

- (1) The amount of employees' and directors' remuneration to be distributed in cash or stock:

The proposed amount of employees' and directors' remuneration: The Company's 2025 employees' and directors' remuneration distribution has been approved by the Board of Directors and the Remuneration Committee on March 5, 2026, and the amount of employees' cash remuneration is NT\$41,457,043 and directors' remuneration is NT\$16,000,521, which shows no difference from the estimated amount for the year.

Of the aforementioned employee compensation, 30% was distributed to non-executive employees, for an amount of NT\$12,437,113 distributed.

- (2) The amount of employees remuneration distributed in stock, and the percentage in the sum of the net profit after tax and total employees remuneration in the parent company only or individual financial report for the current period: Not applicable.

4. The actual distribution of employees' and directors' remuneration (including the number of shares distributed, amount and share price) in the previous year, and the difference between the distribution and the recognition of employees' and directors' remuneration, along with the amount of the difference, the reasons for the difference and the treatment of the difference, shall be described as follows: On March 6, 2025, the Company's Board of Directors and Remuneration Committee approved the distribution of employees' cash remuneration in the amount of NT\$41,314,974 and directors' remuneration in the amount of NT\$17,111,487, which shows no difference from the estimated amount for the year.

- (6) The Company's application for repurchase of the Company's shares in the most recent year and as of the publication date of the annual report: None.

2. Status of corporate bond: None

3. Status of preferred share: None

4. Status of overseas depository receipt: None

5. Status of employee stock options: None

6. Status of new employee restricted share undertaking: None

7. Status of issuance of new shares due to merger and acquisition or acceptance of shares transferred by other companies: None

8. Implementation status of the fund utilization plan: None

IV. Operation Overview

1. Business Contents

(1) Business scope

The Company's business items are the "e-Universal" brand licensing as well as consulting and counseling services; providing cooperative clinics with the introduction, leasing, and maintenance of ophthalmic instruments and equipment; the sale of pharmaceutical consumables; business district evaluation; new store opening, planning, and renovation; store venue leasing; recruitment of personnel; administrative affairs; and other professional logistics support. The Company also operates the optometry business in its self-operated eyeglasses stores.

1. Main businesses

The Company's main business items registered with the Ministry of Economic Affairs are as follows:

1. F102040 Wholesale of Nonalcoholic Beverages
2. F102170 Wholesale of Foods and Groceries
3. F103010 Wholesale of Animal Feeds
4. F104110 Wholesale of Cloths, Garments, Shoes, Hats, Umbrellas and Clothing Accessories
5. F105050 Wholesale of Furniture, Bedding Kitchen Utensils and Fixtures
6. F108021 Wholesale of Western Pharmaceutical
7. F108031 Wholesale of Medical Devices
8. F108040 Wholesale of Cosmetics
9. F109070 Wholesale of Culture, Education, Musical Instruments and Educational Entertainment Supplies
10. F110020 Wholesale of Glasses
11. F113010 Wholesale of Machinery
12. F113030 Wholesale of Precision Instruments
13. F113050 Wholesale of Computers and Clerical Machinery Equipment
14. F118010 Wholesale of Computer Software
15. F119010 Wholesale of Electronic Materials
16. F202010 Retail Sale of Feeds
17. F203010 Retail Sale of Food, Grocery and Beverage
18. F204110 Retail Sale of Cloths, Garments, Shoes, Hats, Umbrellas and Clothing Accessories
19. F205040 Retail Sale of Furniture, Bedding Kitchen Utensils and Fixtures
20. F208021 Retail Sale of Western Pharmaceutical
21. F208031 Retail Sale of Medical Apparatus
22. F208040 Retail Sale of Cosmetics
23. F208050 Retail Over-the-counter drugs class B
24. F209060 Retail Sale of Culture, Education, Musical Instruments and Educational Entertainment Supplies
25. F210020 Retail Sale of Glasses
26. F213030 Retail Sale of Computers and Clerical Machinery Equipment
27. F213040 Retail Sale of Precision Instruments
28. F213080 Retail Sale of Machinery and Tools
29. F218010 Retail Sale of Computer Software
30. F219010 Retail Sale of Electronic Materials
31. JZ99060 Spectacles Shops

32. I103060 Management Consulting
33. I301020 Data Processing Services
34. I301030 Electronic Information Supply Services
35. JZ99050 Agency Services
36. H703100 Real Estate Leasing
37. JE01010 Rental and Leasing
38. F401010 International Trade
39. JZ99080 Beauty and Hairdressing Services
40. JZ99110 Body Shaping Beauty Services
41. ZZ99999 All business activities that are not prohibited or restricted by law, except those that are subject to special approval.

2. Percentage of business

The Company's business items are the sale of ophthalmology and optometry products; brand licensing; consulting and counseling services; providing cooperative clinics with the introduction, leasing, and maintenance of ophthalmic instruments and equipment; the sale of pharmaceutical consumables; business district evaluation; new store opening, planning, and renovation; store venue leasing; recruitment of personnel; administrative affairs; and other professional logistics support. The main business content and its percentage of business are set forth as follows:

Product (service) item	Amount in 2025 (thousand)	Proportion of business %
Product sales revenue	1,092,109	25.98%
Brand licensing, technical and medical services revenue	2,094,293	49.82%
Medical consumables revenue	645,331	15.34%
Consulting revenue	157,642	3.75%
Rental revenue	214,711	5.11%
Total	4,204,086	100.00%

3. Current product (service) items

Main products (merchandise)	Purpose / Function
Prescription for optical glasses, contact lenses, and health care food	Various glasses and lenses for vision correction, contact lens solution, and the relevant eye care product of Universal Gold Lutein
Equipment rental and technical services for laser vision correction instruments	Provide cooperative clinics with leases, maintenance, and technical services for instruments and equipment
Trading of medical and pharmaceutical consumables	Ophthalmic drugs, medical supplies and consumables for cooperative clinics
Cooperative clinic new store opening, decoration and venue rental	Plan business venues and provide administrative affairs and other professional logistics support services for cooperative clinics and eye centers
Provision of cataract and dry eye examination and treatment instruments as well as technical services	Provide technology and services for cataract and dry eye examination and treatment instruments

4. New product (service) items planned to be developed

- (1) Introduce high-end laser instruments and equipment and provide related application consulting services.
- (2) Expansion of business premises for cooperative ophthalmology clinics and eye centers
- (3) Integrate ophthalmologic application software interfaces at cooperative clinics and develop process digitization.
- (4) Research and development of ophthalmic surgical instruments and material textures of optometry products for cooperative clinics
- (5) Development and sales of nutritional supplements for vision care.
- (6) Expansion of the chain channel for “Universal Optical Store”.
- (7) Sales of glasses, contact lenses, and related peripheral products.
- (8) Work with cooperative clinics to expand myopia correction products and services for school children.
- (9) Introducing EVO implantable collamer lens (ICL) technologies and services for partner clinics.

(2) Industry overview

1. Current status and development of the industry: Vision correction mainly includes the market for vision correction surgery, optical glasses and contact lenses, etc., and consumers make choices based on their own needs. The current status and characteristics of the industry are set out as follows.

(1) Laser vision correction market

In 1996, the surgery opened up to a limited extent for clinical use in medical centers in Taiwan; and in 1998, it fully opened up for ophthalmology specialists to perform outpatient surgery. Currently, there are about 30,000-40,000 myopic people in Taiwan who receive laser surgery for vision correction every year. The penetration rate is about 0.13%. Meanwhile, according to the data from Market Scope, a survey research organization, the penetration rate of myopia laser surgery in China in 2021 (unit / per 100 people) was only 0.07%. Compared with that of 0.23% or more in North America and even the highest penetration rate of 0.38% in South Korea, they both have considerable room for growth. As more and more the public have had successful surgeries over the past few years, the formation of “word-of-mouth effect” coupled with media reports will enable the continued growth in the number of the public who are willing and interested in undergoing this surgery. In 2023, in Taiwan (a population of 23 million), about 40,000 people undergo laser surgery for vision correction every year. Compared with South Korea with a population of 50 million, about 200,000-300,000 people receive laser surgery for vision correction every year. It can be expected that there is still a large room for growth for the market in Taiwan. In recent years, the safety and quality of femtosecond laser surgery have continued to improve, and the public's acceptance of femtosecond laser surgery has also gradually increased. There are more than 12 million people with myopia in Taiwan, all of whom are potential clients for laser surgery for vision correction. As the population ages, demand for presbyopia correction is also increasing. Since 2012, laser vision correction surgery has been applied to the treatment of presbyopia. People aged between 40 and 55 often require correction for either myopia with presbyopia or presbyopia alone. MonoVision laser correction for myopia and presbyopia allows patients to see both near and far without wearing glasses after surgery, thereby improving convenience in daily life. It has become increasingly accepted by middle-aged

groups. Currently, presbyopia laser surgery accounts for approximately 20% of all laser vision correction surgeries in Taiwan. As Taiwan's median age has reached 45 to 46 years, it is foreseeable that the market share of presbyopia laser surgery will continue to grow.

(2) Optometry and optical market

Due to their reading habits and ever more frequent use of digital media, the prevalence of myopia among school children and teenagers in Taiwan is increasing year by year, and eyeglasses are required to correct their vision or control the progression of myopia. The following tables show the latest annual survey data announced by the Ministry of Education, as of the publication of the annual report, on the rate of poor uncorrected visual acuity among junior high school and elementary school students (grouped by grade level).

Statistics on the Rate of Poor Uncorrected Visual Acuity Among Junior High School Students (by Grade) - 2024 School Year										
Unit: person; %										
Grade	Gender	Total			Public			Private		
		Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)	Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)	Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)
Sum-total	Total	565,778	407,129	71.96	484,071	345,008	71.27	81,707	62,121	76.03
	Male	293,348	204,692	69.78	251,620	173,660	69.02	41,728	31,032	74.37
	Female	272,430	202,437	74.31	232,451	171,348	73.71	39,979	31,089	77.76
Grade 7	Total	212,507	144,766	68.12	182,286	123,116	67.54	30,221	21,650	71.64
	Male	109,810	72,489	66.01	94,489	61,814	65.42	15,321	10,675	69.68
	Female	102,697	72,277	70.38	87,797	61,302	69.82	14,900	10,975	73.66
Grade 8	Total	180,878	131,426	72.66	154,689	111,301	71.95	26,189	20,125	76.85
	Male	93,715	65,842	70.26	80,406	55,846	69.46	13,309	9,996	75.11
	Female	87,163	65,584	75.24	74,283	55,455	74.65	12,880	10,129	78.64
Grade 9	Total	172,393	130,937	75.95	147,096	110,591	75.18	25,297	20,346	80.43
	Male	89,823	66,361	73.88	76,725	56,000	72.99	13,098	10,361	79.10
	Female	82,570	64,576	78.21	70,371	54,591	77.58	12,199	9,985	81.85

Note: The information in this table is based on the number of students participating in the test; students with uncorrected visual acuity of 0.9 or more in both eyes have normal vision, otherwise they have poor vision.

Statistics on the Rate of Poor Uncorrected Visual Acuity Among Elementary School Students (by Grade) – 2024 School Year										
Unit: person; %										
Grade	Gender	Total			Public			Private		
		Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)	Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)	Number of students participating in the test	Number of person with poor vision	Rate of person with poor vision(%)
Sum-total	Total	1,196,727	536,439	44.83	1,151,540	516,703	44.87	45,187	19,736	43.68
	Male	619,452	272,988	44.07	596,695	263,244	44.12	22,757	9,744	42.82
	Female	577,275	263,451	45.64	554,845	253,459	45.68	22,430	9,992	44.55
Grade 1	Male	93,471	23,794	25.46	89,585	22,889	25.55	3,886	905	23.29
	Female	87,334	23,077	26.42	83,521	22,239	26.63	3,813	838	21.98
Grade 2	Male	100,636	32,911	32.70	96,757	31,716	32.78	3,879	1,195	30.81
	Female	94,247	30,793	32.67	90,330	29,588	32.76	3,917	1,205	30.76
Grade 3	Male	106,575	43,332	40.66	102,601	41,742	40.68	3,974	1,590	40.01
	Female	98,712	40,719	41.25	94,840	39,082	41.21	3,872	1,637	42.28
Grade 4	Male	108,050	52,209	48.32	104,230	50,369	48.32	3,820	1,840	48.17
	Female	100,615	49,766	49.46	96,894	47,882	49.42	3,721	1,884	50.63
Grade 5	Male	101,989	55,853	54.76	98,402	53,860	54.73	3,587	1,993	55.56
	Female	95,247	54,908	57.65	91,723	52,802	57.57	3,524	2,106	59.76
Grade 6	Male	108,731	64,889	59.68	105,120	62,668	59.62	3,611	2,221	61.51
	Female	101,120	64,188	63.48	97,537	61,866	63.43	3,583	2,322	64.81

Note: The information in this table is based on the number of students participating in the test; students with uncorrected visual acuity of 0.9 or more in both eyes have normal vision, otherwise they have poor vision.

Data source: Ministry of Education

The deep impacts of the COVID-19 pandemic on people's lifestyles have become a structural change, which has continued to be reflected in the ways they use their eyes and in their health awareness. Remote work, digital learning, long hours of screen usage, and the burgeoning development of AI have also driven consumers' high degree of concern with eye comfort, eye protection, and preventive care.

Against this background, eyeglasses have already evolved from an implement for simple vision correction into complex products that integrate vision management into lifestyle needs. In addition to protection against harmful light, they now meet specific needs such as reducing glare, relieving eye fatigue, slowing the progression of myopia, providing antibacterial and anti-fog properties, and incorporating special light-filtering features. Beyond fashion and vision correction, big data continues to drive the evolution of lens fields of vision and the adjustment functions for near and distance vision. This is injecting new value propositions centered on "prevention, comfort, and long-term vision quality" into the optometry market.

The development of the contact lens market and trends in vision correction products have shown increasing diversification as consumers' dual demands for aesthetics and vision correction continue to rise. The application scope of contact lenses has further expanded with the introduction of healthier, advanced materials and innovative features such as astigmatism correction, multifocal presbyopia designs, and anti-glare technology. According to continuous observations by the German marketing research consultancy GfK, although the contact lens market was significantly impacted during the peak of the COVID-19 pandemic and experienced a major contraction in scale, products in the professional correction segment—such as silicone hydrogel, multifocal, and astigmatism correction lenses—achieved a notable 5–10% growth due to the structural redistribution of the market. Since 2023, multifocal and astigmatism products have continued to grow at double-digit rates annually. As the population ages and consumers place greater emphasis on vision health, demand for these products continues to grow steadily. Universal Vision's professional optometry and eyeglasses consultation services have laid a solid foundation for future market development.

At Universal Optical, childhood myopia control has developed from an orientation toward single products, to inclusive solutions that integrate medical care, science, technology, and family education. Orthokeratology lenses have gained wide recognition from the global ophthalmology community for their effectiveness and safety. These specially designed lenses reshape the cornea during overnight wear, providing clear vision during the day while effectively slowing the progression of myopia. The method is reversible, as the cornea returns to its original shape after discontinuing lens wear, offering a high level of safety and reliability. It is regarded as an ideal myopia control solution for school children. Notably, this treatment can currently only be fitted and prescribed in ophthalmology clinics. The Company and its cooperating Universal ophthalmology clinics have successfully integrated products, procedures, and services to establish a comprehensive medical channel. Starting in the second half of 2020, innovative soft contact lenses featuring defocus designs were introduced into the market, further expanding the application scope of myopia control solutions. Domestically, Universal Vision has continued to gain recognition and support from families in promoting comprehensive solutions. Looking to the future, as major international manufacturers continue to invest R&D funds, product functions and ease of wear continue to improve. The myopia control market is shifting in orientation from "products" to a "long-term management" era of round-the-clock prevention and control. With Universal Optical's advantages built upon expert integrated functions and family trust, the Company will continue to expand its market scale.

The global trend of population aging and the growth of the health care industry are also gradually emerging in Taiwan, accompanied by the rising popularity of preventive medicine and the rapid development of the health supplement industry. According to a report by Kantar Worldpanel Taiwan, although new products are continuously being introduced into the market, the three health supplements most commonly purchased by consumers remain joint care, vision care (lutein), and beauty and skincare products. The Universal Group's Universal brand Gold Lutein product line is designed with an age- and group-specific approach to meet the health care needs of different demographics. It integrates the channels of self-operated optical stores and cooperative clinics to build a holistic "whole person, whole eye" health care model. At the end of 2024, the Group launched a new product targeting modern dry eye and heavy eye-usage symptoms. Tailored specifically to the eye care habits of Taiwanese people, the product delivers both preventive and wellness benefits. Since launch, the product has received strong positive feedback, and shown strong growth potential. Following launch, the product obtained Symbol of National Quality (SNQ) status, and received affirmation from experts. According to data from the Food Industry Research and Development Institute, Taiwan's dietary supplement and health food market has maintained an annual growth rate of 7–8% in recent years, indicating strong consumer recognition and support. Moreover, the impact of the pandemic has heightened consumer awareness of immune system enhancement, vision health, and joint care, further accelerating market expansion.

(3) Ophthalmic Medical Market

In addition to the high prevalence of myopia in Taiwan, many complications associated with high myopia—such as retinal hemorrhage, retinal detachment, and floaters also threaten people's eye health. According to the medical statistics of the National Health Insurance published by the Ministry of Health and Welfare, the ophthalmology outpatient expenditure under the National Health Insurance in 2024 exceeded 19 billion NHI points, accounting for 4.2% of the total Western medicine outpatient expenditures. However, ophthalmology offers self-paid services such as laser vision correction and premium intraocular lenses (IOLs) for cataract surgery, allowing clinics to enhance added value beyond the limited reimbursement of the National Health Insurance system. For example, with the increase in functionality, cataract lenses now come in various options, including aspheric, astigmatism-correcting, and multifocal designs, with fees ranging from NT\$30,000 to NT\$120,000 per eye, significantly increasing the added value of cataract surgery.

(4) EVO Implantable Collamer Lens (EVO ICL) Market

Via the 100%-owned subsidiary Eyeseer Medical Inc., UVB has introduced EVO implantable collamer lens (EVO ICL) technology from STAAR Surgical. STAAR is the world leader in the ICL field, and sets the standard for technology. STAAR focuses on designing, manufacturing, and marketing their EVO line of ICLs, for use with refractive correction issues such as myopia and astigmatism. The product possesses a high degree of competitiveness within the medical vision correction market, especially as an alternative solution for people with moderate to severe myopia. The lenses can be removed and replaced, which has gained a lot of notice from members of the public who have concerns regarding the permanent changes to the cornea involved in laser eye surgery. Even those without strong myopia are choosing EVO ICL for refraction correction, and as a result, EVO ICL is finding its place within the refraction correction market.

A. Global marketing and adoption status

STAAR Surgical has already built up a record of more than 3,000,000 lenses implanted worldwide (total of EVO ICL and other ICL technologies), in more than 75 countries/regions. EVO ICL market demand continues to increase around the world, particularly in Asia (e.g., Japan and South Korea), the US, Europe, and other such regions. Statistics show that STAAR has a strong proportion of the refraction correction market in Japan, and since obtaining US FDA approval in 2022, STAAR has also been expanding rapidly in the US market. A market research organization estimates that the overall implantable collamer lens market (including EVO ICL) had a global market in 2024 of c. US\$19.5 billion, expected to grow to US\$27 billion or more by 2029, for a compound annual growth rate of approximately 6 to 7%.


B. Technological and clinical advantages

The key technology behind EVO ICL is the patented collamer biocompatible material and the central hole (central port) for aqueous humor flow. The advantages include no corneal cutting, for lowered post-surgical eye dryness; reversible surgery, allowing the lens to be removed or replaced when necessary; and the ability to correct complex refractive issues such as severe myopia and astigmatism.

C. Present status and demand analysis for the Taiwan market

In April 2025, EVO ICL received Taiwan FDA (MOHW TFDA) approval for marketing, allowing ophthalmologists to use the technology in performing surgeries. Clinically, EVO ICL provides an additional option to those with moderate to severe myopia (in the range of -3.00 to -20.00 diopters, accompanied by up to 4.00 diopters of astigmatism). It is especially suited to people for whom LASIK/SMILE is a poor option, such as those with excessively thin corneas. Tens of thousands of people in Taiwan continue to receive refractive corrective surgery (such as for myopia) every year. For the 15–20% of these people who are unable to undergo laser treatment due to their cornea conditions or prescription restrictions, EVO ICL has become one of the major alternatives. Consumer acceptance of EVO ICL is growing; and especially with ophthalmology clinics and specialized physicians providing education and promotion, market trends show that searches for “ICL” have increased (such as vs. searches for “LASIK/SMILE”).

2. Relevance of upstream, midstream and downstream industries



For traditional laser medical instruments, medicinal drugs and consumables, and optical glasses companies, the products they sell are often resold to hospitals, ophthalmology centers, optical shops, and others across the country through agents and distributors. The process of selling such products often ends up with the mere form of purchase and sale and leasing, without being able to create added value for downstream clients; In recent years, the business model of medical management consulting companies and medical technology service companies has emerged. With the Company's own expertise in medical treatment for vision, it can provide users and clients with more professional technology and recommendations in the process of delivering or trading products. In addition, through the outcome of product integration and marketing, it can create more added value for downstream clients. Therefore, the effect of integrating merchandise through professional medical management consulting companies will bring more business opportunities to the industry.

3. Various development trends in products

(1) Laser correction market

As the general myopia patient's understanding of myopia surgery has increased and the safety and precision of myopia surgery technology in Taiwan has been greatly enhanced, the number of corrective surgeries performed annually has reached approximately 30,000 - 40,000. In the future, the number of consumers who are willing and able to undergo surgery is projected to increase year by year. In terms of supply, the post-pandemic boom in SMILE myopia laser corrective surgery and the introduction of new machinery and laser surgery methods have led to a continuous increase in price per procedure, prompting many practitioners to join the market and vie for a piece of the pie and resulting in fierce price competition. However, after the self-adjustment of market functions, only some suppliers with competitive advantages in cost, brand, channels, and technology will continue to survive. It is expected that as the supply stabilizes in the future, the price of surgery will return to normal levels, and the market supply will also be dominated by a few suppliers with competitive advantages in cost, brand, channels, and technology. Continuous improvements in ophthalmic laser correction technology have led femtosecond knifeless laser to become the mainstream technology—due to its higher safety, faster postoperative recovery, and higher acceptance by the public. People are also willing to pay higher fees for more advanced technology. Furthermore, in addition to the correction of general myopia, hyperopia, and astigmatism, presbyopia and presbyopia cataract have also begun to be treated with femtosecond lasers. At present, this market is just starting. As this technology requires investment in high-end and expensive equipment, many ophthalmology clinics in the market cannot afford to introduce it into the market, which also leads to development of the ophthalmic laser market in the direction of the big one always getting the biggest share.

In 2012, a false news report released in the laser market on an ophthalmologist retiring from performing the surgery, which made the public have doubts about the safety of the surgery, and the population having the surgery plummeted. However, the Company introduced blade-free femtosecond laser equipment for cooperative clinics to further improve the safety of surgery. We also educate the public on how to choose a safe laser surgery hospital or clinic. Meanwhile, we introduced laser surgery equipment for presbyopia and myopia, which finally allowed the number of persons doing surgery gradually to stabilize in 2013. Nevertheless, after going through this storm, many small ophthalmology clinics could not continue to operate this business. After market restructuring, the market share of the Company's cooperative clinics in

blade-free femtosecond laser had also increased. At the end of 2019, the Company introduced new femtosecond laser correction surgery equipment - Small Incision Lenticule Extraction (SMILE) to cooperative clinics. The market acceptance was high, and the number of patients doing surgery and equipment installations both increased as well. By 2022, SMILE surgery had become the mainstream surgical method in the refractive market, and both the marketing and technological development had also made SMILE their main focal axis. This trend is not likely to change in the short term. The SMILE PRO procedure was newly launched in 2023. This has been followed by the introduction of SMILE PRO 2.0 (with enhanced AI navigation features) and SMILE PRO 3.0 (which integrates precisely-calculated surgical parameters derived from big data) over the 2024–2025 period. The systems have received positive market acceptance, and their market share continues to grow.

(2) Optometry and Optical Market

The optical industry originally focused on general eyeglasses and contact lens products. However, due to the popularization of digital devices and changes in lifestyle, consumers now rely increasingly on smartphones and computers for information reception and transmission. This has led to a rising incidence of eye fatigue and eye diseases year by year, while also creating more diversified demand for eyeglasses prescriptions. In response to this trend, major lens manufacturers have not only continued to enhance functional and protective lens technologies, but have also actively invested in the development and promotion of presbyopia multifocal lenses and myopia control products for school children.

Following the implementation of domestic optometrist regulations, the transformation of the eyeglasses industry has accelerated in recent years. Professional standards for prescription services have become a key focus for consumers. This shift has promoted the development of optometry centers and brought far-reaching impact to the prescription eyeglasses market. Based on data from the Department of Statistics of the Ministry of Economic Affairs and a specialized survey conducted by the German market research consulting company GfK, the size of Taiwan's optical eyeglasses market is estimated to be between NT\$29 billion and NT\$32 billion. Considering the myopia population growth trend reported by the Health Promotion Administration of the Ministry of Health and Welfare, the market is expected to maintain an annual growth rate of 3–5% even after the pandemic. As the optometrist law continues to be enforced, the number of domestic independent eyeglasses stores will gradually decline. In a market where consumers' expectations for prescription quality have become increasingly polarized, a channel platform with professional medical experience and brand image holds excellent bargaining chips for market reallocation and plays the role of an important supplier in Taiwan's optical market.

The Universal system has demonstrated strong competitiveness in the innovative application of orthokeratology and myopia control products by successfully integrating processes, products, and service management to form a highly differentiated market advantage—distinct from peers in both ophthalmology and optical retail.

Additionally, since the launch of the world's first contact lens product for myopia prevention and control in the United States, its safety and effectiveness have gained widespread market recognition. Myopia control lenses, benefiting from the popularity of eyeglasses with frames, provide consumers with an easily acceptable solution. Universal Vision has successfully combined its services with these products, leveraging its extensive experience in myopia control and its brand advantages to offer a diverse range of product options. Through innovation

in optical technology and professional eye health services, the Company continues to provide consumers with comprehensive and effective vision solutions.

The domestic channels of healthcare food include organizational marketing (direct marketing), open-shelf sales (cosmeceutical stores, pharmaceutical stores, supermarkets, and wholesale stores), e-commerce (and TV shopping), medical hospitals and clinics, etc. The traditional direct sales channel changed its approach many years ago, creating experience centers with open-shelf displays and blurring virtual and real channels to provide more in-depth experiences and services for consumers.

The Universal brand Gold Lutein products are developed based on the Company's ophthalmic expertise and over 10 years of customer usage feedback, offering eye care products tailored specifically to Taiwanese consumers. By leveraging the integrated channel resources of self-operated optical stores and cooperative clinics, these services are brought directly into consumers' lives, creating a more convenient and comprehensive eye care solution. In an era of increased digital device use, growing awareness of vision health, and rising demand for immune support, the Universal Gold Lutein brand continues to provide high-quality health products and contribute to the steady development of the health supplement market.

(3) Ophthalmic medical market

The market of this industry is mainly based on the market of national health insurance, supplemented by self-paid medicines and nutritional foods. It is expected that in the future, with the increase of population, the trend in aging and the increase in diseases of civilization, the output value of this industry will grow steadily year by year. Since most of the market suppliers are regional clinics, the competitors with brand and cost advantages can use their cost advantages and brand awareness to widen the gap with their peers after they join the market in the future.

(4) EVO implantable collamer lens (EVO ICL) market

Myopia rates continue to rise around the globe, and the population of people with myopia (especially moderate to severe myopia) continues to grow. This provides EVO ICL with long-term growth momentum. At present, more than 3,000,000 EVO ICL implant procedures have been performed around the world. Industry analysis shows that the ICL market will continue to grow as a proportion of global corrective surgeries (such as LASIK, SMILE, and PRK), with ICL accounting for at least 12% of total refractive corrective surgery market value. A report also shows that the implantable lens market's total market scale has continued to grow, from c. US\$19.5 billion in 2024 to c. US\$20.7 billion in 2025, for a compound annual growth rate of approximately 6.3%.

For the Taiwan market, EVO ICL received approval for introduction from the Ministry of Health and Welfare in early 2025, thereby officially becoming a legal option for refractive corrective surgery. Since introduction, clinical inquiries have increased rapidly. One report pointed out that inquiries were more than 20 times what they had been at initial market introduction (data primarily from patient and clinic momentum in the latter half of 2025). In Taiwan's ophthalmology circles, EVO ICL is seen as an innovative vision correction option for the population with severe myopia, and discussion has increased markedly. As more ophthalmology centers introduce EVO ICL techniques and as physicians' training becomes fuller, we foresee the number of surgeries and patient awareness both increase rapidly over the next 3–5 years.

4. Product competition

(1) Major competitors

At present, there are no other TWSE/TPEX-listed vision biotechnology medical service companies in Taiwan. For the cooperative clinics, the main competitors are peers in the ophthalmology industry and large hospitals that conduct vision correction. As for eyeglasses products, the competitors are chain eyeglasses channels as well as Japanese-style fast fashion eyeglasses stores. Universal Eyeglasses is the first and only professional channel in Taiwan that combines optometry and medical ophthalmology.

(2) Competitive niche of the Company

The Company has established a brand advantage through its introduction of advanced instruments, equipment, and technology; this has become its main competitive niche and enabled all cooperative clinics to occupy a leading position in the vision surgery and the ophthalmic medical industry. Although the Company's market share in the optical eyeglasses industry is not high, when compared to its competitors, the Company's store performance is growing year by year. Unlike its competitors, whose business models only involve selling goods, the Company combines the medical expertise of its cooperative clinics with its exclusive professional "iCM precision intelligent optometry and eyeglasses prescription method" and uses this as the basis to continuously make breakthroughs and upgrade various product experience scenarios in its stores, using technology to fully integrate services and products. This innovative business model has carved out a niche market, ensuring the Company's future competitiveness and survival as the medical eyeglasses prescription market evolves.

(3) Technology and R&D overview:

1. The technical level and R&D of the business

The Company was formally established in August 1994, engaged in the business of optical instruments and optometry and optics. In August 1997, the Company introduced into Taiwan the first excimer laser refractive surgery instrument from VISX Company in the United States, and cooperated with Cardinal Tien Hospital in technology to start the research and development progress of laser vision correction. The sources of the Company's technology are mainly from the research project plans developed and conducted by the R&D personnel themselves long cultivated by the Company. The Company also maintains close technical cooperation with academic institutions or government research units.

2. Successfully developed technologies or products

The Company's R&D team combined traditional optometry technology with clinical medicine and statistics, researched on the advanced High Order interface software using excimer laser combined with wavefront aberration technology, developed data tailored for individual eyeballs, and further completed the application of individualized laser refractive technology in cooperation with the eye positioning tracking system. At present, there have been concrete achievements in the advanced High Order interface software technology, which is also used in cooperative clinics in various places, and therefore the quality of laser vision correction has been greatly improved; in addition, in terms of the instrument with cataract nucleus emulsification technology, it also applied for a US patent for the small incision nucleus cutter, which was a giant step in the improvement of the current ophthalmic cataract medical technology. In addition, in order to serve the elderly in remote areas,

the Company has cooperated with the Industrial Technology Research Institute and Leo Systems, Inc. to research and develop the AI cloud retinal vision healthcare system, which had received a project subsidy from the Industrial Development Bureau of the Ministry of Economic Affairs. This project helps the screening and development of vision medical services demanded in remote regions with insufficient medical resources. In the future, the Company will cooperate with well-known domestic academic institutions to research, develop and apply application software and hardware facilities related to biotechnology vision optics, using laser refractive optics, cataract medicine and ophthalmology optics as the three major development axes with market development benefits to continue the research and breakthroughs. At the end of 2019, the Company introduced SMILE equipment. At the end of 2022, it further introduced a new generation of “full femtosecond myopia laser” SMILE PRO technology equipment. In 2024, the Company launched SMILE PRO 2.0 with enhanced AI navigation features. In 2025, the Company introduced SMILE PRO 3.0, which integrates precisely-calculated surgical parameters derived from big data, and thus further improving laser safety. As customer satisfaction at cooperative clinics continues to rise, market share has steadily increased, and the procedure has now become one of the mainstream surgical methods. The Company will continue to invest in the development and application of this technology to increase its market share.

The Universal brand Gold Lutein products are meticulously designed by a professional biotechnology team, covering the entire process from formula development, raw material selection, and technical R&D to manufacturing. The products are manufactured in collaboration with top domestic teams using their specialized expertise. The innovative and groundbreaking dosage forms—including micro-granule capsules and candy-coated gummies—are not only unique in the market but also deliver added health benefits.

The micro-granule capsule dosage form adopts advanced plant extract coating technology, encapsulating each layer of nutrients within protective layers to effectively resist damage from gastric acid. This ensures that the nutrients are fully released and efficiently absorbed in the digestive tract. The product formula is meticulously developed with reference to large-scale research findings from the U.S. National Institutes of Health (NIH), as well as numerous research reports from domestic and international experts and scholars. It carefully combines a variety of high-quality ingredients and is specially designed to meet the eye health needs of the Taiwanese people.

The candy-coated gummy dosage form overcomes the technical limitations of traditional high-temperature sugar processing by utilizing a fully low-temperature manufacturing process, which maximizes the retention of nutrient activity and integrity. This process uses the natural preservative properties of sugar to avoid the addition of preservatives, offering a healthier eye care solution for Taiwanese consumers. This innovative dosage form not only enhances product convenience and taste but also underscores the Company’s leadership and commitment to quality in the health food sector.

(4) Long-term and short-term business development plans

1. Short-term plan

- (1) Continue to develop and introduce new medical instruments, equipment, and application technology, and integrate them into cooperative clinics for treatment purposes.
- (2) Actively search for brand-authorized ophthalmic clinics with willingness to cooperate, expand existing marketing channels, and increase market share.

- (3) Integrate virtual and physical channels to strengthen customer relationship management in the optometry sector and provide personalized vision health services for all age groups. Implement segmented marketing strategies to create maximum sales opportunities.
- (4) Optimize process design by leveraging digitalization and AI to enhance stores' operational efficiency and customer experience.
- (5) Establish and strengthen the purchase and distribution systems of medicinal drugs and consumables.

2. Long-term plan

- (1) Become the resource integration platform for the biotechnology industry and an innovative operator of chain channels, and provide more comprehensive vision health related products and services in a one-stop shopping model.
- (2) Continue to cultivate the cross-strait market.
- (3) Deepen engagement in the myopia control and presbyopia prescription markets by launching innovative myopia correction solutions and multifocal lens prescription plans through technology upgrades. Expand service coverage and strengthen market share to become the leading optometry brand of choice.
- (4) Establish its own brand and provide products for the biotechnology vision industry; at the same time, become an international supplier of high-end software interfaces for biotechnology vision in response to market demand to sell products in the global medical and optometry markets.
- (5) Expand the marketing channel of vision biotechnology and vision optics with a global strategy, and build the largest vision biotechnology and medical channel in Asia.

2. Market, production and marketing overview

(1) Market analysis

1. Sales (supply) areas of major products (services)

Unit: NT\$ thousand; %

Year \ Item	2023		2024		2025	
	Amount	%	Amount	%	Amount	%
Taiwan	3,324,469	81.44	3,634,639	85.96	3,719,039	88.46
Mainland China	757,787	18.56	593,663	14.04	485,047	11.54
Total	4,082,256	100.00	4,228,302	100.00	4,204,086	100.00

2. Market Share

As of the date of publication of the annual report, the Company currently has 33 cooperative clinics and 35 direct sales eyewear stores in Taiwan. Based on the currently constructed channel platform, the market shares and statuses of each market, as reflected by business performance, are as follows:

- (1) In the laser surgery for vision correction market, it is currently estimated that about 30,000 - 40,000 people in Taiwan undergo surgery every year. Calculated based on the ratio of femtosecond laser surgery performed by the Company's cooperative eye clinics, it is estimated to account for about 57% of the overall market share, taking a leading position in the domestic market. Clinical statistics show that, among members of the public who intend to get their vision surgically corrected, approximately 10–15% are unable to have such surgery

done via laser due to insufficient corneal requirements. Since the Company has helped partner clinics introduce EVO implantable collamer lens (EVO ICL) technology, the technology has become a superior option for such persons with insufficient corneal thickness who wish to eliminate their reliance on eyeglasses. EVO ICL looks likely to increase the Company's share in the vision correction surgery market.

- (2) According to statistics on the optometry and eyeglasses prescription market released by the German market research consulting company GfKn, the annual demand for general eyeglasses is approximately NT\$18–20 billion, the demand for contact lenses and medicinal fluid is approximately NT\$7–8 billion, and the total market value remains in the range of NT\$29–32 billion. Based on the Company's revenue, its market share is estimated to be about 2%. However, compared with its competitors, whose business models rely solely on the sale of products, the Company pairs the professional medical skills of its cooperative clinics with the "i precision intelligent optometry and prescription method" for its exclusive and original professional eyeglasses. In addition to the professional German-made Carl Zeiss optometry instruments, the Company has also introduced multifocal vision relief experience equipment from Japan's HOYA and France's Essilor, integrating AI technology and big data applications to provide visually verifiable consultation experiences for different consumers. The Company's technology and experience further distinguish it from others in the market. This kind of professional "medical optometry, scientific eyeglasses prescription" model will help the Company stand out in the optometry industry and the eyeglasses prescription market, and increase its market share.
- (3) In the ophthalmic medical market, the total number of Western medicine-based primary ophthalmic disease cases in Taiwan is currently about 20 million per year. Due to population growth, population aging, and the increased prevalence of diseases of affluence, the output value of this industry is expected to grow steadily year by year. The outpatient service volume of the Company's cooperative clinics is approximately 80,000 to 90,000 visits per month. Total service of ophthalmic patients is over one million per year, for an estimated market share of 6%.

3. The Supply and Demand Condition and Growth Potential of the Market in the Future

(1) Vision Biotechnology Industry

In recent years, the minimally invasive and small-incision features of SMILE technology have significantly alleviated concerns about postoperative dry eye, which is a complication associated with traditional LASIK procedures. As a result, since 2019, the laser vision correction market has experienced double-digit annual growth, even during the pandemic. However, growth slowed in 2024, with the market showing a trend of increasing price while maintaining volume. On the supply side, the expansion of equipment deployment by original equipment manufacturers has increased overall supply. The market is expected to become increasingly competitive. Nevertheless, willingness to undergo laser vision correction is not solely affected by pricing. Surgical quality and the reputation of physicians and clinics remain the public's key considerations when choosing a laser vision correction provider. It is anticipated that the market will continue to be dominated by a few suppliers with competitive advantages in cost, brand, channels, and technology. In 2025, the laser vision correction market encountered headwinds, primarily due to the bounce-back in travel following lockdown; in 2024, there was a marked slowdown in the growth of laser, followed by a market downturn in 2025. At the same time, the market also saw South Korean medical cosmetics and myopia laser corrections luring away customers with low prices; this had an impact on the myopia segment who are young and highly sensitive to price. Over the 2020–2024 period, there was a glut

of domestic laser myopia clinics trying to get into the market, leading to sluggish market demand; yet supply was not reduced, which influenced market share in all regions. The Company thus guided partner clinics to continue to increase laser surgery for presbyopia and myopia proportionally among all age segments, while simultaneously introducing the new surgical EVO implantable collamer lens (EVO ICL) technique to take the strategic lead in this currently-undeveloped domestic market.

(2) Optometry and Optical Industry

With the continuous emergence of new products and correction methods in the eyeglasses and contact lens market, the traditional market, once focused solely on vision correction lenses, is gradually undergoing transformation. As consumer needs and habits evolve, market trends are shifting toward technologically advanced and multifunctional product solutions, such as blue-light blocking lenses, frames made with innovative materials, smart glasses, disposable contact lenses, and multifunctional sunglasses. The domestic market output value is expected to remain stable between NT\$29 billion and NT\$32 billion, with steady growth in line with economic scale and inflation levels.

The demand for multifocal vision relief lenses among adults is also on the rise. With global and domestic population aging, presbyopia lens prescriptions have become a growing trend. Although some premium boutiques offer options to consumers, there are only a few channel platforms capable of providing comprehensive solutions. These products are specifically designed for modern adults who use digital devices for extended periods and have near-vision needs. The prescription process involves a high technical threshold. Universal Vision has proactively developed integrated hardware, software, and service procedures, working closely with suppliers on advanced technical cooperation to deliver a complete and holistic consultation experience—creating customized, comfortable, and precise multifocal lenses for every customer. Multifocal vision relief prescription services have become a key growth point in the market and are attracting more consumers in the targeted age range to experience them.

The continuous advancement in myopia control product technology has provided scientifically validated myopia prevention and control solutions for school children and adolescents, helping to slow the progression of myopia during their educational journey and reduce the risk of eye diseases caused by high myopia. Universal Vision has further upgraded this offering to a comprehensive and all-day myopia control concept. In the future, such products will become a significant driver of market growth.

As competition intensifies across distribution channels, consumer expectations regarding prescription quality and service experience have also risen considerably. Only those platforms with professional medical experience, innovative technology, and strong brand image can stand out in the optical prescription industry and become market leaders. A fully integrated online to offline (O2O) service model that delivers personalized vision health solutions will become a key competitive advantage for future market providers.

(3) Medical vision industry

The market of this industry is mainly based on the market of national health insurance, supplemented by self-paid medicines and nutritional foods. It is expected that in the future, with the increase of population, the trend in aging and the increase in diseases of civilization, the output value of this industry will grow steadily year by year. Since most of the market suppliers are regional clinics, the competitors with brand and cost advantages can use their cost advantages and brand awareness to widen the gap with their peers after they join the market in the future.

4. Competition niche

(1) Innovative business model

The Company's business model lies in an innovative business philosophy in the biotechnology industry, focusing on the integration of the upstream and the downstream. The Company provides comprehensive services by integrating upstream suppliers of instruments, pharmaceutical consumables, and optical products, and integrating downstream channels. Due to the characteristics of the industry, competitors face high thresholds for entering this market. The Company's business model of professionally integrating the upstream and the downstream, along with its formulation of product and service strategies in accordance with consumers' vision needs, provide a comprehensive and complete set of solutions for cooperative clinics, making it the only company with both channels and integrated technical service capabilities.

(2) The channel brand of "e Universal"

The Company provides the cooperative ophthalmology clinics with the authorized brand of "e Universal" that goes with the complete software and hardware equipment platform (such as interface software, femtosecond excimer laser, eyeball aberration analyzer), as well as distribution and sales of ophthalmic medicinal drugs and consumables with uniform quality. It even includes the business site selection and decoration; coupled with the optometric service of Universal Vision and the storefront of eyewear stores, so that the best medical environment can be thoroughly replicated in a standardized manner. It allows the cooperative clinics to have a uniform professional image and quality. Through jointly marketing the professional brand "e Universal" by the cooperative clinics in the north, central and south, as well as the number and functions of instruments owned and the years of clinical experience in laser correction accumulated by cooperative clinics, they are even the advantages that other competitors can hardly catch up on.

(3) Standardized module replication

As of the date of publication of the annual report, the Company has signed cooperation contracts with 33 ophthalmic clinics in Taiwan. The Company provides various equipment, facilities, and authorization of the brand "e Universal" required by ophthalmologists to operate a clinic in the form of standardized modules. With the professional judgment and prescription made by doctors, the business of ophthalmology clinics can be rapidly expanded.

(4) Hire professionals and provide professional services with high added value

At present, the Company's employees who have a college degree or above account for 90% or more of the Company's entire employees. It also has a team of professional consultant physicians, administrative management professional managers, marketing and public relations professionals, financial and accounting professionals, and retains prominent personages in the academic and financial circles to serve as independent directors so as to guide and supervise the operation of the Company's finance and business. The optometry service personnel in the store are all highly professionally trained talents who have obtained the optician (optical technician) license, as well as the licenses related to the store service and lens production. In order to expand the marketing, the Company continues to recruit outstanding talents in various professional fields to form a professional service team, and further perfects the personnel system, affirming that "colleagues are the Company's most important asset" to cultivate and motivate multi-skilled employees, so that the ability of colleagues can be effectively exerted.

(5) Perfect professional after-sales service

For the medical instruments, laser eye surgery equipment leasing and technical services, contact lenses, pharmaceutical consumables, etc. provided to cooperative clinics, the Company stipulates in the cooperation contract with cooperative clinics the provision of instrument maintenance and consulting services. In addition, the Company has medical engineering and technical personnel to provide the most timely technical consultation and maintenance, so that cooperative clinics can maintain normal operation.

(6) Recognition of Symbol of National Quality, National Biotechnology Quality Award, National Award of Outstanding SMEs, and National Yushan Quality Award

The Company assists the cooperative clinic in obtaining the certification of Symbol of National Quality as a “high-quality ophthalmic laser vision correction center”. The Symbol of National Quality is a quality inspection standard established by the Institute for Biotechnology and Medicine Industry and the Department of Health, Executive Yuan. It is used by scholars and experts to test the quality of services with professional and strict inspection standards so as to guard the health of the people. Having been implemented for years, it has become the highest honor in Taiwan's biotech and medical industry. The Universal Eye Clinic is the only ophthalmology clinic and ophthalmic laser vision correction center in Taiwan that has passed the certification of Symbol of National Quality. In addition, the Company also won the National Award of Outstanding SMEs in 2006. The National Award of Outstanding SMEs is the highest honor for domestic small and medium-sized enterprises. In the past, most of the winners were in the manufacturing industry. The Company is the first enterprise in the service industry to receive this award over the years. In 2008, due to the innovation of the business model, it was regarded as a model of innovation and entrepreneurship in the biotechnology and medical industry, and won the special honor of Ernst & Young Entrepreneur of the Year.

In 2013, the Company assisted cooperative ophthalmology clinics in winning the recognition of the Symbol of National Quality as well as the National Biotechnology and Medicine Care Quality Award with the blade-free presbyopia and myopia laser. Since 2010, the Company has even successfully assisted the cooperative clinic to pass with high scores the internationally highest standard Joint Commission International (JCI) accreditation for health care, making Universal Eye Center the first ophthalmology medical institution in Taiwan, Mainland China, and Hong Kong and/or Macau to have passed the accreditation for six consecutive times. Passing the JCI certification further proves that the services and technologies provided by Universal Eye Center are in line with high-quality international standards. In conjunction with the medical network spreading across the northern, central and southern Taiwan, it will cooperate with the government to develop medical tourism services in the future, which makes it extremely advantageous whether in terms of the three links across the Taiwan Strait or international routes.

Since its launch, the Universal Gold Lutein series has received numerous accolades, demonstrating its outstanding quality and industry-leading technology. After winning the National Biotechnology & Medical Care Quality Award in 2014, the Universal Gold Lutein series was honored with the National Yushan Quality Award in 2020. In 2022, the Jin Bao Ming (children formula) product line was awarded the Superior Taste Award by the International Taste Institute

(iTQi) for its exceptional product flavor and quality. In 2024, Jin Bao Ming was further honored with the Gold Award from Monde Selection. With over 60 years of history, Monde Selection is a globally recognized quality assessment organization whose evaluation criteria include sensory testing, product quality measurement, and scientific analysis. It is often referred to as the “Oscars of the food industry”. Jin Bao Ming products have not only earned the strong trust of international biotech experts for their outstanding quality but also received widespread acclaim from professional judges for their exceptional taste. In 2025, the newly launched Jin Run Ming (enhanced hydration formula) Lutein product also obtained Symbol of National Quality (SNQ) status, again demonstrating the brand’s continued progress in quality, research, and development.

5. Advantages, disadvantages, and countermeasures of development prospects

(1) Favorable factors for development prospects

A. Advanced technology and medical instruments

The main equipment of the Company is the optical instrument for laser vision correction. Since the introduction of the first Visx excimer laser instrument in Taiwan in 1997, it has now owned the greatest number of laser instruments for vision correction introduced from the top three manufacturers in the world (Alcon、ZEISS、J&J) among all platforms that provide vision biotechnology medical services in Taiwan. In response to the continuous innovation of vision biotechnology and instruments over the years, the Company has also continued to introduce laser instruments with more multiple functions and better effects. In 2019, it took the lead in cooperating with the original manufacturer from Germany Zeiss in introducing the new SMILE femtosecond laser vision correction instrument and introduced the brand-new next-generation SMILE PRO “full femtosecond myopia laser” equipment at the end of 2022 to provide cooperative clinics with more diverse hardware and software equipment. The continuous advancement of ophthalmic equipment technology such as femtosecond laser and eye tracking system has made many competitors in the same industry unable to keep up with the speed of technological development. The Company still continues to lead the industry in terms of software and hardware facilities provided. For the EVO ICL technology introduced in 2025, only Universal’s cooperating ophthalmology clinics have received technical certification from the original manufacturer, meaning that domestic competitors are not yet able to operate this technology, and thus creating a major advantage for Universal.

B. Effective channel deployment strategy

Since the Company selected the Universal Eye Center (Xinnan) as the Company's first cooperative clinic in 1999. In recent years, it has cooperated with clinic physicians all over the country. The cooperative clinics are located in Greater Taipei Area, Taoyuan, Hsinchu, Taichung, Chiayi, Tainan, and in the Greater Kaohsiung Area. It is currently the largest consulting company providing laser vision correction technology in the country. After the expansion of channels, no matter in the joint purchase of medical consumables or the sales of eyeglasses and eyeglass prescription, economies of scale can be achieved. In the future, the Company will continue to expand its channels of cooperative clinics and self-operated eyeglasses stores, aiming to become the No. 1 brand in the Chinese vision health industry.

C. The Company introduced excimer laser instruments to cooperative clinics, so that cooperative clinics can provide the most professional surgery for myopia patients; and after patients receive laser vision correction services, they can enjoy the most complete after-sale service and regular postoperative follow-up, so as to establish the professional image in the eyes of myopia correction patients. With the help of word-of-mouth marketing from consumers, it also improves the competitiveness and advantages of the Company, cooperative ophthalmology clinics and other ophthalmology clinics.

D. Ability to build a brand

Compared with clinics opened by individual physicians, the “e Universal” corporate brand and popularity of cooperative clinics authorized by the Company are the most important attracting factors for first-time consumers.

E. Continued service

Through the country-wide channel platform and the complete product line of care for the elderly, middle-aged, youth, and preschoolers, it can provide vision products and services for a customer at different stages or different members of a family to meet various needs, so that cooperative ophthalmology clinics possess uniqueness from competitors.

F. Continuously develop new products

The Company will continue to integrate the upstream instrument suppliers and downstream cooperative clinics for their clinical experience and practice, and continue to innovate, research, and development various software and hardware equipment. In addition, the Company will be committed to the research and development of health care equipment or functional products, including the improvement of eye health food formulations so as to meet various needs.

G. The cooperative clinic is the first ophthalmology medical institution in Taiwan, Mainland China, and Hong Kong and/or Macau to have passed the Joint Commission International (JCI) international accreditation for health care for six consecutive times

In 2010, the Company has succeeded in counseling the cooperative Universal Eye Center to pass the highest international standard of JCI (Joint Commission International) health care accreditation with the high scores, making the Universal Eye Center the first ophthalmology medical institution among the three places on both sides of the Taiwan Strait to pass this certification for six consecutive times. Passing the JCI certification further proves that the services and technologies provided by Universal Eye Center are in line with high-quality international standards. In conjunction with the medical network spreading across the northern, central and southern Taiwan, it will cooperate with the government to develop medical tourism services in the future, which makes it extremely advantageous whether in terms of the three links across the Taiwan Strait or international routes.

(2) Unfavorable factors of development prospects and countermeasures

A. People's doubts about eye laser surgery

The Company mainly provides laser surgery equipment and technical services required by cooperative eye clinics. Laser surgery is a new vision correction technology. Although laser surgery for vision correction has been quite common in Taiwan, there are still quite a few myopia patients who have doubts about undergoing the surgery, and many consumers still hold a wait-and-see and hesitant attitude towards laser surgery for vision correction.

Countermeasures:

- (a) The Company provides professional education and training for the staff of each cooperative clinic, so that they have sufficient knowledge to explain the process of ophthalmic laser surgery to the public and answer various questions from the public. In addition, the cooperative clinics provide free computerized optometry, post-mydriatic computerized optometry, corneal thickness, tear test, intraocular pressure, and other test, and the ophthalmologist personally examines the most important part of the dilated pupil retinal fundus and conducts face-to-face communication with the public to let the public understand the success rate, safety and medical process of ophthalmic laser surgery so as to reduce consumer doubts.
 - (b) We introduced a new generation of SMAll Incision Lenticule Extraction (SMILE) Pro VM800 myopia laser equipment to assist cooperative clinics in introducing the latest surgical techniques, upgraded the laser process and positioning, added the visual axis and astigmatism axis as the auxiliary navigation function, and shortened the monocular laser time for one eye to less than 10 seconds only, so as to make patients more comfortable and at ease. We introduced the laser vision correction equipment for elders of the internationally major manufacturer Zeiss LBV from Germany to provide precise and customized technology that meets demand for the eye age, with clear and full focus length and large depth of field for comfortable and easy far and near focusing.
- B. The number of clinics engaged in laser surgery increases, resulting in price competition

Since laser surgery is a new vision correction technology, the medical expenses required are relatively high. For performing ophthalmic laser surgery, the attending physician not only must have extensive clinical experience, but also have to conduct detailed examinations including vision correction, corneal topography, tear analysis, intraocular pressure, corneal thickness, and the most important part of the dilated pupil retinal fundus examination before surgery, etc. It must also be performed with expensive equipment to ensure the quality of medical effects. Due to the large number of ophthalmologists in the market of variant levels of quality, there may be cases of unfair price competition in order to win over the public for medical treatment, which in turn affects the pricing of the Company and its cooperative clinics in the market.

Countermeasures:

The Company's operating policy is to provide sophisticated medical instruments to cooperative clinics, supplemented by advanced vision correction technology and services, the sale of ophthalmic medical consumables, the provision of administrative services and other professional logistics consultants and counseling by cooperative ophthalmology clinics, and the support for cooperative clinics to provide safe vision medical services to the general public. The Company carefully selects both professional and reputable ophthalmologists to cooperate with, and establishes the professional image of the Company and its cooperative clinics with the brand of "e Universal" to be differentiated from other competitors that pursue promotion and price reduction. It provides the public with advanced, perfect, friendly, trustworthy, and safe medical services so as to build medical reputation and credibility.

To sum up, the Company will assist partner clinics to:

- (a) Continue developing the market for middle-aged presbyopia laser correction and adjustments following myopia laser correction for patients with presbyopia.
- (b) Employ the Company's brand and quality to maintain flexibility in price competition against domestic competitors; continue to expand domestic market share, and take the place of competitors that have overexpanded themselves.
- (c) By exclusively introducing the high-tech new EVO ICL procedure, meet unsatisfied market demand and create word of mouth.

(2) Important purpose and production processes of main products

1. Important purpose of the main products

Main Product (merchandise)	Purpose / Function
Technical service	Provide professional instruments, brand licensing, technical services, and consultation for vision medical and vision biotech medical treatment in ophthalmic medical institutions
Medical consumables	Provide ophthalmic medicinal drugs and medical consumables for ophthalmic medical institutions
Venue rental	Provide rental of the business sites of ophthalmic medical institutions
Sale of eyeglasses	Provide the general public with optometry products for vision correction

2. Production processes: The Company belongs to the vision biotechnology service industry, and therefore there is no production and manufacturing process as for the general manufacturing industry.

(3) Supply status of main raw materials:

Supplier Name	Main purchasing items	Supply status
Carl Zeiss AG, Alcon Services AG, Eyecare Tech and others	Instruments, equipment, and consumables	Good
Brighten Optix Co., CooperVision Taiwan, Biowell Nutriscience, Greenyn Biotechnology Co., Ltd., Hoya Taiwan, Essilor, Dianlian Optical Co., Ltd., Bausch & Lomb, Carl Zeiss AG, Euclid System Corporation USA and others	Eyeglass frames, eyeglass lenses, contact lenses, medicinal liquid, healthcare food (Universal Gold Lutein)	Good
Carl Zeiss AG, Alcon Services AG, Acute Medical, Inc., Eyecare Tech, Zuellig Pharma Holdings Pte. Ltd., United Medical Inc., Winston Medical Supply Co., Ltd., Shih Chieh Ming Co., Ltd., Aseptic Innovative Medicine Co., Ltd., Taiwan Patron Chemical and Pharmaceutical Co. and others	Ophthalmic medication	Good

The Company is in the vision biotechnology service industry. The main purchase items can be divided into three major categories, namely laser vision correction consumables, medical and pharmaceutical consumables, and eyeglasses products. Products are procured according to the needs of cooperative clinics. The purchase of laser consumables is mainly from Carl Zeiss, Alcon Services AG, Eyecare Tech and other companies. The purchase prices are stable without large fluctuations, and there is no concern about the supply of goods. The main purchases in the eyeglasses and optical trading business are from Brighten Optix Co., CooperVision Taiwan, Biowell Nutriscience, Greenyn Biotechnology Co., Ltd., Hoya Taiwan, Essilor, Dianlian Optical Co., Ltd., Bausch & Lomb, Carl Zeiss AG, Euclid System Corporation USA and other companies. The Company has established long-term cooperative relationships with many manufacturers, and these manufacturers can also cooperate with the Company's inventory policy for the supply of eyeglasses and lenses, resulting in an excellent partnership. For medicinal drugs and consumables, we cooperate with Carl Zeiss AG, Alcon Services AG, Acute Medical, Inc., Eyecare Tech, Zuellig Pharma Holdings Pte. Ltd., United Medical Inc., Winston Medical Supply Co., Ltd., Shih Chieh Ming Co., Ltd., Aseptic Innovative Medicine Co., Ltd., Taiwan Patron Chemical and Pharmaceutical Co. and other companies. On the whole, the Company has many suppliers, and purchases are made based on the orders of cooperative clinics; therefore, there is no inventory risk or purchase concentration risk. There have been no shortages or supply interruptions during the past 3 years, indicating that the Company's supply of raw materials is stable.

(4) The names of clients that have accounted for 10% or more of the total purchases (sales) in any of the last two years, and their purchases (sales) amounts and proportions

1. Purchase

NT\$ thousand

2024				2025				As of March 31, 2026 (Note)			
Name	Amount	Percentage of annual net purchase (%)	Relationship with the issuer	Name	Amount	Percentage of annual net purchase (%)	Relationship with the issuer	Name	Amount	Percentage of net purchase as of the previous quarter in the current year (%)	Relationship with the issuer
B	347,361	28.40	None	B	309,651	25.03	None	Not applicable			
A	133,138	10.88	None	A	157,540	12.74	None				
Other	742,637	60.72	None	Other	769,810	62.23	None				
Net purchase	1,223,136	100.00	-	Net purchase	1,237,001	100.00	-				

Note: As of the publication date of the annual report, there is no financial information reviewed by certified public accountants.

Explanation of reasons for changes: There were no significant changes in the Company's suppliers in the last two years.

2. Sales: Not disclosed since there are no clients with 10% or more of the total sales in the last two years.

3. The number of employees, average years of seniority, average age, and educational level in the last two years and as of the publication date of the annual report (including employees of subsidiaries)

Year		2024			2025			As of March 31, 2026		
Gender		Female	Male	Total	Gender	Female	Male	Total	Gender	Female
Number of employees	Business staff	259	153	412	265	156	421	265	157	422
	Management staff	116	58	174	112	63	175	110	63	173
	Total	375	211	586	377	219	596	375	220	595
Average age		32	37	34	33	38	35	33	38	35
Average years of seniority		4.6	6.4	5.3	5.1	6.7	5.7	5.3	6.9	5.9
Educational level %	Ph. D	0.5%	1.0%	0.7%	0.5%	0.9%	0.7%	0.5%	0.9%	0.7%
	Master	3.7%	7.1%	5.0%	4.2%	7.8%	5.5%	4.3%	7.7%	5.5%
	College and University	92.6%	86.7%	90.4%	91.8%	86.8%	90.0%	91.7%	86.9%	89.9%
	Senior high	3.2%	5.2%	3.9%	3.5%	4.5%	3.8%	3.5%	4.5%	3.9%
	Under senior	0%	0%	0%	0%	0%	0%	0%	0%	0%

4. Information on environmental protection expenditures

In the most recent year and as of the publication date of the annual report, disclose the losses incurred due to environmental pollution (including compensation and environmental protection audit results that violate environmental protection laws and regulations, the date of penalty, the penalty number, the laws and regulations violated, the content of violation, and the penalty shall be listed) and the estimated amount that may occur at present and in the future as well as the corresponding measures. If it is impossible to carry out the estimation, the reason shall be stated: None

5. Labor-management relations

- (1) Various employee welfare measures, further education, training, retirement systems, and their implementation status, as well as labor-management agreements and various employee rights and interests protection measures.

1. Welfare measures

All employees participate in labor insurance and national health insurance. In order to strengthen employee welfare measures and improve employee welfare, the Company established an Employee Welfare Committee on January 3, 2003, and regularly held dinner parties, distributed wedding and funeral subsidies, condolences for injuries and illnesses, gifts for three major festivals, etc. In addition, beginning February 1, 2024, the Company added employee group insurance to strengthen protections for employees.

2. Further education and training

The Company's training fee for the year 2025 was NT\$1,656 thousand, and various educational and training sessions were designed and organized for all colleagues. In addition, an enterprise management consulting company was commissioned to make up for the insufficiency of the Company's internal training, so that employees can work in a growing environment.

3. Retirement system and its implementation status

The Company has formulated the retirement guidelines, which have been in line with the implementation of the Labor Pension Act (hereinafter referred to as the "New System") since July 1, 2005. The payment of the pension is made by the Company by setting aside not less than 6% of the monthly salary on a monthly basis to be deposited in the individual dedicated account for labor pensions. The original labor retirement reserve appropriation account under the Labor Standards Act had been settled in accordance with the law on June 30, 2011.

4. Labor-management agreements and various measures to protect the rights and interests of employees

The Company is an industry subject to the Labor Standards Act, and all operations are carried out in accordance with the Labor Standards Act. The labor-management relationship is harmonious, and there is no labor-management dispute.

The Company has established a labor-management meeting by election in accordance with the law, and regularly holds meetings on corporate governance communication and coordination, labor-management relations, and labor-management cooperation matters.

- (2) In the most recent year and as of the publication date of the annual report, disclose the losses incurred due to labor disputes (including labor inspection results that violate the Labor Standards Act, the date of penalty, the penalty number, the laws and regulations violated, the content of violation, and the penalty shall be listed) and the estimated amount that may occur at present and in the future as well as the corresponding measures. If it is impossible to carry out the estimation, the reason shall be stated: none.

6. Cyber security management


- (1) Cyber security management strategy and structure, cyber security policy, specific management plan, and resources invested in cyber security management:

1. Cyber security management strategy and structure

The unit in charge of information security of the Company is the Information System and Equipment Division, which is staffed with one director and several professional information personnel, is responsible for formulating internal information security policies, planning and implementing information security operations, and the promotion and implementation of information security policies, reports the Company's information security governance overview to the Audit Committee.

The Company's information security supervision and inspection unit is the Audit Office, which is staffed with one audit director and several dedicated auditors, is responsible for supervising and inspecting the implementation of internal information security matters. If relevant deficiencies are found in the inspection, the inspected unit will be required to submit relevant improvement plans and specific actions, which will be tracked for the improvement results so as to reduce internal information security risks.

Organizational operation mode - The PDCA cycle management is adopted to ensure the achievement of reliability goals and continuous improvement.



2. Cyber security policy:

In order to implement the effective operation and implementation of the Company's various information management systems, we maintain the confidentiality, integrity, and availability of important information systems so as to ensure the safe operations of information systems, equipment, and networks.

The Company has established an information security management mechanism, including the following three major items:

- (1) System norms: Formulate the Company's information security management systems and guidelines, and standardize the information-related operation behavior of colleagues.
- (2) Application of new technology: Import and build information security management related software and hardware, and implement information security management measures.
- (3) Personnel training: Regularly conduct information security education and training to enhance the information security concept of all colleagues and implement various information security measures.

Described as follows:

- System norms: The Company has formulated a number of information security management guidelines and systems to regulate the information security behavior of the Company's personnel. It regularly inspects whether the relevant systems conform to the changes in the operating environment every year, and makes adjustments in a timely manner according to needs.
- Application of new technology: In order to prevent various internal and external information security threats, in addition to adopting a multi-layer network architecture design, the Company also builds various information security protection systems and mechanisms, such as high reliability architecture (HA) of high availability, host environment backup, data backup (transaction records, differential backup, and full backup), off-site backup mechanism to improve the security of the overall information environment. In addition, in order to ensure that the operation behavior of internal personnel conforms to the Company's system norms, asset management system tools are also introduced to implement equipment and personnel information security management measures.
- Personnel training: The Company regularly organizes information security education and training courses and establishes an online learning (E-Learning) system to enhance internal personnel information security knowledge and professional skills.

3. Specific management plan:

Information Security Management Measures		
Type	Description	Relevant operations
Authority management	Management measures for personnel account, authority management, and system operation behavior	Personnel account permission application management and review Regular personnel account permissions inventory
Access control	Control measures for personnel access to internal and external systems and data transmission channels	Internal / external access control measures Operation behavior tracking record

Information Security Management Measures		
Type	Description	Relevant operations
External threat	Internal potential weaknesses, poisoning channels, and protective measures	Host / computer vulnerability inspection and update measures Virus protection and malware detection Malicious attacks prevention equipment
System availability	System availability status and handling measures when service is interrupted	Routine inspection of computer room System / network availability monitoring and reporting mechanism Response measures to service interruption Information backup, local / remote backup mechanism, regular data restoration test Host restore test Regular disaster recovery drills

4. Resources Invested in Cybersecurity Management in 2025

- ◆ In May, 2025, conducted a Computer Network Information Security Operations Awareness Campaign across the entire Company.
 - ◆ In June 2025, the Company held an Information Security Awareness on-the-job training course. As of December 31, 2025, a total of 319 participants had completed the training.
 - ◆ In December, 2025, budgeted more than NT\$6 million for information security software and hardware upgrades.
 - ◆ In 2025, a New Employee Information Security Awareness onboarding training course was conducted, with a total of 91 participants as of December 31, 2025.
 - ◆ In 2025, a Personal Data Protection Act onboarding training course for new employees was conducted, with a total of 103 participants as of December 31, 2025.
5. The Company has adopted the ISO/IEC 27001 international standard for information security management and obtained third-party certification for ISO/IEC 27001:2022 in August 2025. The current certificate is valid from August 22, 2025, to October 31, 2026. Through the implementation of the ISO/IEC 27001 Information Security Management System, the Company aims to strengthen its incident response capabilities in cybersecurity and ensure the confidentiality, integrity, availability, and legal compliance of its information and communication systems, as well as the protection of customers' personal data.

【ISO/IEC 27001 Certificate】 : Please refer to the Company's official website **【Information Security】** Section.

(Please refer to https://www.uvb.com.tw/investor/investor_a05_08)

Universal Vision Information Security Elements



Confidentiality

Accessible only to authorized individuals.



Integrity

Cannot be altered or tampered with without authorization.



Availability

Accessible at any time by authorized individuals.



Legal Compliance

Compliant with legal and regulatory requirements.

6. Professional Training and Certification of Information Security Officers and Personnel

◆ Information Security Officer:

February 2025: 6-hour information security class held by the Taiwan Academy of Banking and Finance.

June 2025: 6-hour training on ISO/IEC 27001:2022 Information security management systems internal auditing.

◆ Information Security Personnel:

February 2025: 6-hour information security class held by the Taiwan Academy of Banking and Finance.

August 2025: 36 hours of Cloud Computing and AI Information Security classes for industrial talent investment program.

- (2) The loss and possible impact due to major cyber security incidents in the most recent year and as of the publication date of the annual report, and the countermeasures. If it cannot be reasonably estimated, the fact that it is impossible to reasonably estimate should be explained: None.

7. Important Contracts

Nature of contracts	Contracting Parties	Period of Contract	Term of Agreement	Limitation Article
Revenue contract	UNIVERSAL-cooperative ophthalmology clinics	April 2022–	Cooperation contract (Services include providing cooperative clinics with introduction to, leasing of, and maintenance for ophthalmic instruments and equipment; sales of pharmaceutical consumables; business district evaluation; new store opening, planning, and décor; store venue leasing; personnel recruitment; administrative affairs; and other professional logistics support)	None
Expense contract	Several companies providing maintenance and warranty services for ophthalmic surgical equipment	February 2021–	Instrument/Equipment Maintenance Warranty	None

V. Review of Financial Position, Financial Conditions, and Risk Matters

1. Financial Position

(1) Consolidated Balance Sheet

Unit: NT\$ thousand

Item \ Year	2025	2024	Variation	
			Increase (decrease) amount	Variation Ratio (%)
Current assets	3,001,314	2,841,821	159,493	5.61
Non-current assets	3,091,762	2,920,881	170,881	5.85
Total assets	6,093,076	5,762,702	330,374	5.73
Current liabilities	1,028,992	1,090,724	(61,732)	(5.66)
Non-current liabilities	904,879	916,250	(11,371)	(1.24)
Total liabilities	1,933,871	2,006,974	(73,103)	(3.64)
Share capital	847,249	847,249	-	-
Capital surplus	381,924	381,924	-	-
Retained earnings	2,795,035	2,388,335	406,700	17.03
Other equity	(1,185)	4,505	(5,690)	(126.30)
Non-controlling interest	136,182	133,715	2,467	1.84
Total equity	4,159,205	3,755,728	403,477	10.74
The main reasons for the changes in 20% or more for the previous and later periods with the amount of changes exceeding NT\$10,000,000 or more, and their impact are analyzed and explained as follows: None				

(2) Parent Company Only Balance Sheet

Unit: NT\$ thousand

Item \ Year	2025	2024	Variation	
			Increase (decrease) amount	Variation Ratio (%)
Current assets	2,368,182	2,226,923	141,259	6.34
Non-current assets	3,400,869	3,167,899	232,970	7.35
Total assets	5,769,051	5,394,822	374,229	6.94
Current liabilities	868,984	903,560	(34,576)	(3.83)
Non-current liabilities	877,044	869,249	7,795	0.90
Total liabilities	1,746,028	1,772,809	(26,781)	(1.51)
Share capital	847,249	847,249	-	-
Capital surplus	381,924	381,924	-	-
Retained earnings	2,795,035	2,388,335	406,700	17.03
Other equity	(1,185)	4,505	(5,690)	(126.30)
Total equity	4,023,023	3,622,013	401,010	11.07
The main reasons for the changes in 20% or more for the previous and later periods with the amount of changes exceeding NT\$10,000,000 or more, and their impact are analyzed and explained as follows: None				

2. Financial Conditions:

(1) Consolidated Statements of Comprehensive Income

Unit: NT\$ thousand

Item \ Year	2025	2024	Variation	
			Increase (decrease) amount	Variation Ratio (%)
Operating revenue	4,204,086	4,228,302	(24,216)	(0.57)
Operating costs	1,721,499	1,695,016	26,483	1.56
Operating gross profit	2,482,587	2,533,286	(50,699)	(2.00)
Operating expense	1,102,351	1,135,379	(33,028)	(2.91)
Operating profit	1,380,236	1,397,907	(17,671)	(1.26)
Non-operating income and expenses	(34,653)	(79,866)	45,213	56.61
Net profit before tax	1,345,583	1,318,041	27,542	2.09
Income tax expenses	290,984	267,816	23,168	8.65
Net profit for the current period	1,054,599	1,050,225	4,374	0.42
Other comprehensive income for the current period (net post-tax amount)	(8,185)	22,702	(30,887)	(136.05)
Total comprehensive income for the current period	1,046,414	1,072,927	(26,513)	(2.47)

The main reasons for the changes in 20% or more for the previous and later periods with the amount of changes exceeding NT\$10,000,000 or more, and their impact are analyzed and explained as follows:

1. Non-operating income and expenses: mainly due to the decrease in valuation losses on financial assets measured at fair value through profit or loss and the increase in interest income in the current period.
2. Other comprehensive income for the current period (net post-tax amount): mainly due to exchange differences in the translation of financial statements of foreign operating institutions.

(2) Parent Company Only Statements of Comprehensive Income

Unit: NT\$ thousand

Item \ Year	2025	2024	Variation	
			Increase (decrease) amount	Variation Ratio (%)
Operating revenue	3,649,649	3,513,460	136,189	3.88
Operating costs	1,474,950	1,361,200	113,750	8.36
Operating gross profit	2,174,699	2,152,260	22,439	1.04
Operating expense	810,424	736,663	73,761	10.01
Operating profit	1,364,275	1,415,597	(51,322)	(3.63)
Non-operating income and expenses	(39,831)	(96,858)	57,027	58.88
Net profit before tax	1,324,444	1,318,739	5,705	0.43
Income tax expenses	281,807	254,018	27,789	10.94
Net profit for the current period	1,042,637	1,064,721	(22,084)	(2.07)
Other comprehensive income for the current period (net post-tax amount)	(5,690)	15,889	(21,579)	(135.81)
Total comprehensive income for the current period	1,036,947	1,080,610	(43,663)	(4.04)

The main reasons for the changes in 20% or more for the previous and later periods with the amount of changes exceeding NT\$10,000,000 or more, and their impact are analyzed and explained as follows:

1. Non-operating income and expenses: mainly due to the decrease in valuation losses on financial assets measured at fair value through profit or loss and the increase in interest income in the current period.
2. Other comprehensive income for the current period (net post-tax amount): mainly due to exchange differences in the translation of financial statements of foreign operating institutions.

3. Cash Flow

(1) Flow analysis for the most recent two years

Item	Year	2025	2024	Increase (decrease) Ratio %
	Cash flow ratio		161.95	153.30
Cash flow adequacy ratio		150.40	157.49	(7.09)
Cash reinvestment ratio		14.60	17.01	(2.41)

(2) Cash flow analysis for the next year

Unit: NT\$ thousand

Beginning of year cash balance	Expected net operating activities cash flow for the whole year	Cash outflow for the whole year	Cash surplus (deficit)	Correction action for cash deficit	
				Investment	Wealth management
779,239	1,600,000	1,100,000	1,279,239	-	-

1. Status of cash flow analysis for the next year:

- (1) Operating activities: The estimated net inflow is in the amount of NT\$1,600,000 thousand, which is the net cash inflow after deducting various operating expenses from the estimated profit generated by the operation in the future years.
- (2) Investing and financing activities: The estimated net cash outflow is in the amount of NT\$1,100,000 thousand, which is mainly due to distribution of cash dividends, the purchase of instruments and equipment for expansion of business scale, house decoration projects, payment of lease deposits, reinvestment, etc.

4. The impact of major capital expenditures on finance and business in the most recent year: The Company has no major capital expenditures in 2025.

5. Reinvestment policy in the most recent year, the main reasons for its profit or loss, improvement plan, and investment plan for the next year:

(1) Reinvestment policy in the most recent year:

The Company's reinvestment is based on the operation and sales of core professional medical technology and vision optical products.

(2) Reasons for profit or loss from reinvestment:

Revenue from the Mainland China region in 2025 was affected by the overall economic slowdown in the Mainland China region, with the personal spending economy showing a marked decline. In addition, newly-established organizations in the ophthalmology market are attempting to compete on low prices, resulting in relatively large market price fluctuations. Given this environment, the Company is internally increasing high-end procedures as proportion of the whole, and thus raising the price per customer. In addition to the original business in correction and optometry, the Company strengthened the business in presbyopia lens placement and replacement, while simultaneously controlling internal costs and expenses. As a result, this year's losses were greatly reduced.

(3) Investment plan for the next year:

In order to continue expanding into the mainland China medical ophthalmology market, the Company will turn toward high-end procedures, presbyopia, and optometry. In combination with using AI tools to achieve high-precision in-house marketing, service optimization will enhance the customer experience, increase member passthrough rates, and further optimize costs and expenses, in order to turn losses into profit. Also, in combination with foreign investment policy for the mainland China region, the Company expects to add one ophthalmological hospital in 2026.

6. Risk events in the most recent year and up to the date of publication of the annual report that should be analyzed and assessed:

(1) The impact of interest rate, exchange rate changes, and inflation on the Company's profit and loss and future countermeasures:

In 2025, the Company's interest income, interest expenses, exchange gains, and exchange losses were NT\$67,532 thousand, NT\$24,846 thousand, NT\$0 thousand, and NT\$5,507 thousand, respectively, accounting for 1.61%, 0.59%, 0.00%, and 0.13% of the net operating revenue, which was minimal and did not have a significant impact on the Company's profit or loss. In response to changes in interest rates, the Company closely monitors interest rate trends and adjusts its borrowing structure in a timely manner. With respect to the risk of exchange rate changes, the Company collects market information and keeps informed of exchange rate changes, and adopts appropriate hedging instruments when necessary to hedge the risk of exchange rate changes. The Company's product quotations are adjusted in a timely manner according to market conditions, and the cost of materials has not shown significant fluctuations in the recent year, so there has been no inflationary impact thus far.

(2) Policies, main reasons for profit or loss and future countermeasures for engaging in high-risk, high-leverage investments, lending funds to others, endorsement and guarantees, and derivatives trading:

The Company has not engaged in high-risk, high-leverage investments or derivatives trading in the most recent year. As of the publication date of the annual report, all endorsements and guarantees provided by the Company and its subsidiaries for loan commitments have been applied for at banks. Lending of funds engaged in by the Company's subsidiaries have consisted of funding allocation between affiliated enterprises. Fund purposes were for use in normal operating turnover, and fully comply with relevant laws and have been handled in accordance with applicable regulations. To manage related risks and ensure sound financial and operational management, the Company and its subsidiaries have established the Operational Procedures for Endorsements and Guarantees, the Operational Procedures for Lending Funds to Others, along with other relevant management measures and operating procedures in accordance with the laws and regulations of the Financial Supervisory Commission.

(3) Future R&D plans and estimated R&D expenses:

The Company will continue to invest in the research and development of new products (services) in response to changes in market demand and industry development trends to maintain and enhance brand competitiveness. The R&D expenses for 2026 are expected to account for 0.3% to 0.5% of the net operating revenue. Please refer to the section of this annual report titled "IV. Overview of Operations" for details on new products (services) slated for future development.

- (4) The impact of important domestic and foreign policies and legal changes on the Company's finance and business, and countermeasures:

The operation of the Company is based on the principle of complying with relevant laws and regulations. The relevant departments pay attention to important domestic and foreign policies and regulatory changes at any time, and cooperate in the adjustment of the Company's internal system so as to ensure smooth operation and evaluate its impact on the Company. The changes in domestic and foreign policies and laws in the recent year have no material adverse impact on the finance and business of the Company.

- (5) The impact of technological changes (including cybersecurity risks) and industrial changes on the Company's finance and business, and countermeasures:

The medical and biotechnology industry is growing steadily, and the Company maintains a high sensitivity to changes in industrial technology and responds quickly so as to meet customer needs.

- (6) The impact of changes in the corporate image on corporate crisis management, and countermeasures:

At present, there are no foreseeable crises. The Company adheres to the principle of ethical corporate management and continues to invest resources to build a good corporate image.

- (7) Expected benefits, possible risks and countermeasures of mergers and acquisitions: The Company is not involved in any of such situations, and thus it is not applicable.

- (8) Expected benefits, possible risks and countermeasures of plant expansion: The Company is not involved in any of such situations, and thus it is not applicable.

- (9) Risks and countermeasures faced by purchase or sales concentration: The Company is not involved in any of such situations, and thus it is not applicable.

- (10) The impact, risks and countermeasures of directors, supervisors or major shareholders holding 10% or more of the shares, and the large-scale transfer or replacement of equity shares on the Company: The Company is not involved in any of such situations, and thus it is not applicable.

- (11) The impact, risks and countermeasures of the change of management rights on the Company: The Company is not involved in any of such situations, and thus it is not applicable.

- (12) For litigation or non-litigation events, in case of major litigation, non-litigation, or administrative disputes involving the Company and its directors, supervisors, presidents, substantive responsible person, major shareholders with a shareholding ratio of 10% or more and affiliated companies that have been rendered a judgment which has become final and binding or whose cases are still pending, the results of which may have a significant impact on shareholder equity or securities prices, the facts at issue, the amount of the subject matter, the commencement date of the litigation, the main parties involved, and the handling situation as of the date of publication of the annual report shall be disclosed:

In the matter of the Company's Chairperson Ou Shu-Fang and Division Director Liu Chun-Chieh, who were indicted by the Taiwan Chiayi District Prosecutors Office on June 23, 2021, on charges of forgery and fraud in connection with the reporting of case-based cataract surgery fees, the Taiwan Chiayi District Court rendered a first-instance judgment finding Chairperson Ou Shu-Fang not guilty. Following appeal to the second-instance court, the Taiwan High Court Tainan Branch Court rendered its verdict on January 27, 2026, with judgment as follows: The public prosecutor's appeal against Chairperson Ou Shu-Fang was dismissed, and the original finding of "not guilty" was upheld. The original guilty judgment against Division Director Liu Chun-Chieh was reversed and changed to "not guilty".

The Company hereby states that the Company and the clinic concerned are independent legal entities. Based on the cooperation contract entered into between the two parties, the Company provides staff training, consultation on clinic setup, purchase and lease of professional equipment, authorization of trademarks and service marks, procurement of pharmaceuticals, and related consultation services to Universal Eye Clinic Chiayi. The Company has not performed any cataract surgery, nor has the Company applied for National Health Insurance payment nor has it received any payment from the National Health Insurance Administration. The aforementioned judgements have clarified the facts of the matter, which will not impact the Company's operations, shareholders' equity, or future development.

(13) Other important risks and countermeasures: None.

7. Other important matters:

(1) Information security risk assessment analysis and countermeasures

The Company has formulated various information system processing related operating guidelines, implemented the internal control system and maintained information security policy. It re-examines and evaluates its safety rules and procedures annually so as to ensure their adequacy and effectiveness. The following is a description of each sub-item.

1. Information security policy

- (1) Ensure the security of the Company's data, systems, equipment and network communications, and prevent external or internal intrusion and destruction.
- (2) Ensure that system account access authority and system-related changes are all authorized in accordance with the Company's prescribed procedures.
- (3) Establish a destruction procedure, and the computer storage media that have been scrapped should be destroyed to avoid accidental exposure of data.
- (4) Monitor the security status and activity records of the information system to effectively grasp and handle information security incidents.
- (5) Maintain the availability and integrity of data and systems, and resume normal operations in the event of a disaster or damage.

It also regularly backs up the system environment, system data and public files, etc., in order to reduce the system recovery time and the risk of data loss when a system abnormality occurs.

2. Information security network architecture

The Company's internal systems are located in the internal and external virtual network. The employee network and host network are isolated and access controlled by firewalls, and located at the firewall and intrusion prevention connection screening system at the front end of the network. Internal hosts and user endpoints are all managed and controlled by anti-virus software deployed on the central console, which updates virus patterns at any time and identifies malicious behavior characteristics in real time so as to reduce the risk of being attacked and damaged by hackers.

3. System account life cycle management and authority account management

The user's account and authority are set according to each business scope, functions and responsibilities. The access to the data must be applied and approved by the supervisor in charge through the sign-off process before it can be used and changed. Once the user leaves office, it will immediately deactivate the user's account and authority so as to prevent unauthorized use.

4. Continuous operation of the information system

The system and files are backed up daily, weekly and monthly both locally and off-site, and the daily backup data are separately transferred to off-site storage devices for storage. It also regularly conducts system data disaster recovery test drills every year to ensure the normal operation of the information system and data preservation, so as to reduce the risk of data loss caused by unwarranted natural disasters and man-made disasters.

The Information Department can properly implement these operations in accordance with the procedures stipulated by the Company to ensure the completeness and security of the data. The risk assessment results are quite good. Therefore, in the recent year and up to the date of publication of the annual report, technological changes have no significant adverse impact on the Company's information security, and there is no significant operational risk either.

VI. Special Disclosure

1. Information regarding the Company's Affiliates: The consolidated business reports of affiliates, consolidated financial statements of affiliates, and affiliated reports for the most recent year have been prepared in accordance with the Regulations Governing the Preparation of Consolidated Business Reports, Consolidated Financial Statements, and Affiliated Reports of Affiliated Enterprises prescribed by the Financial Supervisory Commission. Please refer to the **Market Observation Post System (MOPS) > Single Company > Electronic File Downloads > Three Forms for Affiliate Section**

(Website: https://mopsov.twse.com.tw/mops/web/t57sb01_q10)

2. Private placement of securities in the most recent year and up to the date of publication of the annual report: None
3. Other necessary supplementary notes: None

VII. Any matter in the most recent year and up to the date of publication of the annual report which has a significant impact on shareholders' equity or securities prices as stipulated in subparagraph 2 of paragraph 3 of Article 36 of the Securities and Exchange Act: None

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Chairperson: Ou Shu-Fang